METHOD TO IMAGE A PLURALITY OF PARTICLES USING A PARTICLE ANALYSIS SYSTEM CONFIGURED FOR COMBINED VI

专利摘要:
hematology systems and methods. These are aspects and embodiments of the present disclosure that provide an intracellular organelle and/or particle aligning agent for a particle analyzer used to analyze particles contained in a sample. wherein an exemplary intracellular organelle and/or particle aligning agent includes an aqueous solution, a viscosity modifier, and/or a buffer. the modalities also encompass systems, compositions and methods for analyzing a sample that contains particles. Particles such as blood cells can be categorized and counted using a digital image processor. a digital microscopic camera can be directed, for example, using certain focusing techniques, into a flow cell that symmetrically defines a narrowing flow path where the sample current flows in a flat ribbon by the flow parameters and viscosity between layers of coating fluid. blood cell images can be collected and analyzed using dynamic range extension processes and systems.
公开号:BR112015021577B1
申请号:R112015021577-7
申请日:2014-03-18
公开日:2021-06-22
发明作者:Bart J. Wanders；Gregory A. Farrell；Thomas H. Adams；Warren Groner；Xiaodong Zhao；Brett Jordan；Jack Cremins；Carol Quon
申请人:Iris International, Inc.；
IPC主号:

专利说明:

REFERENCES TO RELATED DEPOSIT REQUESTS
[001] This application claims priority benefit to Provisional Patent Application No. US 61/799,152 filed on March 15, 2013 and also claims priority for Patent Applications Nos. 14/215,834, 14/216,533, 14/216,339, 14/216,811 and 14/217,034 the contents of which are incorporated herein by reference. This application is also related to International Patent Applications Nos. PCT/US2014/030902, PCT/US2014/030928, PCT/US2014/030850, and PCT/US2014/030851 filed on March 17, 2014, and PCT/US2014 /030939 filed on March 18, 2014. The contents of each such file are incorporated herein by reference. BACKGROUND OF THE INVENTION
[002] This disclosure relates to the field of apparatus, systems, compositions and methods for analyzing particles, including imaging particles in fluid samples, with the use of fully or partially automated devices to discriminate and quantify particles such as cells of blood in the sample. The present disclosure also relates to an intracellular organelle and/or particle alignment liquid (IOPAL) useful for analyzing particles in a sample from a subject, methods for producing the liquid, and methods for using the liquid to detect and analyze particles. Compositions, systems, devices, and methods useful for conducting image-based biological fluid sample analysis are also presented. The compositions, systems, devices and methods of the present disclosure are also useful for detecting, counting and characterizing particles in biological fluids, such as red cells, reticulocytes, nucleated red cells, platelets, and for differential white blood cell count on a morphological and imaging basis, categorization, subcategorization, characterization and/or analysis.
[003] Blood cell analysis is one of the most commonly performed medical tests to provide an overview of a patient's health status. A blood sample can be taken from a patient's body and stored in a test tube that contains an anticoagulant to prevent clotting. A whole blood sample typically comprises three major classes of blood cells including red blood cells (erythrocytes), white blood cells (leukocytes) and platelets (thrombocytes). Each class can be further divided into member subclasses. For example, five main types or subclasses of white blood cells (WBCs) have different shapes and functions. White blood cells can include neutrophils, lymphocytes, monocytes, eosinophils and basophils. There are also subclasses of red cell types. Particle appearances in a sample may differ according to pathological conditions, cell maturity and other causes. RBC subclasses can include reticulocytes and nucleated RBCs.
[004] A blood cell count that estimates the concentration of RBCs, WBCs or platelets can be performed manually or with the use of an automated analyzer. When blood cell counts are performed manually, a drop of blood is applied to a smear-thick microscope slide. Traditionally, manual examination of a dried blood smear with staining on a microscope slide is used to determine the number or relative amounts of the five types of white blood cells. Histological dyes and pigments were used for staining cells or cell structures. For example, Wright's stain is a histological pigment that has been used to stain blood smears for examination under a microscope light. A Whole Blood Count (CBC) can be obtained using an automated analyzer, a type that counts the amount of different particles or cells in a blood sample based on impedance or dynamic light scattering as the particles or cells pass. through a detection area along a small tube. Automated CBC can employ instruments or methods to differentiate between different cell types that include RBCs, WBCs and platelets (PLTs), which can be counted separately. For example, a counting technique that requires a minimum particle size or volume can be used to count only large cells. Certain cells, such as abnormal blood cells, may not be counted or identified correctly. Small cells that stick together can be mistakenly counted as one large cell. When erroneous counts are suspected, manual review of instrument results may be necessary to verify and identify cells.
[005] Automated blood cell counting techniques may involve flow cytometry. Flow cytometry involves providing a narrow flow path and detecting and counting the passage of individual blood cells. Flow cytometry methods were used to detect particles suspended in a fluid, such as cells in a blood sample, and to analyze the particles for particle type, size, and volume distribution in order to infer the concentration of the respective type. of particle or particle volume in the blood sample. Examples of suitable methods for analyzing particles suspended in a fluid include sedimentation, microscopic characterization, impedance-based counting, and dynamic light scattering. Such tools are subject to testing errors. On the other hand, accurate characterization of particle types and concentration can be critical in applications such as medical diagnosis.
[006] In imaging-based counting techniques, pixel data images of a prepared sample that can pass through a viewing area are captured using an objective microscope lens coupled to a digital camera. Pixel image data can be analyzed using data processing techniques and further displayed on a monitor.
Aspects of automated flow cell diagnostic systems are disclosed in U.S. Patent No. 6,825,926 to Turner et al. and in U.S. Patent Nos. 6,184,978; 6,424,415; and 6,590,646, all to Kasdan et al., which are incorporated herein by reference as set forth in full herein.
[008] Automated systems with the use of dynamic light scattering or impedance were used to obtain a whole blood count (CBC): Total white blood cell count (WBC), total red cell volume (red cell distribution of the blood), hemoglobin HGB (the amount of hemoglobin in the blood); mean cell volume (MCV) (mean red blood cell volume); MPV (average volume of PLT); hematocrit (HCT); MCH (HGB/Red Blood Cells) (the average amount of hemoglobin per red blood cell); and MCHC (HGB/HCT) (the mean concentration of hemoglobin in cells). Automated or partially automated processes were used to facilitate five-part white blood cell differential counting and blood sample analysis.
[009] Although such particle analysis systems and methods, along with related medical diagnostic techniques, can provide real benefits to physicians, clinicians and patients, further improvements are still desirable. For example, there is a continuing need for improved methods and compositions useful for intracellular organelle and/or particle alignment when performing image-based sample analysis using automated systems. Embodiments of the present invention provide solutions to at least some of these more evident needs. BRIEF SUMMARY OF THE INVENTION
[0010] Embodiments of the present invention relate to apparatus, systems, compositions and methods for analyzing a prepared sample containing particles. In some aspects, the system comprises an analyzer which can be a visual analyzer. In some aspects, the device contains a visual analyzer and a processor. In one aspect, this disclosure relates to an automated particle imaging system in which a liquid sample containing particles of interest flows through a flow cell that has a viewing port through which a high-resolution optical imaging device captures an image. In some aspects, the high resolution optical imaging device comprises a camera, such as a digital camera. In one aspect, the high resolution optical imaging device comprises an objective lens.
[0011] The flow cell is coupled to a source of sample fluid, such as a prepared sample, and to a source of intracellular organelle and/or particle alignment liquid (PIOAL). The system allows the capture of focused images of particles in a flowing sample. In some embodiments, images can be used in high-throughput automated processes to categorize and subcategorize particles. An exemplary visual analyzer may include a processor to facilitate automated image analysis. In some cases, the visual analyzer can be used in methods of this disclosure to provide WBC differential count based on automated image or other blood sample particle analysis protocols. In some cases, the methods of this disclosure refer to automated identification of morphological abnormalities to determine, diagnose, predict, predict, and/or support a diagnosis to determine whether an individual is healthy or has a disease, condition, abnormality, and/or infection. and to monitor whether an individual is responsive or unresponsive to treatment.
[0012] PIOAL aligns non-spherical particles in a plane substantially parallel to the direction of flow, which results in image optimization. PIOAL also assists spherical cells in positioning, repositioning and/or better positioning intracellular structures, organelles or lobes substantially parallel to the direction of flow. In some modalities, platelets, reticulocytes, nucleated RBCs and WBCs including neutrophils, lymphocytes, monocytes, eosinophils, basophils and immature WBCs including blastulas, promyelocytes, myelocytes or metamyelocytes are counted and analyzed as particles.
[0013] Embodiments of the present invention provide fluid sheath systems, methods and compositions useful for intracellular organelle and/or particle alignment in cells treated with particle contrast agent compositions. Such techniques overcome certain difficulties associated with conventional sheath fluids used in flow cytometry that may suffer from the disadvantages of maintaining cell morphology and/or not providing optimized image capture that allows the determination of one or more blood components.
[0014] In certain embodiments, a viscosity difference and/or velocity difference between a tape-shaped sample stream and a coating fluid and/or a thickness of the tape-shaped sample stream, for example, in combination with a geometric focusing effect provided by a narrowing flow path transition zone, it can introduce shear forces to act on particles while in flow, thus causing particles to align or remain in alignment across an imaging process in a visual analyzer. In some modalities, the sample will be contrast enhanced. In some embodiments, the coating fluid can comprise up to 100% of a viscosity agent. In another embodiment, the coating fluid has up to 60% v/v of a viscosity agent. Depending on the types of viscosity agent used, in some embodiments the coating fluid may comprise a viscosity agent that is commercially available in dry form at a concentration of about 5 to 7%, or more specifically, at 6.5% ( weight by volume).
[0015] In other embodiments, this disclosure relates to a sheath fluid that can be used in particle analysis based on images in samples such as cells and other particle resources in other biological fluids such as cerebrospinal fluid and effusions associated with specific affections. Cell category and/or subcategory counts are described for use on blood samples in this disclosure as non-limiting examples of the type of samples that can be analyzed. In some embodiments, cells present in samples can also include bacterial or fungal cells as well as white blood cells, red blood cells or platelets. In some embodiments, particle suspensions obtained from tissues or aspirates can be analyzed.
[0016] In some embodiments, a stream of sample fluid may be injected through a cannula with a flat slit to establish a flow path of considerable width. The sheath fluid can be introduced into the flow cell and transport the sample fluid through the imaging area, then towards an outlet. A coating fluid has a different viscosity, eg higher than sample fluid and optionally a different flow rate at the injection point to the tape-shaped sample stream results in the sample fluid to flatten to a shape. of thin ribbon. The thin strip of sample fluid is transported along with the coating fluid, through a transition zone of the narrowed flow path to pass in front of a viewing port in which a high-resolution optical imaging device and a source are arranged to visualize the sample stream in tape format.
[0017] In one embodiment, the sheath fluid viscosity may be greater than the sample viscosity. The viscosity of the coating fluid, the viscosity of the sample material, the flow rate of the coating fluid and the flow rate of the sample material are coordinated, for example, in combination with a tape compression effect provided by a zone of taper transition, to provide the flow in a tape-format sample stream with predetermined dimensional characteristics such as tape-format sample stream thickness advantageous. Maintaining an advantageous tape format sample stream thickness provides, as an example, a high percentage of focus cells or focus cell components.
[0018] The modalities of the present disclosure are based, at least in part, on the finding that the addition of an adequate amount of a viscosity agent in the coating fluid significantly improves particle/cell alignment in a flow cell, for example, in a flow cell that has a narrowing transition zone and increases intracellular contents in focus of cells, so as to result in high quality images of cells in flow compared to using a conventional sheath fluid not modified by viscosity used in flow cytometry. The addition of the viscosity agent increases shear forces on elongated non-spherical particles or red cell-like cells (RBCs) which then align the cells in a plane substantially parallel to the flow direction, resulting in image optimization. For white blood cell-like cells (WBCs), this further results in the positioning, repositioning and/or better positioning of intracellular structures, organelles or lobes substantially parallel to the flow direction. For example, white blood cells may be compressible or deformable in response to shear forces imparted by the agent or viscosity differential, thus leading to particle elongation or compression and alignment upon shear.
[0019] Alignment of particles that are smaller in diameter than the flow stream can be achieved by increasing the viscosity of the coating fluid. This results in improved alignment of particles in a plane substantially parallel to the flow direction.
[0020] The thickness of the tape-shaped sample stream can be affected by the viscosities and relative flow rates of the sample fluid and the coating fluid, for example, in combination with the narrowing transition zone geometry of the cell. flow. The sample power supply and/or coating fluid power supply, for example, which comprise precision displacement pumps, can be configured to supply the sample and/or coating fluid at stable flow rates to optimize the dimensions of the tape-shaped sample stream, especially as a thin tape at least as wide as the imaging device's field of view.
[0021] An exemplary sheath fluid modality is used in a flow cell for particle analysis. A sample is enveloped in the sheath fluid stream and passed through the flow cell of the analyzer device. Then, the sample information as it passes through the detection area is collected, in order to enable an analyzer to analyze the particles/cells contained in the sample. The use of sheath fluid in such an analyzer allows for accurate categorization and subcategorization and counting of cells and/or particles contained in samples.
[0022] As used in this document, the sheath fluid is useful in obtaining information regarding the tracking of cells and/or particles related thereto: including, for example; neutrophil, lymphocyte, monocyte, eosinophil, basophil, platelet, reticulocyte, nucleated red blood cells, blastula, promyelocyte, myelocyte and/or a metamyelocyte.
[0023] The present disclosure provides innovative compositions and methods for using them to conduct particle analysis. In particular, the present disclosure relates to an intracellular organelle and/or particle alignment liquid (IOPAL) used in an analyzer to analyze particles in a sample. The terms sheath fluid and PIOAL may be used interchangeably throughout this disclosure. The present disclosure further provides methods for making PIOAL and methods for using PIOAL to analyze particles. The PIOAL of this invention is useful, as an example, in methods for automated categorization and subcategorization of particles in a sample.
[0024] In one aspect, embodiments of the present invention encompass methods for generating images of a plurality of particles using a particle analysis system. The system can be configured to perform combined viscosity and geometric hydrofocus. Particles can be included in a blood fluid sample that has a sample fluid viscosity. Exemplary methods may include flowing a sheath fluid along a flow path of a flow cell and the sheath fluid may have a sheath fluid viscosity different from the sample fluid viscosity by a viscosity difference in a predetermined range of viscosity difference. The methods may also include injecting the blood fluid sample into the sheath fluid flowing within the flow cell so as to provide a stream of sample fluid surrounded by the sheath fluid. In addition, the methods may include flowing the sample fluid stream and coating fluid through a reduction in the size of the flow path towards an imaging site such that an interaction-induced viscosity hydrofocus effect between the coating fluid and the sample fluid stream associated with the viscosity difference, in combination with a geometric hydrofocal effect induced by an interaction between the coating fluid and the sample fluid stream associated with the reduction in the size of the trajectory. flow, is effective to provide a target-imaging state in at least a portion of the plurality of particles at the imaging site, while a viscosity agent in the coating fluid maintains cell viability in the sample fluid stream so as to leave the structure and contents of intact cells when cells extend from the sample fluid stream to the flowing sheath fluid . Furthermore, the methods can include generating images of the plurality of particles at the imaging site. In some cases, the sheath fluid has a refractive index of n = 1.3330. In some cases, the sheath fluid has a refractive index that is equal to the refractive index of water. In some cases, the interaction between the sheath fluid and the sample fluid stream associated with the reduction in flow path size contributes to providing the target imaging state by producing a shear force on the plurality of particles. In some cases, the target imaging state includes a target orientation of one or more target particles in the stream relative to the focal plane of an imaging device used to capture images at the imaging location.
[0025] According to some embodiments, the flow path at the imaging location defines a plane that is substantially parallel to the focal plane. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane at the imaging site. In some cases, the target alignment corresponds to an alignment of the target particle with respect to the focal plane at the imaging site. In some cases, the target alignment corresponds to an intraparticle target structure alignment relative to the focal plane at the imaging site. In some cases, the target orientation corresponds to a target position in relation to the focal plane at the imaging site. In some cases, the target position corresponds to a target particle position relative to the focal plane at the imaging site. In some cases, the target position corresponds to a position of the target intraparticle structure in relation to the focal plane at the imaging site. In some cases, the target position is covered by the focal plane. In some cases, the target position is at a distance from the focal plane, where the distance corresponds to a position tolerance. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane and a target position in relation to the focal plane. In some cases, the target imaging state corresponds to a target orientation of one or more intraparticle target structures in the flow relative to a focal plane of an imaging device used to capture images at the imaging site. In some cases, the flow path at the imaging site defines a plane that is substantially parallel to the focal plane. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane at the imaging site. In some cases, the target alignment corresponds to an alignment of the target particle with respect to the focal plane at the imaging site. In some cases, the target alignment corresponds to an intraparticle target structure alignment relative to the focal plane at the imaging site. In some cases, the target orientation corresponds to a target position in relation to the focal plane at the imaging site. In some cases, the target position corresponds to a target particle position relative to the focal plane at the imaging site. In some cases, the target position corresponds to a position of the target intraparticle structure in relation to the focal plane at the imaging site. In some cases, the target position is covered by the focal plane. In some cases, the target position is at a distance from the focal plane, where the distance corresponds to a position tolerance. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane and a target position in relation to the focal plane. In some cases, the target imaging state corresponds to a target deformation of one or more target particles or one or more intraparticle target structures.
[0026] According to some embodiments, the process of injecting the blood fluid sample is performed by directing a stream of the blood fluid sample through an injection tube sample with a sample fluid velocity. The injection tube may have a port in the flow path. The gate can define a width, thickness, and geometric flow axis that extend along the flow path. The width can be greater than the thickness so that the sample stream has main surfaces across the imaging path adjacent to the imaging location. In some cases, the sheath fluid flowing along the flow cell's flow path extends along the main surfaces of the sample stream and has a sheath fluid velocity different from the sample fluid velocity. In some cases, an interaction between the sheath fluid and the sample fluid associated with the different velocities, in combination with the interaction between the sheath fluid and the sample fluid associated with the different viscosities, provides the target imaging state. In some embodiments, the plurality of particles can include a red blood cell, a white blood cell and/or a platelet. In some embodiments, the plurality of particles can include a cell that has an intraparticle structure. In some cases, an intraparticle structure can be an intracellular structure, an organelle, or a lobule.
[0027] In some embodiments, the coating fluid has a viscosity between 0.001 and 0.01 Pa.s (1 and 10 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value in the range of about 0.0001 to about 0.1 Pa.s (0.1 to about 10 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value in the range of about 0.001 to about 0.009 Pa.s (1.0 to about 9.0 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value in a range of from about 0.001 to about 0.005 (1.0 to about 5.0 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value of about 0.003 (3.0 centipoise (cP)). In some cases, the sheath fluid viscosity agent includes glycerol, glycerol derivative, ethylene glycol, propylene glycol (dihydroxypropane), poly(ethylene glycol), polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), soluble polymer(s) in water and/or dextran. In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of between about 1 to about 50% (v/v). In some cases, the sheath fluid viscosity agent includes glycerol and polyvinylpyrrolidone (PVP). In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of 5% (v/v) and glycerol and polyvinylpyrrolidone (PVP) at a concentration of 1% (weight to volume). In some cases, the sheath fluid viscosity agent includes glycerol present at a final concentration of between about 3 to about 30% (v/v) under operating conditions. In some cases, the sheath fluid viscosity agent includes glycerol present at a final concentration of about 30% (v/v) under operating conditions. In some cases, the sheath fluid viscosity agent includes glycerol present at a final concentration of about 6.5% v/v under operating conditions. In some cases, the sheath fluid viscosity agent includes glycerol present at a final concentration of about 5% (v/v) and polyvinylpyrrolidone (PVP) present at a concentration of about 1% (weight to volume) under conditions of operation.
[0028] According to some embodiments, the blood fluid sample at the imaging site has a linear velocity in a range of 20 to 200 mm/second. In some cases, the blood fluid sample at the imaging site has a linear velocity in a range of 50 to 150 mm/second. In some cases, the blood fluid sample has a sample stream thickness of up to 7 µm and a sample stream width in a range of 500 to 3000 µm at the imaging site. In some cases, the blood fluid sample has a sample stream thickness in a range of 2 to 4 µm and a sample stream width in a range of 1000 to 2000 µm at the imaging site. In some cases, the plurality of particles includes a set of non-spherical particles, the blood fluid sample has a flow direction at the imaging site, and more than 75% of the set of non-spherical particles are aligned substantially in a plane parallel to the flow direction such that a major surface of each aligned non-spherical particle is parallel to the plane parallel to the flow direction. In some cases, the plurality of particles includes a set of non-spherical particles, where the blood fluid sample has a flow direction at the imaging site and at least 90% of the set of non-spherical particles are aligned by 20 degrees in with respect to a plane substantially parallel to the direction of flow. In some cases, the plurality of particles include intraparticle structures, wherein the blood fluid sample has a flow direction at the imaging site and at least 92% of the intraparticle structures are substantially parallel to the flow direction.
[0029] In another aspect, embodiments of the present invention encompass systems for imaging a plurality of particles in a blood fluid sample that has a fluid sample viscosity. The system can be configured for use with a sheath fluid that has a sheath fluid viscosity that differs from the sample fluid viscosity by a viscosity difference within a predetermined range of viscosity difference. Exemplary systems may include a flow cell that has a flow path and a sample fluid injection tube, where the flow path has a reduction in flow path size, a sheath fluid inlet in fluid communication with the flow path of the flow cell so as to transmit a flow of sheath fluid along the flow path of the flow cell, and a blood fluid sample inlet in fluid communication with the injection tube of the flow cell. flow in order to inject a flow of the blood fluid sample into the sheath fluid flowing within the flow cell, so that as the sheath fluid and the sample fluid flow through the reduction in the size of the flow path and towards an imaging site, a viscosity hydrofocus effect induced by an interaction between the coating fluid and the sample fluid associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the sheath fluid and a sample fluid associated with a reduction in flow path size, provide a target imaging state in at least a portion of the plurality of particles at the imaging site while a viscosity agent in the coating fluid maintains the viability of the cells in the sample fluid stream so as to leave the structure and contents of the cells intact when the cells extend from the sample fluid stream into the flowing coating fluid. The systems can additionally include an imaging device that images the plurality of particles at the imaging site.
[0030] According to some embodiments, the target imaging state corresponds to a target orientation of one or more target particles in the stream relative to a focal plane of an imaging device used to acquire images at the imaging location. In some cases, the plurality of particles includes a member selected from the group consisting of a red blood cell, a white blood cell, and a platelet. In some cases, the plurality of particles includes a cell that has an intraparticle structure. An intracellular structure can be an intracellular structure, an organelle or a lobule. In some cases, the predetermined viscosity difference has an absolute value in the range of about 0.0001 to about 0.1 Pa.s (0.1 to about 10 centipoise (cP)). In some cases, the sheath fluid viscosity agent includes glycerol, a glycerol derivative, ethylene glycol, propylene glycol (dihydroxypropane), poly(ethylene glycol), polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), soluble polymer(s) ) in water and/or dextran. In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of between about 1 to about 50% (v/v). In some cases, the sheath fluid viscosity agent includes glycerol and polyvinylpyrrolidone (PVP). In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of 5% (v/v) and glycerol and polyvinylpyrrolidone (PVP) at a concentration of 1% (weight to volume).
[0031] According to some embodiments, the plurality of particles includes a set of non-spherical particles, the blood fluid sample has a flow direction at the imaging site, and at least 90% of the set of non-spherical particles are aligned with 20 degrees from a plane substantially parallel to the direction of flow. In some cases, the target orientation corresponds to a target particle orientation relative to a focal plane at the imaging site. A particle can be a red blood cell, a white blood cell, or a platelet in some modalities. In some cases, the target orientation corresponds to an intraparticle target structure orientation relative to a focal plane at the imaging site. (for example, the intraparticle structure can be an intracellular structure, an organelle or a lobule). In some cases, the flow path at the imaging site defines a plane that is substantially parallel to the focal plane. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane at the imaging site. In some cases, the target-alignment corresponds to a target-particle alignment relative to a focal plane at the imaging site. In some cases, target alignment corresponds to an intraparticle target structure alignment relative to a focal plane at the imaging site. In some cases, the target orientation corresponds to a target position in relation to the focal plane at the imaging site. In some cases, the target position corresponds to a target particle position relative to the focal plane at the imaging site. In some cases, the target position corresponds to a position of the target intraparticle structure in relation to the focal plane at the imaging site. In some cases, the target position is covered by the focal plane. In some cases, the target position is at a distance from the focal plane, where the distance corresponds to a position tolerance. In some cases, the target orientation corresponds to a target alignment in relation to the focal plane and a target position in relation to the focal plane. In some cases, the target-imaging state corresponds to a target deformation at the imaging site.
[0032] According to some embodiments, a blood fluid sample source may be configured to provide the blood fluid sample with a velocity of sample fluid into the fluent coating fluid, so that the coating fluid have a coating fluid velocity that is different from the sample fluid velocity. In some cases, an interaction between the sheath fluid and the sample fluid associated with the different velocities, in combination with the interaction between the sheath fluid and the sample fluid associated with the different viscosities, provides the target imaging state.
[0033] According to some embodiments, the flow cell flow path includes a zone with a change in the size of the flow path and an interaction between the sheath fluid and the sample fluid associated with the change in the size of the flow path. flux, in combination with the interaction between the sheath fluid and the sample fluid associated with the different viscosities, provides the target imaging state. In some cases, the interaction between the sheath fluid and the sample fluid associated with the change in flow path size contributes to providing the target imaging state by producing a lateral fluid compression force. In some cases, the plurality of particles include a red blood cell, a white blood cell and/or a platelet. In some cases, the plurality of particles includes a cell that has an intraparticle structure, and the structure can be an intracellular structure, an organelle, or a lobule.
According to some embodiments, the predetermined viscosity difference has an absolute value in a range of about 0.0001 to about 0.01 Pa.s (0.1 to about 10 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value in the range of about 0.001 to about 0.009 Pa.s (1.0 to about 9.0 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value in a range of from about 0.001 to about 0.005 (1.0 to about 5.0 centipoise (cP)). In some cases, the predetermined viscosity difference has an absolute value of about 0.003 Pa.s (3.0 centipoise (cP)). In some cases, the coating fluid includes a viscosity agent which may include glycerol, a glycerol derivative, ethylene glycol, propylene glycol (dihydroxypropane), poly(ethylene glycol), polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), polymer(s) soluble(s) in water and/or dextran. In some cases, the sheath fluid comprises glycerol at a concentration of between about 1 to about 50% (v/v).
[0035] According to some embodiments, the blood fluid sample at the imaging site has a linear velocity in a range of 20 to 200 mm/second. In some cases, the blood fluid sample at the imaging site has a linear velocity in a range of 50 to 150 mm/second. In some cases, the blood fluid sample has a sample stream thickness of up to 7 µm and a sample stream width of more than 500 µm at the imaging site. In some cases, the blood fluid sample has a sample stream thickness in a range of 2 to 4 µm and a sample stream width in a range of 1000 to 2000 µm at the imaging site. In some cases, the plurality of particles includes a set of non-spherical particles, the blood fluid sample has a flow direction at the imaging site, and at least 90% of the set of non-spherical particles are aligned and/or positioned substantially in a plane parallel to the flow direction. In some cases, the plurality of particles includes a set of non-spherical particles, where the blood fluid sample has a flow direction at the imaging site and at least 95% of the set of non-spherical particles are aligned at 20 degrees in with respect to a plane substantially parallel to the direction of flow. In some cases, the plurality of particles include intraparticle structures, wherein the blood fluid sample has a flow direction at the imaging site and at least 92% of the intraparticle structures are substantially parallel to the flow direction.
[0036] In another aspect, embodiments of the present invention encompass an intracellular organelle and particle alignment liquid (PIOAL) for use in a combined geometric hydrofocus and viscosity analyzer. The PIOAL can direct a flow of a blood sample fluid of a certain viscosity that is injected into a narrow flow cell transition zone of the visual analyzer so as to produce a stream of sample fluid surrounded by the PIOAL. PIOAL can include a fluid that has a viscosity greater than the viscosity of the blood sample fluid. A viscosity hydrofocus effect induced by an interaction between the PIOAL fluid and the sample fluid associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the PIOAL fluid and the sample fluid associated with the Narrow flow cell transition zone, is effective to provide a target imaging state in at least a portion of the plurality of particles at an imaging site of the visual analyzer while a viscosity agent in the PIOAL maintains cell viability in the stream. of sample fluid so as to leave the structure and contents of the cells intact as the cells extend from the sample fluid stream to the flowable coating fluid. In some cases, the sheath fluid viscosity agent includes glycerol, a glycerol derivative, ethylene glycol, propylene glycol (dihydroxypropane), poly(ethylene glycol), polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), soluble polymer(s) ) in water and/or dextran. In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of between about 1 to about 50% (v/v). In some cases, the sheath fluid viscosity agent includes polyvinylpyrrolidone (PVP). In some cases, polyvinylpyrrolidone (PVP) is at a concentration of 1% (weight to volume). In some cases, the sheath fluid viscosity agent additionally includes glycerol. In some cases, the sheath fluid viscosity agent includes glycerol at a concentration of 5% (v/v) and glycerol and polyvinylpyrrolidone (PVP) at a concentration of 1% (weight to volume). In some cases, PIOAL has a viscosity between about 0.001 to 0.01 Pa.s (1 to 10 cP).
[0037] In yet another aspect, embodiments of the present invention encompass an intracellular organelle and particle alignment liquid (PIOAL) for use in a visual analyzer configured to direct the flow of a sample of a particular viscosity in a flow path. PIOAL can include a fluid that has a viscosity greater than the viscosity of the sample fluid. PIOAL can be effective in sustaining sample flow and in aligning particles and increasing the in-focus content of intracellular particles and organelles of cells flowing in the flow path, whereby the cells' aligned intracellular particles and organelles can be imaged. In some cases, PIOAL additionally includes a viscosity agent. In some cases, PIOAL additionally includes a buffer, a pH adjusting agent, an antimicrobial agent, an ionic strength modifier, a surfactant, and/or a chelating agent. In some cases, the intracellular organelle and particle alignment fluid is isotonic. In some cases, the intracellular organelle and particle alignment fluid includes sodium chloride. In some cases sodium chloride is present at a concentration of around 0.9%. In some cases, the pH of the PIOAL sample is between about 6.0 to about 8.0 under operating conditions. In some cases, the pH of the PIOAL sample mixture is between about 6.5 to about 7.5 under operating conditions. In some cases, PIOAL includes a pH adjusting agent to adjust the pH between about 6.8 to about 7.2 under operating conditions. In some cases, the PIOAL liquid has a target viscosity between about 0.001 to 0.01 (1 to 10 centipoise) under operating conditions.
[0038] In yet another aspect, embodiments of the present invention encompass a concentrated PIOAL stock solution. In some cases, the concentrated stock solution can be diluted to reach the target viscosity. In some cases, the concentration of the stock solution is present at at least about 1.1x to at least about 100x concentration of PIOAL under operating conditions. In some cases, 139.
[0039] The PIOAL of claim 127, wherein the viscosity agent is selected from at least one of glycerol, glycerol derivative; PVP, CMC, ethylene glycol; propylene glycol (dihydroxypropane); poly(ethylene glycol); water soluble polymer and dextran. In some cases, the viscosity agent includes glycerol. In some cases, the viscosity agent includes glycerol and polyvinylpyrrolidone (PVP). In some cases, the viscosity agent includes glycerol and carboxymethylcellulose (CMC). In some cases, the viscosity agent includes glycerol and dextran sulfate. In some cases, the viscosity agent includes a glycerol derivative. In some cases, the viscosity agent includes PVP. In some cases, the viscosity agent includes propylene glycol (dihydroxypropane). In some cases, the viscosity agent includes poly(ethylene glycol). In some cases, the viscosity agent includes water-soluble dextran. In some cases, glycerol is present at a final concentration of between about 1 to about 50% (v/v) under operating conditions. In some cases, said glycerol is present at a final concentration of between about 3 to about 30% (v/v) under operating conditions. In some cases, said glycerol is present at a final concentration of about 30% (v/v) under operating conditions. In some cases, said glycerol is present at a final concentration of about 6.5% v/v under operating conditions. In some cases, said glycerol is present at a final concentration of about 5% v/v and PVP is present at a concentration of about 1%, weight to volume, under operating conditions. In some cases, said PVP is present at a final concentration of about 1%, weight to volume, under operating conditions. In some cases, embodiments of the present invention encompass kits that include a PIOAL as disclosed herein.
[0040] In another aspect, embodiments of the present invention encompass methods for analyzing a plurality of cells in a blood fluid sample that has a sample fluid viscosity, wherein the cells have opposing major surfaces. Exemplary methods can include flowing a sheath fluid along a flow path of a flow cell. The coating fluid can have a coating fluid viscosity greater than the sample fluid viscosity. Methods may also include injecting the blood fluid sample into the sheath fluid flowing within the flow cell. The plurality of cells may include a first subset with main surfaces oriented transversely to an orientation of an imaging path. The methods may also include imaging particles along the imaging path at an imaging location while the plurality of cells include a second subset with the main surfaces oriented transversely to the imaging path, where the second subset is more numerous than the first subset. Methods may also include directing the fluid blood sample and sheath fluid through a reduction in the size of the flow path such that an interaction between the sheath fluid and sample fluid associated with different viscosities reorients at least a portion of the plurality of cells, so that the second subset is more numerous than the first subset.
[0041] In another aspect, embodiments of the present invention encompass systems for imaging a plurality of cells in a blood fluid sample that has a fluid sample viscosity. The systems can be configured for use with a sheath fluid that has a sheath fluid viscosity greater than the sample fluid viscosity, where the cells have opposing major surfaces. Exemplary systems may include a flow cell having a flow path and a sample fluid injection tube, a sheath fluid inlet in fluid communication with the flow cell flow path to transmit a flow of the sheath fluid along the flow path of the flow cell and a blood fluid sample inlet in fluid communication with the injection tube of the flow cell so as to inject a flow of blood fluid sample into the sheath fluid that flows within the flow cell, such that the plurality of injected cells include a first subassembly with main surfaces aligned transversely to an orientation of an imaging path. In some cases, the flow cell flow path may have a zone with a change in flow path size configured so that an interaction between the sheath fluid and the blood sample fluid associated with different viscosities redirects at least one part of the particles. The systems may also include an imaging device that images the plurality of particles along the imaging path at an imaging location while the major surfaces of the second subset of the plurality of cells are oriented transversely to the imaging path.
[0042] In one aspect, this invention relates to a method for imaging a particle comprising: treating particles in a sample using the particle contrast agent compositions of this disclosure; illuminating the stained particle with light in a visual analyzer comprising a flow cell and autofocus apparatus; obtain a digitized image of the particle encased in an intracellular organelle and/or particle alignment liquid (PIOAL); and; analyze a particle in the sample based on the image information. In some embodiments, the particle is selected from at least one of neutrophil, lymphocyte, monocyte, eosinophil, basophil, platelet, reticulocyte, nucleated red blood cell (red blood cells), blastula, promyelocyte, myelocyte, metamyelocyte, red blood cell ), platelet, cell, bacteria, particulate matter, cell nodule or cell fragment or component. For example, in some modalities, the device can be used for automated image-based differential white blood cell count (WBC) as well as automated identification of morphological anomalies useful in determining, diagnosing, prognosing, predicting and/or sustaining a diagnosis to determine whether an individual is healthy or has a disease, condition or infection and/or is responsive or non-responsive to treatment.
[0043] In one aspect, embodiments of the present invention encompass methods for generating particle images using a particle analysis system that is configured to perform combined geometric and viscosity hydrofocus. Particles can be included in first and second sample fluids from a blood fluid sample. Exemplary methods can include flowing a sheath fluid along a flow path of a particle analyzer flow cell and the sheath fluid can have a viscosity that is different from a blood fluid sample viscosity. In some cases, the coating fluid has a coating fluid viscosity that differs from the sample fluid viscosity by a viscosity difference, and the viscosity difference has a value within a predetermined range of viscosity difference. The methods may also include injecting the first sample fluid from a sample fluid injection tube into the sheath fluid flowing within the flow cell so as to provide a sample fluid stream having a first thickness adjacent to the tube. of injection. The flow path of the flow cell may have a decrease in flow path size such that the thickness of the sample fluid stream decreases from the initial thickness to a second thickness adjacent to an image capture site. The methods may further include imaging a first plurality of particles of the first sample fluid at the flow cell image capture site and initiating sample fluid transients by interrupting injection of the first sample fluid into the fluid. flowing coating fluid and injecting the second sample fluid into the flowing coating fluid. In addition, the methods may include imaging a second plurality of particles from the second sample fluid at the flow cell image capture site. Imaging the second plurality of particles can be performed substantially after the sample fluid transients and within 4 seconds after imaging the first plurality of particles. In some cases, the decrease in flow path size is defined by a proximal flow path portion having a proximal thickness and a flow path distal portion having a distal thickness less than the proximal thickness. A downstream end of the sample fluid injection tube may be positioned distal to the proximal portion of the flow path. The difference in viscosity between the blood and coating fluid samples, in combination with the decrease in flow path size, can be effective for hydrofocusing the first and second sample fluids at the imaging site as an imaging agent. viscosity in the coating fluid maintains cell viability in the first and second sample fluids so as to leave the structure and contents of the cells intact as the cells extend from the sample fluid stream to the fluent coating fluid.
[0044] In some methods, the injection tube may include an internal volume based on a ratio of an injection tube flow area cross section to a flow cell flow area cross section, a cut ratio cross section of the injection tube flow area to an outside diameter of the flow cell or a ratio of the cross section of the injection tube flow area to a flow area cross section of the sample stream. In some cases, the decrease in flow path size can be defined by opposing walls of the flow path that angulate radially inward along the flow path, generally symmetrical around a transverse plane that bisects the first. and second sample fluid stream thicknesses. In some cases, the symmetry of the decrease in flow path size is effective in limiting the RBC imaging orientation misalignment in the blood fluid sample to less than about 20%. In some cases, the blood fluid sample includes spherical particles, and a viscosity differential between the sample fluid and the sheath fluid is effective to align the intracellular organelles of the spherical particles in a focal plane at the image capture site of the flow cell. In some cases, a distal portion of the sample fluid injection tube is positioned an axial separation distance from the image capture site and the axial separation distance has a value in a range from about 16 mm to about 26 mm. mm. In some cases, the injection tube has an internal volume of less than about 30 µL.
[0045] In some methods, the injection tube has a proximal portion that has a first cross-sectional area of flow and a distal portion that has a second cross-sectional area of flow and the cross-sectional area of flow of the proximal portion is greater than 1.5 times the flow cross-sectional area of the distal portion. In some methods, the injection tube has a central portion disposed between the proximal portion and the distal portion, wherein the central portion has a third flow cross-section and the third flow cross-section is larger than the first and second cross-sections. flow.
[0046] In some methods, a distal portion of the sample fluid injection tube includes an outlet port that has a height and a width and the height may be less than the width. In some cases, the height is around 150 µm and the width is around 1350 µm. In some cases, height has a value in a range from about 50 µm to about 250 µm and width has a value in a range from about 500 µm to about 3000 µm.
[0047] In some methods, a ratio of sheathing fluid flow rate to fluid sample flow rate is about 70. In some cases, the ratio of sheathing fluid flow rate to fluid flow rate of sample is about 200. In some cases, the coating fluid has a flow rate of about 35 µL/s and the sample fluid has a flow rate of about 0.5 µL/s. In some cases, the sample fluid has a velocity between about 20 and 200 mm/second at the image capture site. In some cases, the sheath fluid velocity and fluid sample velocity may be different at a flow path position close to the injection tube outlet port and the sheath fluid velocity and fluid sample velocity may be the same in the image capture location. In some cases, the first thickness of the sample fluid stream is about 150 µm, for example where the sample fluid exits the injection tube. In some cases, the second thickness of the sample fluid stream is in a range from about 2 µm to about 10 µm, for example, where the sample fluid stream flows through the image capture site. In some cases, the second thickness of the sample fluid stream is in a range from about 2 µm to about 4 µm. In some cases, a ratio of the first thickness of the sample fluid stream to the second thickness of the sample fluid stream has a value in a range from about 20:1 to about 70:1. In some cases, a ratio of the first thickness of the sample fluid stream to the second thickness of the sample fluid stream has a value in a range from about 5:1 to about 200:1. In some cases, a ratio of the proximal thickness of the flow path proximal portion to the distal thickness of the flow path distal portion has a geometric thinning value selected from the group consisting of 10:1, 15:1, 20:1 , 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85 :1, 90:1, 95:1, 100:1, 105:1, 110:1, 115:1, 125:1, 130:1, 140:1, 150:1, 160:1, 170:1 , 180:1, 190:1 and 200:1. In some cases, the flow cell has a minimum compression ratio of about 50:1 and a maximum compression ratio of about 125:1.
[0048] In some methods, the flow cell is oriented so that the sample fluid and sheath fluid flowing inside the flow cell flow against gravity. In some cases, the flow cell is oriented so that the sample fluid and sheath fluid flowing inside the flow cell flow with gravity. Exemplary methods may also include removing bubbles from the flowing sample fluid. In some cases, the first sample fluid reaches a stabilized state in about 1 to 3 seconds after injecting the first sample fluid from the sample fluid injection tube into the flowing coating fluid. In some cases, the first sample fluid reaches a stabilized state in less than 1 second after injecting the first sample fluid from the sample fluid injection tube into the flowing coating fluid. In some cases, the first sample fluid reaches a stabilized state about 1.8 seconds after injecting the first sample fluid from the sample fluid injection tube into the flowing coating fluid. In some cases, the sample fluid has a transit time through the flow cell in a range of about 2 to 4 seconds. In some cases, the image capture site has a field of view between about 150 μm x 150 μm and 400 μm x 400 μm. In some cases, the first sample fluid has a volume in a range of about 50 to about 150 µL. In some cases, a proximal portion of the injection tube is attached to a sample port of a sample inlet fitting.
[0049] In another aspect, embodiments of the present invention encompass particle analysis systems that perform combined viscosity and geometric hydrofocus to generate images of particles in a blood fluid sample. Particles can be included in a first and second sample fluid. Exemplary systems can include a flow cell that has a flow path configured to transmit a flow of sheath fluid. The sheath fluid may have a viscosity that is different from a blood fluid sample viscosity. In some cases, sheath fluid viscosity is greater than blood fluid sample viscosity. In some cases, the coating fluid has a coating fluid viscosity that differs from the sample fluid viscosity by a viscosity difference, and the viscosity difference has a value within a predetermined range of viscosity difference. Systems may also include a sample fluid injection system in fluid communication with the flow path. The sample fluid injection system can be configured to inject the sample fluids into the flowing sheath fluid within the flow cell so as to provide a stream of sample fluid having a first thickness adjacent to the injection tube. The flow path of the flow cell may have a decrease in flow path size such that the thickness of the sample fluid stream decreases from the initial thickness to a second thickness adjacent to an image capture site. Furthermore, the systems may include an image capture device aligned with the image capture site so as to image a first plurality of particles of the first sample fluid at the image capture site of the flow cell. In addition, the systems can include a processor coupled to the sample fluid injector system and the image capture device. The processor can be configured to stop an injection of the first sample fluid into the flowing coating fluid and inject the second sample fluid into the flowing coating fluid so that sample fluid transients are initiated, and to image a second plurality of the particles of the second sample fluid at the flow cell image capture site after the sample fluid transients and within 4 seconds after imaging the first plurality of particles. In exemplary systems, the difference in viscosity between the blood and coating fluid samples, in combination with the decrease in flow path size, is effective to hydrofocus the first and second sample fluids at the image capture site of the flow cell, while a viscosity agent in the sheath fluid maintains cell viability in the first and second sample fluids so as to leave cell structure and contents intact as the cells extend from the sample fluid stream to the fluent coating fluid.
[0050] In some systems, the injection tube includes an internal volume based on a ratio of an injection tube flow area cross section to a flow cell flow area cross section, a cross section ratio from the injection tube flow area to an outside diameter of the flow cell or a ratio of the injection tube flow area cross section to a sample stream flow area cross section. In some cases, the decrease in flow path size is defined by opposing walls of the flow path that angulate radially inward along the flow path, generally symmetrical around a transverse plane that bisects the first and second thickness of the sample fluid stream. In some cases, the symmetry of the decrease in flow path size is effective in limiting the RBC imaging orientation misalignment in the blood fluid sample to less than about 20%. In some cases, a distal portion of the sample fluid injection tube is positioned an axial separation distance from the image capture site and the axial separation distance has a value in a range from about 16 mm to about 26 mm. mm. In some cases, the injection tube includes a proximal portion that has a first cross-sectional area of flow and a distal portion that has a second cross-sectional area of flow, and the cross-sectional area of flow of the proximal portion is greater than 1.5 times the flow cross-sectional area of the distal portion. In some cases, the sample fluid has a transit time through the flow cell in a range of about 2 to 4 seconds. In some cases, the flow cell is configured to receive sheath fluid from a source of sheath fluid in the flow path in a first flow direction that is perpendicular to the second direction of sheath fluid flow along the flow path. flow at the imaging site. In some cases, the flow cell includes an auto focus target for the image capture device.
[0051] Embodiments of the present invention encompass systems and methods for quantifying cells or particles present in a blood fluid sample using exemplary detection range extension techniques or dynamics.
[0052] For example, exemplary embodiments encompass techniques for correcting inaccurate particle counts associated with at least one detection range based on a parameter, such as particle volume. By operating the apparatus as described in the present disclosure, particles that are outside the detection range in concentration and/or in volume can be detected and measured accurately.
[0053] As used herein, the term "detection limit" or "out of detection range" associated with a particle counter used in this disclosure will be understood to encompass a range, where the particle count is more accurate and/ or outside where particle counting is less accurate or even inoperable. A detection range can include an upper and/or lower detection limit, typically expressed as a maximum or minimum concentration, but possibly also expressed as a maximum or minimum frequency at which particles are counted within a given precision tolerance. Therefore, embodiments of the present invention encompass systems and methods for parallel flow cell and impedance analysis of blood fluid samples for the quantification of species counts made at irregular and/or abundant periods.
[0054] A detection range can be based on concentration, which can include a local concentration and/or other specific criteria or criteria. For example, a particle such as a cell or blood fragment less than a normal PLT (ie, having a diameter less than 2 µm) may be difficult to detect and accurately count in a particle counter. An abnormal cell larger than a normal white blood cell (ie, one that has a diameter greater than 15 µm) can be difficult to detect and accurately count in a particle counter. Also, at high concentrations, RBCs and PLTs can be difficult to accurately count. Even after dilution, RBCs and PLTs can aggregate to form nodules, resulting in false particle count readings obtained using a particle counter. Furthermore, it is difficult to provide an accurate count of some immature or abnormal blood cells present in the sample at low concentrations.
[0055] As an example, using the apparatus described in this document and the measurement detection range, the upper detection limit for WBCs can be extended up to 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000 or 1,000,000 per (unit volume) in some modes. The lower detection limit for PLTs can be extended below 20,000, 19,000, 18,000, 17,000, 16,000, 15,000, 14,000, 13,000, 12,000, 11,000, 10,000, 9,500, 9,000, 8,500, 8,000, 7,500, 7,000, 6,500, 6,000, 5,500, 5,000, 4,500, 4,000, 3,500, 3,000, 2,500, 2,000, 1,500 or 1,000 or 500 per μL, in some modalities.
[0056] Associated, the exemplary modalities cover techniques to correct inaccurate results obtained in a particle counter by differentiating different classes (including members of each class) of particles detected in a channel. As described in this document, some particles have a similar volume or morphology and can be detected in a channel. For example, clusters or nodules of PLTs, "giant" PLTs, and nucleated RBCs can be counted as "WBCs" in a channel designed to detect WBCs. In addition, other species such as unlysed cells, cryoglobulin, heinz bodies, and malaria parasites can be counted as "WBCs" to provide a higher WBC count than actually exists in the sample. Similarly, the high concentration of giant WBCs and PLTs can be counted as "RBCs" and result in a red blood cell count higher than the true value. The presence of microcytic red cells, red cell inclusions, white blood cell fragments, dust particles, hemolysis/schistocytes, and even electronic/electrical noise can result in a higher-than-real PLT count. Conversely, clotted and stained cells within the same class, or the conflict of one class of cells with another class may result in an inaccurate and lower count of the corresponding class of cells in the particle counter.
[0057] In some aspects of the methods of this disclosure, a first category and/or subcategory of particles is present in the sample at a concentration above a detection range applicable to the first category and/or subcategory of particles; and a second category and/or subcategory of particles is present in the sample in a detection range applicable to the second category and/or subcategory of particles. In other aspects of the methods of this invention, the first category and/or subcategory of particles is present in the sample at a concentration below a detectable range applicable to the first category and/or subcategory of particles and the second category and/or subcategory of particles is present in the sample in a detection range applicable to the second category and/or subcategory of particles. In other aspects, the first category and/or subcategory of particles comprises at least one type of abnormal blood cells, immature blood cells, blood cells in nodules, blood cells having a diameter greater than 15 microns and blood cells which have a diameter less than 2 microns; and the second category and/or subcategory of particles comprises white blood cells.
[0058] By operating the apparatus as described in this disclosure, particles that are erroneously counted as another particle type in a particle counter channel can be measured separately and accurately. Exemplary methods can also be used to determine a particle count or particle concentrations that cannot be accurately detected in the particle counter. Such particles include, but are not limited to, particles outside of normal volume ranges and/or particles present in concentrations near or outside the upper or lower ends of concentrations detectable in the particle counter. Associated with operating a system apparatus as described, specifically comprising a particle counter and an image analyzer in combination with the exemplary compositions of particle contrast agent and PIOAL as described in this disclosure, some particles that may be erroneously counted as another type of particle in a particle counter channel can be measured separately and accurately. The methods of this invention can further be used in some cases to determine particle counts or particle concentrations that cannot be accurately detected in the particle counter. Such particles include, but are not limited to, particles outside of a detection range and/or particles present at concentrations near or beyond the upper and lower ends of detectable concentrations in the particle counter. This occurs through the application of information obtained through the image analyzer.
[0059] In general, operating an apparatus as disclosed herein, for example, with the use of exemplary compositions of particle contrast agent fluids and PIOAL coating, analyzing a sample that contains particles such as blood cells or other fragments can be performed in detection ranges that are outside the nominal detection range for a particle counter. Associatedly, with the use of systems and compositions as described in this document, analysis of a blood fluid sample can be performed over extended detection ranges based on a parameter such as particle concentration or volume. Extended detection ranges may be outside the detection range for a particle counter.
[0060] In some embodiments, a system or apparatus may include a particle counter. In other embodiments, such a particle counter has at least one detection range. In certain aspects, the analyzer and processor can be configured to provide additional information to correct testing errors associated with the particle counter and further determine an accurate particle count or concentration of different categories and/or subcategories of particles in the sample. Considering that the information is available by the particle counter and the analyzer regarding the counts, one or more reasons and/or the distribution over at least two of the categories and/or subcategories of particles, then errors in the counts, in the Particle counter categorization and/or subcategorization can be corrected and counts, categories and/or subcategories that were not initially reported by the particle counter can be derived.
[0061] Embodiments of the present invention encompass certain focusing techniques that allow hematology systems and methods to produce high quality images of particles that are present in fluid blood samples. Such high quality images provide the basis for achieving high levels of discrimination that are useful for accurately classifying cells and allow the use of optical systems that have a high magnification objective and high numerical aperture. Exemplary optical alignment or focusing techniques facilitate the production of high-resolution images with a short depth of field that corresponds to a thin sliver of fluid sample that carries the particles.
[0062] In some cases, hematology systems can be refocused to a normal base to be adjusted for changes in local temperature and other factors. For example, autofocus techniques as discussed in this document can compensate for thermal expansion or other factors present in a hematology analyzer, which changes the distance between an imaging objective and a flow cell and therefore negatively impacts the Imaging results, for example, by producing an image that is out of focus. Embodiments of the present invention also encompass autofocus systems and methods for hematology instruments that involve automatically focusing an imaging system without the need for a focus liquid or solution or other user intervention. For example, exemplary autofocus techniques might involve getting an initial focus on a fixed target relative to the flow cell, rather than using techniques that are based on maximizing the contrast of the individual appearing in the image.
[0063] Certain embodiments of the present invention are based, at least in part, on the observation that the position of the flow within the flow cell does not change in response to temperature fluctuations and may involve focusing on a target somewhere in the flow cell and then use a fixed offset to achieve a good focus on the sample stream. Such approaches can be implemented without the use of a focus solution that flows through the flow cell and can be carried out automatically and completely transparent to the user.
[0064] According to some embodiments, this disclosure relates to a visual analyzer for generating images of a sample comprising particles suspended in a liquid, wherein the apparatus includes a flow cell coupled to a sample source and a source of a PIOAL, where the flow cell defines an internal flow path, where the flow cell is configured to direct a flow of a tape-shaped sample stream wrapped with the PIOAL through a display zone in the cell flow. An objective lens associated with a high-resolution optical imaging device is arranged on an optical geometric axis that intercepts the tape-shaped sample stream. The relative distance between the objective and the flow cell is variable through the operation of a motor drive coupled to a controller to resolve and collect a digitized image on a photosensor array. An auto focus pattern or imaging target is provided in a fixed position relative to the flow cell, where the auto focus pattern is located at a predetermined distance from the plane of the sample stream prepared in tape format. A light source illuminates the tape-shaped sample stream and auto focus pattern. At least one digital processor is associated with the coupled controller to operate the motor drive. The processor is also arranged to analyze the scanned image. The processor determines a focus position from the auto focus pattern to generate a focused image and then moves relative to the objective and flow cell along the predetermined distance (eg, a shift distance) from the focused position to focus the high-resolution optical imaging device on the tape-format sample stream.
[0065] In one aspect, embodiments of the present invention encompass methods for generating particle images in a blood fluid sample using a particle analysis system. The particle analysis system can be configured to perform geometric hydrofocus. In some cases, the system can be configured to perform combined viscosity and geometric hydrofocus. In some cases, particles can be included in a blood fluid sample that has a sample fluid viscosity. Exemplary methods can include flowing a sheath fluid along a flow path of a particle analysis system flow cell. In some cases, the sheath fluid may have a sheath fluid viscosity that differs from the sample fluid viscosity by a viscosity difference within a predetermined range of viscosity difference. The methods may also include injecting the blood fluid sample into the flowing sheath fluid within the flow cell so that the blood fluid sample fluid flows in a sample flow stream with a larger flow stream width. that a flux stream thickness, in which the sample flux stream flows through a decrease in size of the flux path and traverses an imaging axis. Furthermore, the methods may include focusing an image capture device by imaging an imaging target that has a fixed position relative to the flow cell. In addition, the methods may include acquiring a focused image of the particles suitable for particle characterization and counting, within the flow stream with the image capture device, where the image capture device is focused on the flow stream. of sample using an offset distance. Under some embodiments, a difference in viscosity between the sheath fluid and the blood fluid sample, in combination with a decrease in flow path size, is effective to hydrofocus the sample flow stream on the geometric axis. of imaging while a viscosity agent in the sheath fluid maintains cell viability in the sample flow stream so as to leave cell structure and content intact when the cells extend from the sample flow stream to the sheath fluid fluent. In some cases, the sample flow stream has a thickness on the imaging axis in a range from about 2 µm to about 10 µm. In some cases, the flow path has a thickness of about 150 µm on the geometric axis of imaging. In some cases, the imaging target is located in a viewport window disposed between the sample stream stream and the image capture device. In some cases, the imaging target is located in an illumination window and the sample stream stream is disposed between the illumination window and the image capture device. In some cases the offset distance is zero. In some cases, the imaging target is located between an illumination window and a viewport window. In some cases, in the capture step, the image capture device is focused on the sample stream stream by adjusting a focal length of the image capture device based on the offset distance.
[0066] According to some embodiments, the focused image capture process includes adjusting a distance between the image capture device and the flow cell using the offset distance. In some cases, adjusting the distance between the image capture device and the flow cell includes moving a component of the image capture device. The component of the image capture device can be a zoom lens, a mirror of the image capture device, or an assembly that includes the image capture device. In some cases, adjusting the distance between the image capture device and the flow cell includes moving the flow cell. In some cases, adjusting the distance between the image capture device and the flow cell includes moving at least one optical element of the image capture device and the flow cell. In some cases, the offset distance is a distance along the imaging axis between the imaging target and the sample stream stream. In some cases, the offset distance is a distance difference between a first focal distance between the image capture device and the target and a second focal distance between the image capture device and the sample stream stream. In some cases, the methods include an autofocus step that involves injecting a test fluid sample into the coating fluid to form a test sample flow stream within the flow cell, obtaining a first focused image of the imaging target with the image capture device, so that the focused imaging target and the image capture device define a first focal length, obtaining a second focused image of the test sample stream stream using the image capture device, so that the focused test sample stream stream and the image capture device define a second focal length and obtain the offset distance by calculating a difference between the first focal length and the second focal length. In some cases, the test fluid sample is the same blood fluid sample and the test sample flow stream is equal to the sample flow stream. In some cases, the auto focus step establishes a focal plane associated with the image capture device and the focal plane remains stationary relative to the image capture device. In some cases, the image capture device is focused on the sample flow stream using a temperature such as a sample fluid temperature, a sheath fluid temperature, a flow cell temperature, or a temperature of image capture device. In some cases, the image capture device can be focused on the sample flow stream using a temperature, such as a flow cell temperature at the imaging site, a flow cell temperature at an upstream location. of the imaging site and a flow cell temperature at a location downstream of the imaging site. In some cases, the image capture device can be focused on the sample flow stream using a rate of temperature change, such as a rate of change of temperature of sample fluid, a rate of change of temperature of sheath fluid, a flow cell temperature change rate, or an image capture device temperature change rate.
[0067] According to some embodiments, the methods may include detecting an auto focus reset signal and repeating the auto focus and image capture steps in response to the auto focus reset signal. In some cases, the auto focus reset signal includes or is based on a change in temperature, a decrease in focus quality, an elapsed time interval, or user input. In some cases, focusing of the image capture device on the sample stream stream is performed independently of a temperature of the image capture device. In some cases, the imaging target includes a scale for use in positioning the imaging axis of the image capture device in relation to the sample stream stream. In some cases, the imaging target includes an iris aligned with the geometric imaging axis so that the imaged particles are arranged in an aperture defined by the iris and one or more iris edge portions are imaged during autofocus. In some cases, the image capture device is focused on the sample flow stream by implementing the axial rotation of the image capture device around the geometric axis of imaging, the axial rotation of the flow cell around an axis axis that extends along the imaging axis and in the field of view of the imaging device, tip rotation of the image capture device around a geometric axis that extends along the flow path, tip rotation of the flow cell around a geometric axis that extends along and within a flow path, tilt rotation of the image capture device around a geometric axis that spans the flow path and the imaging geometric axis, and /or tilt rotation of the flow cell around a geometric axis that traverses the flow path and the imaging axis and in the field of view of the cap device image ture. In some cases, the image capture device is focused on the sample flow stream by deploying a rotation of the flow cell, where the rotation is centered in the field of view of the image capture device. In some cases, the image capture device's autofocus includes determining an optimal focus position from a plurality of focus positions.
[0068] In another aspect, embodiments of the present invention encompass methods for imaging particles in a blood fluid sample. Exemplary methods may include flowing a sheath fluid along a flow path of a flow cell and injecting the blood fluid sample into the fluent sheath fluid within the flow cell such that the blood fluid sample blood flows in a sample stream stream with a stream stream width greater than a stream stream thickness. The flow cell can have an associated temperature. The methods may also include focusing an image capture device along an imaging axis in the flow stream to a first focal state while the temperature associated with the flow cell is at a first temperature, and capturing a first focused image of a first subset of the particles within the flow stream with the image capture device in the first focal state. Methods may additionally include determining that the temperature associated with the flow cell has undergone a change from the first temperature to a second temperature and automatically adjusting the focus of the image capture device from the first focal state to a second focal state in response to the change in temperature and a known relationship between the flow cell temperature and the desired focus. Furthermore, the methods may include capturing a second focused image of a second subset of the particles within the flow stream with the image capture device in a second focal state. In some cases, adjusting the focus of the image capture device involves adjusting a distance between the image capture device and the flow cell using the change in temperature and the known relationship between the flow cell temperature and the focus wanted. In some cases, adjusting the focus of the image capture device involves adjusting a focal length of the image capture device using the change in temperature and the known relationship between the flow cell temperature and the desired focus. In some cases, adjusting the focus of the image capture device involves deploying an axial rotation of the image capture device around the imaging axis, an axial rotation of the flow cell around a geometric axis that extends along. of the imaging axis and within the imaging device's field of view, a tip rotation of the image capture device around a geometric axis that extends along the flow path, a tip rotation of the imaging cell. flow around a geometric axis that extends along and within the flow path, a tilt rotation of the image capture device around a geometric axis that spans the flow path and the imaging geometric axis and/ or an inclination rotation of the flow cell about a geometric axis that traverses the flow path and the imaging axis and within the device's field of view. image capture tool. In some cases, the image capture device is focused on the sample flow stream by deploying a rotation of the flow cell, where the rotation is centered in the field of view of the image capture device.
[0069] In another aspect, embodiments of the present invention encompass particle analysis systems that perform geometric hydrofocus or, in some cases, combined viscosity and geometric hydrofocus, to image particles in a blood fluid sample. Exemplary systems may include a flow cell that has a flow path with an injection tube and an imaging window with an imaging axis therethrough. The flow cell flow path may have a decrease in flow path size. Systems may also include a sheath fluid inlet in fluid communication with the flow path. Furthermore, the systems can include a blood fluid inlet in fluid communication with the infection tube. The blood fluid inlet can be configured to inject the blood fluid sample into the flowing sheath fluid within the flow cell so that the blood fluid sample flows in a sample flow stream having a stream width of flux greater than a thickness of flux stream. In some cases, the sheath fluid may have a viscosity that is greater than a blood fluid sample viscosity. In addition, the systems may include an image capture device, a focusing mechanism configured to define a focal state of the image capture device with respect to the flow cell, and an imaging target that has a fixed position with respect to the cell. flow. In some cases, the imaging target and sample stream stream may define an offset distance along the imaging axis. In addition, the systems may include a processor and a focusing module that has machine readable code embedding tangible media executed in the processor to operate the focusing mechanism to define the focal state of the image capture device suitable for characterization. and particle counting using displacement distance. In some cases, a viscosity difference between the sheath fluid and the blood fluid sample, in combination with a decrease in flow path size, is effective to hydrofocus the sample flow stream on the imaging axis. while a viscosity agent in the coating fluid maintains cell viability in the sample flow stream so as to leave the structure and contents of the cells intact as the cells extend from the sample flow stream into the flowing coating fluid. In some cases, the focusing mechanism may include a drive motor configured to adjust a distance between the image capture device and the flow cell. In some cases, the imaging target is located in a viewport window disposed between the sample stream stream and the image capture device. In some cases, the imaging target is located in an illumination window and the sample stream stream is disposed between the illumination window and the image capture device. In some cases, the system is configured to perform a capture step that includes focusing the image capture device on the sample stream stream by adjusting a focal length of the image capture device based on the offset distance. In some cases, the system is configured to perform a capture step to obtain a focused image by adjusting a distance between the image capture device and the flow cell using the offset distance. In some cases, the system is configured to adjust the distance between the image capture device and the flow cell by moving the flow cell. In some cases, the system is configured to perform an autofocus step that includes injecting a test fluid sample into the coating fluid to form a test sample flow stream within the flow cell, obtaining a first focused image of the imaging target using the image capture device, so that the focused imaging target and the image capture device define a first focal length, obtaining a second focused image of the test sample stream stream using the capture device of image, so that the focused test sample stream stream and the image capture device define a second focal length and obtain the offset distance by calculating a difference between the first focal length and the second focal length. In some cases, the system is configured to focus the image capture device on the sample flow stream using a temperature such as a sample fluid temperature, a sheath fluid temperature, a flow cell temperature, or a temperature of image capture device. In some cases, the system is configured to detect an auto focus reset signal and repeat the auto focus and image capture steps in response to the auto focus reset signal.
[0070] In another aspect, embodiments of the present invention encompass systems for generating particle images in a blood fluid sample. Exemplary systems may include a flow cell having a flow path with an injection tube and an imaging window with an imaging axis therethrough, a sheath fluid inlet in fluid communication with the flow path, and a blood fluid inlet in fluid communication with the injection tube. The blood fluid inlet can be configured to inject the blood fluid sample into the flowing sheath fluid within the flow cell so that the blood fluid sample flows in a sample flow stream with a stream width of flux greater than a thickness of flux stream. Systems may also include an image capture device, a focusing mechanism configured to define a focal state of the image capture device with respect to the flow cell, a temperature sensor thermally coupled to the flow cell, a processor, and a focusing module. The focusing module may include machine readable code embedding tangible media executed in the processor to operate the focusing mechanism to define the focal state of the image capture device, suitable for characterizing and counting particles in response to a change on the temperature detected by the temperature sensor and a known relationship between the temperature and the desired focus. In some cases, the focusing mechanism includes a drive motor configured to adjust a distance between the image capture device and the flow cell.
[0071] In another aspect, embodiments of the present invention encompass methods for analyzing cells in a blood fluid sample. Exemplary methods may include flowing a sheath fluid along a flow path of a flow cell and injecting the blood fluid sample into the fluent sheath fluid within the flow cell so that the sample fluid flows. blood fluid flows in a sample flow stream with a flow stream width wider than a flow stream thickness. The sample flow stream may be offset along an imaging axis of a flow cell imaging window by a first distance. The methods may further include automatically focusing an image capture device by imaging an imaging target affixed to the flow cell. The imaging target may be positioned a second distance from the imaging window along the imaging axis. Furthermore, the methods may include capturing focused images of cells, suitable for cell characterization and counting, within the flow stream with the image capture device. In some cases, the image capture device may be focused on the sample stream stream using the auto focus step and a known relationship between the first distance and the second distance.
[0072] In another aspect, embodiments of the present invention encompass systems for analyzing cells in a blood fluid sample. Exemplary systems may include a flow cell that has a flow path with an injection tube and an imaging window with an imaging axis therethrough. The systems may also include a sheath fluid inlet in fluid communication with the flow path and a blood fluid inlet in fluid communication with the infection tube. The blood fluid inlet may be configured to inject the blood fluid sample into the fluent sheath fluid within the flow cell, so that the blood fluid sample flows in a sample flow stream having a width of flux stream greater than a flux stream thickness. The sample flow stream may be offset along the geometric axis of imaging from the flow cell imaging window by a first distance. The systems may also include an image capture device steerable along the geometric axis of imaging. The image capture device may include a focusing mechanism. Furthermore, the systems can include an imaging target affixed to the flow cell. The imaging target may be at a second distance from the imaging window surface along the imaging axis. In addition, systems can include a processor coupled to the focusing mechanism. The processor can be configured to capture focused images of particles in the flow stream, sufficient for cell characterization and counting, by focusing the image capture device on the target and using a known relationship between the first distance and the second distance.
[0073] In yet another aspect, embodiments of the present invention encompass systems for analyzing cells in a blood fluid sample. Exemplary systems may include a flow cell that has a flow path with an injection tube and an imaging window with an imaging axis therethrough. Furthermore, the systems may include a sheath fluid inlet in fluid communication with the flow path and a blood fluid sample inlet in fluid communication with the injection tube. The sample fluid inlet can be configured to inject the blood fluid sample into the fluent sheath fluid within the flow cell so that the blood fluid sample flows in a sample flow stream having a width of flux stream greater than a flux stream thickness. Furthermore, the systems may include an image capture device steerable along the geometric axis of imaging and the image capture device may include a focusing mechanism. Systems may further include a temperature sensor thermally coupled to the flow cell and a processor coupled to the temperature sensor and focusing mechanism. In some cases, the processor is configured to adjust the image capture device's focus, sufficient for cell characterization and counting, in response to a change in temperature and a known relationship between temperature and desired focus.
[0074] According to some embodiments, a visual analyzer may include a flow cell coupled to a source of a sample and a source of a sheath fluid. The flow cell can define an internal flow path and can be configured to direct a flow of sample enveloped with sheath fluid through a viewing zone in the flow cell. The analyzer may also include a high-resolution optical imaging device with an objective on an optical geometric axis that intercepts the tape-shaped sample stream, and a relative distance between the objective and the flow cell may be variable during the operation of a motor drive to resolve and collect a digitized image onto a photosensor array. The analyzer may further include an autofocus pattern that has a fixed position relative to the flow cell, wherein the autofocus pattern is located at an offset distance from the plane of the tape-shaped sample stream. The offset distance can be predetermined. The analyzer may also include a light source configured to illuminate the tape-shaped sample stream and auto focus pattern. Furthermore, the analyzer may include at least one digital processor coupled to operate the motor drive and to analyze the digitized image. The processor can be configured to determine a focus position of the auto focus pattern and to relatively move a high-resolution optical imaging device and the flow cell along the focused position displacement distance, whereby the high resolution optical imaging device becomes focused on the tape-format sample stream. According to some embodiments, the auto focus pattern includes shapes of limited size and the displacement distance is sufficient so that the shapes are substantially invisible in the digitized image when focused on the tape-shaped sample stream. In some cases, the optical axis is substantially perpendicular to the tape-shaped sample stream.
[0075] In another aspect, embodiments of the present invention encompass methods for focusing a visual analyzer for sample analysis. Exemplary methods may include focusing a high-resolution optical imaging device in a fixed autofocus pattern relative to a flow cell, wherein the autofocus pattern is located at a displacement distance from a shaped sample stream. of tape that is predetermined, wherein the high-resolution optical imaging device with an objective on an optical geometric axis that intercepts the tape-shaped sample stream, wherein a relative distance between the high-resolution optical imaging device and the flow cell is variable through the operation of a motor drive, where the high resolution optical imaging device is configured to resolve and collect a digitized image onto a photosensor array. Furthermore, the methods may include operating the motor drive over the displacement distance to focus the high resolution optical imaging device on the tape-format sample stream.
[0076] In another aspect, embodiments of the present invention encompass methods for generating images of particles in a sample. Exemplary methods may include providing a visual analyzer for a sample that comprises particles suspended in a liquid, which establish a flow that has laminar sections that have the highest and lowest viscosity on the visual analyzer. The analyzer may include a flow cell coupled to a sample source and a source of a PIOAL that has a viscosity greater than the viscosity of the sample. The flow cell can define an internal flow path and can direct a flow of sample wrapped with the PIOAL through a viewing zone in the flow cell. The analyzer may further include a high-resolution optical imaging device with an objective on an optical geometric axis that intercepts the tape-shaped sample stream, where the relative distance between the high-resolution optical imaging device and the The flow cell is variable through the operation of a motor drive to resolve and collect a digitized image onto a photosensor array. The analyzer may further include an autofocus pattern that has a fixed position relative to the flow cell, wherein the autofocus pattern is located at an offset distance from the plane of the tape-shaped sample stream that has been predetermined, a light source configured to illuminate the tape-shaped sample stream and the auto focus pattern, at least one digital processor coupled to operate the motor drive and to analyze the digitized image, wherein the processor is configured to determining a focus position of the auto focus pattern and to relatively move the high resolution optical imaging device and the flow cell along the offset distance from the focused position, whereby the high resolution optical imaging device moves makes it focused on the tape-shaped sample stream. In some cases, an analyzer may include a flow cell coupled to a sample source and a source of a PIOAL where the flow cell defines an internal flow path and is configured to direct an enveloped sample flow with the PIOAL through a viewing zone in the flow cell, a high-resolution optical imaging device with an objective on an optical geometric axis that intercepts the tape-shaped sample stream, in which a relative distance between the objective and the flow cell. flux is variable by operating a motor drive to resolve and collect a digitized image onto a photosensor array, where an auto focus pattern has a fixed position relative to the flow cell, where the auto focus pattern is located at an offset distance from the plane of the tape-shaped sample stream that has been predetermined, a light source configured to illuminate the f-shaped sample stream. ita and the autofocus pattern and at least one digital processor coupled to operate the motor drive and to analyze the digitized image, wherein the processor is configured to determine a focus position of the autofocus pattern and to relatively shift the device high resolution optical imaging device and the flow cell along the displacement distance from the focused position, whereby the high resolution optical imaging device becomes focused on the tape-shaped sample stream.
[0077] A particle contrast agent composition is developed to color a blood fluid sample that is imaged in an automated particle analysis system. The particle contrast agent composition may include at least one particle contrast agent selected from the group consisting of Crystal Violet, Novo Methylene Blue, Methyl Green, Eosin Y and Safranin O. The particle contrast agent composition it can additionally include a permeabilizing agent selected from the group consisting of a surfactant, a saponin, a quaternary ammonium salt, a nonionic surfactant, a detergent; and a zwitterionic surfactant. The particle contrast agent composition can additionally include a fixing agent selected from the group consisting of gluteraldehyde and formaldehyde.
[0078] In one embodiment, the permeabilizing agent can be a saponin present in amounts sufficient to result in concentrations between about 50 mg/L and about 750 mg/L under staining conditions. The fixing agent can be a gluteraldehyde present in sufficient amounts to result in concentrations of 0.1% or less under staining conditions.
[0079] In one embodiment, the at least one particle contrast agent can include Crystal Violet, New Methylene Blue and Eosin-Y. The ratio of Crystal Violet to New Methylene Blue can be between about 1:90 to about 1:110 under staining conditions. Eosin-Y can be present in sufficient amounts to result in concentrations from about 3 µm to about 300 µm under staining conditions.
[0080] In one embodiment, the Violet Crystal may be present in sufficient amounts to result in concentrations from about 6 µm to about 10 µm under staining conditions. Novo Methylene Blue can be present in sufficient amounts to result in concentrations from about 70 µm to about 2.4 mM under staining conditions. Eosin-Y can be present in sufficient amounts to result in concentrations from about 10 µm to about 50 µm under staining conditions.
[0081] In some embodiments, the Violet Crystal is approximately 90% pure or greater. New Methylene Blue can be approximately 70% pure or greater. Eosin-Y can be approximately 80% pure or greater.
[0082] In some embodiments, Crystal Violet is present in sufficient amounts to result in concentrations of about 7.8 µm under staining conditions. Novo Methylene Blue is present in sufficient amounts to result in concentrations of about 735 µm under staining conditions. Eosin-Y can be present in sufficient amounts to result in concentrations of about 27 µm under staining conditions. In some embodiments, the particle contrast agent composition can additionally include buffer components.
[0083] A method is disclosed for treating particles from a blood fluid sample that will be imaged using an automated particle analysis system. The method may include combining the blood fluid sample with a particle contrast agent composition to obtain a sample mixture and incubating the sample mixture at a temperature between about 37°Celsius and about 60°Celsius for less than 90 seconds. The particle contrast agent composition includes at least one particle contrast agent selected from the group consisting of Crystal Violet, New Methylene Blue, Methyl Green, Eosin Y and Safranin O; a permeabilizing agent selected from the group consisting of a surfactant, a saponin, a quaternary ammonium salt, a nonionic surfactant, a detergent; and a zwitterionic surfactant; and a fixing agent selected from the group consisting of gluteraldehyde and formaldehyde.
[0084] In some embodiments, the particle contrast agent may include Crystal Violet and New Methylene Blue in sufficient amounts to result in a ratio of Crystal Violet to New Methylene Blue between about 1:1 to about 1: 500 under staining conditions. Saponin can be included in amounts sufficient to result in concentrations between about 50 mg/L and about 750 mg/L under staining conditions. Gluteraldehyde can be included in amounts sufficient to result in concentrations of 0.1% or less under staining conditions. The method can include mixing the sample by being incubated for less than 60 seconds.
[0085] In some embodiments, the particle contrast agent composition may include Crystal Violet present in amounts sufficient to result in concentrations of about 6 µm to about 10 µm under staining conditions. Novo Methylene Blue can be present in sufficient amounts to result in concentrations from about 70 µm to about 2.4 mM under staining conditions. Eosin-Y can be present in sufficient amounts to result in concentrations from about 10 µm to about 50 µm under staining conditions. The blood fluid sample can be combined with the particle contrast agent composition at a ratio of the blood fluid sample to the particle contrast agent composition of about 1:2 to about 1:10.
[0086] In some embodiments, the method may include heating the sample mixture to between 46°C and about 49°C for between 40 and 50 seconds.
[0087] In some embodiments, the Violet Crystal may be approximately 90% pure or greater. New Methylene Blue can be approximately 70% pure or greater. Eosin-Y can be approximately 80% pure or greater.
[0088] In some embodiments, the particle contrast agent may include Crystal Violet present in amounts sufficient to result in concentrations of about 7.8 µm under staining conditions; Novo Methylene Blue present in sufficient amounts to result in concentrations of about 735 µm under staining conditions; and Eosin-Y present in sufficient amounts to result in concentrations of about 27 µm under staining conditions. The particle contrast agent composition can additionally include buffer components. The blood fluid sample can be combined with the particle contrast agent composition at a ratio of the blood fluid sample to the particle contrast agent composition of about 1:3 to about 1:4. The sample mixture can be heated to about 47°C for about 45 seconds.
[0089] The features described above and many other additional features and advantages of the embodiments of the present invention will become apparent and further understood by reference to the following detailed description when considered in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0090] Figure 1 is a schematic illustration, partially in section rather than to scale, showing operational aspects of an exemplary flow cell and autofocus system and optical high resolution imaging device for sample image analysis using a digital image processing, in accordance with embodiments of the present invention.
[0091] Figures 1A and 1B show an optical bank arrangement, according to embodiments of the present invention.
[0092] Figure 1C is a block diagram of a hematology analyzer, according to the embodiments of the present invention.
[0093] Figure 1D shows a flowchart of a process, according to embodiments of the present invention.
[0094] Figure 1E is a simplified block diagram of an exemplary module system, according to the embodiments of the present invention.
[0095] Figure 2 shows parts of a flow cell, according to the embodiments of the present invention.
[0096] Figures 3, 3A and 3B show aspects of flow cells, according to the embodiments of the present invention.
[0097] Figure 4 illustrates aspects of an analyzer system, according to the embodiments of the present invention.
[0098] Figure 4A shows a flow cell, according to the embodiments of the present invention.
[0099] Figures 4B-1 and 4B-2 show aspects of flow cell flow paths, according to the embodiments of the present invention.
[00100] Figures 4A-1 and 4A-2 illustrate changes in sample stream dimensions, in accordance with embodiments of the present invention.
[00101] Figure 4C represents features of an exemplary cannula or sample feed tube, according to the embodiments of the present invention.
[00102] Figure 4D represents a longitudinal cross-section of the cannula, according to the embodiments of the present invention.
[00103] Figure 4E illustrates a cross section of a distal flat section, according to the embodiments of the present invention.
[00104] Figure 4F illustrates a cross-section of a central tapered section, according to embodiments of the present invention.
[00105] Figure 4G illustrates a cross-section of a proximal section, according to the embodiments of the present invention.
[00106] Figure 4C-1 shows an exemplary sample feeding cannula or tube, in accordance with the embodiments of the present invention.
[00107] Figure 4D-1 shows an exemplary sample feeding cannula or tube, in accordance with the embodiments of the present invention.
[00108] Figure 4H shows a portion of a cannula, in accordance with embodiments of the present invention.
[00109] Figures 4I and 4J represent flow cells, according to the embodiments of the present invention.
[00110] Figures 4K and 4L show a sample stream flowing through an image capture site of a flow cell, in accordance with the embodiments of the present invention.
[00111] Figures 4K-1, 4K-2 and 4K-3 show the target imaging site, according to embodiments of the present invention.
[00112] Figure 4L-1 shows parabolic flux profiles, according to embodiments of the present invention.
[00113] Figures 4M and 4N show aspects of intracellular particle alignment, in accordance with embodiments of the present invention.
[00114] Figure 4O shows a comparison between images obtained with the use of PIOAL as a function of images obtained with the use of a non-PIOAL coating fluid, according to embodiments of the present invention.
[00115] Figures 4P and 4Q show a comparison between images obtained using a standard coating fluid and exemplary PIOAL fluid, according to embodiments of the present invention.
[00116] Figure 4R shows a graph of the percentage of non-aligned cells obtained using 0% to 30% glycerol in PIOAL with symmetric vs. flow cells. asymmetric, in accordance with embodiments of the present invention.
[00117] Figure 5 represents a timeline that corresponds to the injection of one or more sample fluids into a flow cell, according to embodiments of the present invention.
[00118] Figures 5A, 5B, 5C and 5D represent results obtained with the use of certain processing techniques, according to embodiments of the present invention.
[00119] Figure 5E represents image capture results based on a traditional microscope wet mount technique compared to a flow cell technique, according to embodiments of the present invention.
[00120] Figure 6 depicts aspects of an exemplary method for imaging a plurality of particles using a particle analysis system configured to perform combined viscosity and geometric hydrofocus, in accordance with embodiments of the present invention.
[00121] Figures 6A and 6B represent exemplary flow current characteristics, according to embodiments of the present invention.
[00122] Figure 6C represents aspects of an exemplary method for generating particle images in a blood fluid sample, according to embodiments of the present invention.
[00123] Figures 7 and 8 represent flow current strain rate aspects, according to embodiments of the present invention.
[00124] Figure 9A represents an exemplary autofocus target, according to embodiments of the present invention.
[00125] Figure 9B shows a captured image that includes portions of an autofocus target, in accordance with embodiments of the present invention.
[00126] Figures 10 and 11 represent exemplary autofocus targets, according to embodiments of the present invention.
[00127] Figure 12A represents an exemplary autofocus target, according to embodiments of the present invention.
[00128] Figure 12B shows a close view of the central portion of the auto focus target, according to embodiments of the present invention.
[00129] Figures 13A, 13B and 13C, represent views of a flow cell temperature sensor, according to embodiments of the present invention.
[00130] Figure 13D represents aspects of flow cell bubble removal techniques, according to embodiments of the present invention.
[00131] Figure 14 is a block diagram showing additional aspects of systems and methods to achieve a detection range extension or dynamics for particle analysis in blood samples, according to embodiments of the present invention.
[00132] Figure 15 shows an exemplary apparatus for analyzing a sample, according to embodiments of the present invention.
[00133] Figure 15A represents aspects of an exemplary counter or counting module, according to embodiments of the present invention.
[00134] Figure 16 represents aspects of systems and methods for measuring an amount of a first cell type in a blood fluid sample, in accordance with embodiments of the present invention.
[00135] Figure 17 shows a method for analyzing a sample containing particles, according to embodiments of the present invention.
[00136] Figure 18 illustrates an exemplary method for determining the concentration of two subcategories of particles, according to embodiments of the present invention.
[00137] Figures 19A, 19B, 19C and 19D show the detection of categories of particles, according to embodiments of the present invention.
[00138] Figures 20A and 20B provide cross-sectional side views illustrating aspects of imaging systems and methods, according to embodiments of the present invention.
[00139] Figure 20C represents an end cross-sectional view of a flow cell, according to embodiments of the present invention.
[00140] Figure 20D shows a focal length of the image capture device, according to embodiments of the present invention.
[00141] Figure 21 represents an elevation view showing embodiments of an autofocus pattern, according to embodiments of the present invention.
[00142] Figures 22A and 22B show focus configurations, according to embodiments of the present invention.
[00143] Figure 23 represents aspects of sample processing techniques, according to embodiments of the present invention.
[00144] Figure A1 is a schematic diagram of the preparation of a particle contrast agent composition, according to an embodiment.
[00145] Figure A2 is a flowchart of a fast one-step staining process, according to a modality.
[00146] Figure A3 is a representative illustration of stained white blood cells selected according to the one-step rapid staining process, according to a modality.
[00147] Figure A4 is a representative illustration of white blood cells selected from a sample stained with a particle contrast agent composition, according to an embodiment.
[00148] Figure A5 is a representative illustration of stained cells according to an early Example 1.
[00149] Figure A6 is a representative illustration of stained cells according to an early Example 2 .
[00150] Figure A7 is a representative illustration of cell staining in accordance with an early Example 3 .
[00151] Figure A8 is a representative illustration of cell staining, according to an early Example 4 .
[00152] Figure A9 is a representative illustration of stained cells, according to an early example.
[00153] Figure A10 is a representative illustration of stained cells according to an early Example 5 .
[00154] Figure A11 is a representative illustration of stained cells according to an early Example 6 . DETAILED DESCRIPTION OF THE INVENTION
[00155] The present disclosure relates to an apparatus, systems, compositions and methods for analyzing a sample that contains particles. In one embodiment, the invention relates to an automated particle imaging system comprising an analyzer which can be, for example, a visual analyzer. In some embodiments, the visual analyzer may additionally comprise a processor to facilitate automated image analysis.
[00156] According to this disclosure, a system comprising a visual analyzer is provided to obtain images of a sample comprising particles suspended in a liquid. The system can be useful, for example, in the characterization of particles in biological fluids, such as detection and quantification of erythrocytes, reticulocytes, nucleated red cells, platelets and white blood cells, including differential white blood cell count, categorization and subcategorization and analysis. Other similar uses, such as the characterization of blood cells from other fluids are also encompassed within the embodiments of the present invention. Typically, the blood fluid sample is introduced into a flowing sheath fluid and the combined sheath and sample fluids are compressed with a narrowed flow path transition zone that reduces the thickness of the fluid flow in sample tape . Therefore, particles such as cells can be oriented and/or compressed in the blood fluid sample by the surrounding viscous sheath fluid, for example, in combination with a geometric focusing effect provided by a narrowing transition zone. Similarly, internal features in blood cells can be aligned and oriented as a result of a viscosity differential between the sample fluid and the sheath fluid, for example, in combination with a geometric focusing effect provided by a zone. transition of narrowing.
[00157] To facilitate the capability, speed and efficiency by which particles such as cells are categorized and/or subcategorized, it is advantageous to provide clear, high quality images of blood cells for automated analysis through the data processing system. In accordance with the present disclosure, a prepared sample stream is disposed on a thin strip which has a stable position between opposite walls of a flow cell. The positioning of the sample stream and its flattening to a thin ribbon shape can be achieved by interlayer flow of a PIOAL introduced into the flow cell which differs in viscosity of the sample fluid and flows through a transition zone of symmetrical narrowing of a flow channel. Hematology - Particle Analysis System
[00158] Turning now to the drawings, Figure 1 schematically shows an exemplary flow cell 22 for transporting a sample fluid through a display zone 23 of a high resolution optical imaging device 24 at a setup for generating microscopic particle images in a stream of sample stream 32 using digital image processing. The flow cell 22 is coupled to a source 25 of sample fluid that may have undergone processing, such as contacting a particle contrast agent composition and heating. The flow cell 22 is further coupled to one or more sources 27 of an intracellular organelle and/or particle alignment liquid (IOPAL), such as a clear glycerol solution which has a viscosity that is greater than the viscosity of the sample fluid.
[00159] The sample fluid is injected through a flat slit in a distal end 28 of a sample feed tube 29 and into the flow cell 22 at a point where the PIOAL flow has been substantially established, resulting in a stable and symmetrical laminar flow of the PIOAL above and below (or on opposite sides) of the tape-shaped sample stream. Sample and PIOAL currents can be delivered through precision metering pumps that move the PIOAL with the injected sample fluid along a substantially narrowed flow path. PIOAL envelops and compresses the sample fluid in zone 21, where the flow path narrows. Therefore, the decrease in flow path thickness in zone 21 can contribute to a geometric focusing of the sample stream 32. The sample fluid strip 32 is wrapped and transported together with the PIOAL downstream of the narrowing zone 21, which passes in front of or otherwise through the viewing zone 23 of the optical high resolution imaging device 24 where images are collected, for example, using a CCD 48. The processor 18 may receive as input , pixel data from the CCD 48. The sample fluid strip flows along with the PIOAL to a discharge 33.
[00160] As shown in this document, the narrowing zone 21 may have a flow path proximal portion 21a that has a proximal thickness PT and a flow path distal portion 21b that has a distal thickness DT, so that the thickness distal DT is less than the proximal PT thickness. Sample fluid can therefore be injected through the distal end 28 of the sample tube 29 at a location that is distal to the proximal portion 21a and proximal to the distal portion 21b. For this reason, sample fluid can enter the PIOAL envelope as the PIOAL stream is compressed by zone 21, where the sample fluid injection tube has a distal outlet port through which the sample fluid is injected into the flowing sheath fluid, where the distal outlet port is bounded by the decrease in flow path size of the flow cell.
[00161] The high-resolution digital optical imaging device 24 with objective lens 46 is directed along an optical geometric axis that intercepts the tape-shaped sample stream 32. The relative distance between the objective 46 and the flow cell 33 is variable through the operation of a motor drive 54 to resolve and collect a focused digitized image on a photosensor array.
[00162] According to some embodiments, the system can operate to hydrofocus the sample fluid strip 32. The term hydrofocus or hydrofocus may refer to a focusing effect that is influenced by a difference in viscosity between the fluids of coating and sample, a flow cell geometric narrowing transition zone, and a velocity difference between the coating and sample fluids. The hydrodynamic flow results from the velocity difference between the sample and coating fluid streams, which affects the flow tape thickness and shape.
[00163] The present disclosure provides a technique to automatically achieve a correct working position of the optical high resolution imaging device 24 to focus on the tape format sample stream 32. The flow cell structure 22 can be so configured that the tape-shaped sample stream 32 has a fixed and reliable location in the flow cell that defines the sample fluid flow path, on a thin tape between layers of PIOAL, so as to pass through a viewing zone 23 in the flow cell 22. In certain flow cell arrangements, the cross section of the flow path to the PIOAL narrows symmetrically at the point where the sample is inserted through a flat hole such as a tube 29 with a rectangular lumen in the orifice or cannula. The narrowing flow path (eg, which geometrically narrows in cross-sectional area by a ratio of 20:1 or by a ratio between 20:1 and 70:1) along with a viscosity differential between PIOAL and the sample fluids and, optionally, a difference in the linear velocity of the PIOAL compared to the sample flow, cooperate to compress the sample cross section by a ratio of about 20:1 to 70:1. In some embodiments, the cross section thickness ratio can be 40:1.
[00164] In one aspect, the symmetrical nature of the flow cell 22 and the way of performing the injection of sample fluid and PIOAL provide a repeatable position in the flow cell 22 for the tape-shaped sample stream 32 between the two layers of PIOAL. As a result, process variations such as sample-specific and PIOAL-specific linear velocities do not tend to displace the tape-shaped sample stream from its location in the stream. With respect to the structure of the flow cell 22, the location of the tape-shaped sample stream 32 is stable and repeatable.
[00165] However, the relative positions of the flow cell 22 and the optical high resolution optical imaging device 24 of the optical system may be subject to change and may benefit from occasional position adjustments to maintain an ideal or desired distance between the high resolution optical imaging device 24 and the tape format sample stream 32, thus providing a quality focus image of the enveloped particles in the tape format sample stream 32. According to some embodiments, there may be a ideal or desired distance between the high resolution optical imaging device 24 and the tape format sample stream 32 to obtain focused images of the enveloped particles. The optical elements may first be positioned precisely relative to the flow cell 22 through autofocus or other techniques to locate the high resolution optical imaging device 24 at the ideal or desired distance from an autofocus target 44 having a position fixed relative to the flow cell 22. The displacement distance between the autofocus target 44 and the tape-shaped sample stream 32 is precisely known, for example, as a result of initial calibration steps. After autofocusing on autofocus target 44, flow cell 22 and/or optical high resolution imaging device 24 are then moved along the known displacement distance between autofocus target 44 and the current. of tape-format sample stream 32. As a result, the objective lens of the high-resolution optical imaging device 44 is precisely focused on the tape-format sample stream 32 that contains the enveloped particles.
[00166] Exemplary embodiments of the present invention involve automatically focusing on the focus or imaging target 44, which is a high contrast figure defining a known location along the optical axis of the high resolution optical imaging device or imaging device. digital image capture 24. The target 44 may have a known offset distance from the location of the tape-format sample stream 32. A contrast measurement algorithm may be employed specifically on the target resources. In one example, the position of the high-resolution optical imaging device 24 can be varied along a line parallel to the optical geometric axis of the high-resolution optical imaging device or the digital image capture device to find the depth or distance at which one or more maximum differential amplitudes lie among the pixel luminance values that occur along a line of pixels in the image which is known to cross over an edge of the contrasting figure. In some cases, the autofocus pattern has no variation along the line parallel to the optical geometric axis, which is also the line along which a motorized control operates to adjust the position of the high-resolution optical imaging device 24 to provide the registered offset distance.
[00167] In such a way, it may not be necessary to autofocus or rely on an aspect of image content that is variable between different images, that has a lower high definition with respect to contrast, or that may be located somewhere in a range of positions as the basis for determining a distance location for reference. With the ideal or desired focus location being found on the autofocus target 44, the relative positions of the high resolution optical imaging device objective 24 and the flow cell 22 can be shifted by the registered displacement distance to provide the position of ideal or desired focus for particles in the sample stream in tape format 32.
[00168] According to some embodiments, the optical high-resolution imaging device 24 can outperform an image of the tape-format sample stream 32 when backlit by a light source 42 applied through an illumination aperture (window) 43 In the embodiments shown in Figure 1, the perimeter of the illumination aperture 43 forms an autofocus target 44. However, the objective is to collect a precisely focused image of the tape-format sample stream 32 through optical elements of the imaging device. 46 high-resolution optical in an array of photosensitive elements such as an integrated charge-coupled device.
[00169] The high-resolution optical imaging device 24 and its optical elements 46 are configured to resolve an image of the particles in the tape-format sample stream 32 that is in focus at distance 50, where such distance can be a result of the dimensions of the optical system, the shape of the lenses and the refractive indices of their materials. In some cases, the ideal or desired distance between the high resolution optical imaging device 24 and the tape format sample stream 32 is not changed. In other cases, the distance between the flow cell 22 and the high-resolution optical imaging device and its optical elements 46 may be changed. Move the high resolution optical imaging device 24 and/or flow cell 22 so that they are closer or further apart from each other (for example, by adjusting the distance 51 between the imaging device 24 and the flow cell 22 ), moves the location of the focus point at the end of the distance 50 with respect to the flow cell.
[00170] According to embodiments of the present invention, a focus target 44 may be located at a distance from the tape-shaped sample stream 32, in this case directly attached to the flow cell 22 at the edges of the slit 43 for the light of the illumination source 42. The focus target 44 is a constant displacement distance 52 of the tape format sample stream 32. Often the displacement distance 52 is constant due to the fact that the location of the format sample stream of tape 32 in the flow cell remains constant.
[00171] An exemplary autofocus procedure involves adjusting the relative positions of the high-resolution optical imaging device 24 and flow cell 22 using a motor 54 to arrive at the proper focal length, thereby causing the device to optical high resolution imaging 24 focuses on autofocus target 44. In this example, autofocus target 44 is behind the tape-shaped sample stream 32 in the flow cell. Then, the high resolution optical imaging device 24 is moved towards or against the flow cell 22 until the auto focus procedures establish that the image resolved in the photosensor is a precisely focused image of the auto focus target 44 Thereafter, motor 54 is operated to shift the relative positions of the high resolution optical imaging device 24 and the flow cell 22 to cause the high resolution optical imaging device to focus the tape-format sample stream. 32, more specifically by moving the high resolution optical imaging device 24 away from the flow cell 22, precisely in the amplitude of the displacement distance 52. In this exemplary embodiment, the imaging device 24 is shown to be moved by the 54 motor to achieve a focus position. In other embodiments, flow cell 22 is moved, or both flow cell 22 and imaging device 24 are moved, by similar means to obtain focused images.
[00172] Such motion directions would obviously be reversed if the focus target 44 were located in the front viewport window instead of the backlight window 43. In this case, the displacement distance would be the amplitude between the current of tape-shaped sample 32 and a target 44 in the front viewing port (not shown).
[00173] The displacement distance 52, which is equal to the distance between the tape-shaped sample stream 32 and the autofocus target 44 along the optical axis of the high-resolution optical imaging device 24, can be established in a factory or user established calibration step. Typically, when set, offset distance 52 is not changed. The variations and vibrations of thermal expansion can cause the exact position of the high resolution optical imaging device 24 and flow cell 22 to vary relative to one another, thus necessitating the reset of the auto focus process. However, automatically focusing on the target 44 provides a position reference that is fixed relative to the flow cell 22 and therefore fixed relative to the tape-shaped sample stream 32. Similarly, the offset distance is constant. Therefore, by autofocusing on the target 44 and shifting the high resolution optical imaging device 24 and the flow cell 22 in the amplitude of the shift distance, the result is that the high resolution optical imaging device is focused on the current. of sample in tape format 32.
According to some embodiments, the focusing target is provided as a high contrast circle stamped or applied around the illumination aperture 43. Alternative focusing target configurations are discussed elsewhere in this document. When a square or rectangular image is collected in focus on target 44, a high contrast edge appears around the center of illumination. Searching for the position where the greatest contrast is obtained in the image at the inner edges of the slit automatically focuses the high-resolution optical imaging device on the target's workplace 44. Under some modalities, the term "working distance" may become refer to the distance between the objective and its focal plane and the term "workplace" can refer to the focal plane of the imaging device. The largest measure of contrast for an image is where the brightest white pixel and darkest black pixel measured are adjacent to each other along a line through an inner edge. The highest contrast measure can be used to assess whether the focal plane of the imaging device is in the desired position relative to the target 44. Other autofocus techniques can also be used, such as edge detection techniques, segmentation and integration of differences in amplitude between adjacent pixels and search for the greatest sum of differences. In one technique, the sum of differences is calculated over three distances covering working positions on both sides of the target 44 and corresponds to the resulting values to a characteristic curve, where the ideal distance is at the peak value of the curve. Combined, exemplary autofocus techniques may involve collecting images of the target flow cell at different positions and analyzing the images to find the best focus position using a measurement that is highest when the target image is sharpest. During a first (rough) step the autofocus technique can operate to find a better preliminary position of a set of images collected at 2.5 μm intervals. From such a position, the auto focus technique can then involve collecting a second set of (fine) images at 0.5 µm intervals and calculating the best final focus position on the target.
[00175] In some cases, the focus target (auto focus pattern) may be situated at the periphery of the viewing area where the sample should appear. It is also possible that the focus target can be defined by contrasting shapes that are situated in the field of view, such as that shown in Figure 15. Typically, the auto focus target is mounted in the flow cell or rigidly fixed in a fixed position in relation to the flow cell. Powered by a detector-driven positioning motor responsive to maximizing the contrast of the autofocus target image, the instrument automatically focuses on the target instead of the tape-shaped sample stream. Then, by shifting the flow cell and/or the high-resolution optical imaging device relative to each other, the shift distance known to be the distance between the auto focus target and the sample current at tape format, the working position or the focal plane of the high resolution optical imaging device is shifted from the auto focus target to the tape format sample stream. As a result, the tape-shaped sample stream appears in focus on the collected digital image.
[00176] In order to distinguish particle types through data processing techniques such as categories and/or subcategories of red blood cells and white blood cells, it is advantageous to record microscopic pixel images that have sufficient resolution and clarity to reveal the distinguishing features one category or subcategory of the others. It is an object of the invention to facilitate autofocus techniques as described.
[00177] In a practical embodiment, the apparatus may be based on an optical bank arrangement as shown in Figure 1A and as enlarged in Figure 1B, which has an illumination source 42 directed over a flow cell 22 mounted on a conductor of flow cell or gimbals 55, so as to back-illuminate the contents of flow cell 22 in an image obtained through a high resolution optical imaging device 24. Conductor 55 is mounted on a motor drive so as to be precisely movable towards and away from the optical high resolution imaging device 24. The conductor 55 further allows for precise alignment of the flow cell with respect to the optical display geometric axis of the optical high resolution imaging device or from the digital image capture device such that the tape-shaped sample stream flows in a plane normal to the geometric axis of display in the zone where the stream. The tape-shaped sample tube is imaged, more specifically between the illumination aperture 43 and the viewing port 57 as depicted in Figure 1. The focus target 44 can aid in the adjustment of the conductor 55, for example, to establish the plane of the sample stream in normal tape format with respect to the optical axis of the high-resolution optical imaging device or the digital image capture device.
[00178] Therefore, the carrier 55 provides a very precise linear and angular adjustment of the position and orientation of the flow cell 22, for example, in relation to the image capture device 24 or the objective of the image capture device. As shown in this document, conductor 55 includes two pivot points 55a, 55b to facilitate angular adjustment of the conductor and flow cell relative to the image capture device. Angular adjustment pivot points 55a, 55b are located in the same plane and centered with respect to the flow cell channel (eg at the image capture site). This allows adjustment of angles without causing any linear translation of the flowcell position. Conductor 55 can be rotated around a geometric axis of pivot point 55a or around a geometric axis of pivot point 55b or around both geometric axes. Such rotation may be controlled by a processor and a flow cell motion control mechanism, such as processor 440 and flow cell control mechanism 442 depicted in Figure 4.
[00179] Again with reference to Figure 1B, it can be seen that either of the two, or both the image capture device 24 and the conductor 55 (along with the flow cell 22), can be rotated or translated along of several geometric axes (eg X, Y, Z) in three dimensions. For this reason, an exemplary technique for adjusting the focus of the image capture device may include deploying an axial rotation of the image capture device 24 around the geometric axis of imaging, for example, through the rotation device 24 around the X axis. Focus adjustment can also be achieved by axial rotation of flow cell 22 and/or conductor 55 around a geometric axis that extends along the imaging axis, for example, around the geometric axis X and within the imaging device's field of view. In some cases, focus adjustment may include a tip rotation (for example, rotation around the geometric Y axis) of the image capture device. In some cases, focus adjustment may include a tip rotation (for example, rotation around the Y axis or around the pivot point 55a) of the flow cell. As shown in this document, pivot point 55a corresponds to a geometric axis Y that extends along and into the flow path of the flow cell. In some cases, focus adjustment may include a tilt rotation (for example, rotation around the geometric Z axis) of the image capture device. In some cases, the focus adjustment may include a tilt rotation (for example, rotation around the Z axis or around the pivot point 55b) of the flow cell. As shown in this document, the pivot point 55b corresponds to a geometric axis Z that traverses the flow path and the imaging axis. In some cases, the image capture device can be focused on the sample flow stream by implementing a rotation of the flow cell (eg, around the X axis) so that the rotation is centered in the field. view of the image capture device. The three-dimensional rotation adjustments described in this document can be deployed to account for positional slip in one or more components of the analyzer system. In some cases, three-dimensional rotation adjustments can be implemented to account for temperature fluctuations in one or more components of the analyzer system. In some cases, tuning an analyzer system may include translating the imaging device 24 along the geometric X axis. flow 22 along the X axis.
[00180] According to some embodiments, a visual analyzer for obtaining images of a sample that contains particles suspended in a liquid includes a flow cell 22 coupled to a source 25 of the sample and a source 27 of the PIOAL material, as shown. in Figure 1. As shown in the sectional view of Figure 3, the flow cell 22 defines an internal flow path that narrows symmetrically in the direction of flow (right to left in Figure 3 or bottom to top in Figure 1). The flow cell 22 is configured to direct a flow 32 of the sample wrapped with the PIOAL through a display zone in the flow cell, more specifically through the display port 57.
[00181] Referring again to Figure 1, the high-resolution digital optical imaging device 24 with the objective lens 46 is directed along an optical geometric axis that intercepts the tape-shaped sample stream 32. The relative distance between the objective 46 and flow cell 33 is variable through the operation of a motor drive 54 to resolve and collect a focused digitized image on a photosensor array.
[00182] The autofocus pattern 44, which has a position that is fixed relative to the flow cell 22, is located at an offset distance 52 relative to the plane of the tape-shaped sample stream 32. In the embodiment shown , the autofocus pattern (target 44) is applied directly to the flow cell 22 at a location that is visible in the image collected by the high-resolution optical imaging device 24. In another embodiment, the target may be transported in one part. which is rigidly fixed in position with respect to the flow cell 22 and the tape-shaped sample stream 32 therein, if not directly applied to the flow cell body in an integral manner.
[00183] The light source 42, which can be a stable source or can be a strobe that is flashed synchronously with the photosensor operation of the high-resolution optical imaging device, is configured to illuminate the sample stream in format of tape 32 and also contributes to the contrast of the target 44. In the illustrated modality, the illumination comes from the backlight.
[00184] Figure 1C provides a block diagram showing additional aspects of an exemplary hematology analyzer. As shown in this document, the analyzer 100c includes at least one digital processor 18 coupled to operate the motor drive 54 and to analyze the digitized image of the photosensor array as collected at different focus positions relative to the auto focus target pattern. 44. Processor 18 is configured to determine a focus position of auto focus pattern 44, that is, to automatically focus on auto focus target pattern 44 and thus establish an optimal distance between the high resolution imaging device optics 24 and the autofocus pattern 44. This can be achieved through image processing steps, such as applying an algorithm to assess the contrast level in the image at a first distance, which can be applied to the entire image or at least on one edge of the auto focus pattern 44. The processor moves the motor 54 to another position and evaluates the contrast at that position or edge and after d u or more interactions determines an optimal distance that maximizes focus accuracy in autofocus pattern 44 (or optimizes focus accuracy if moved to such a position). The processor relies on the fixed spacing between the auto focus pattern of the auto focus target 44 and the tape format sample stream, the processor 18 then controls the motor 54 to move the high resolution optical imaging device 24 to the correct distance to focus on the 32 tape format sample stream. More specifically, the processor operates the motor to shift the distance between the high resolution optical imaging device and the 32 tape format sample stream by the distance of offset 52 (for example, as depicted in Figure 1) whereby the tape-shaped sample stream is offset from the auto focus target pattern 44. In this way, the high resolution optical imaging device is focused on the stream. of sample in tape format.
[00185] The motor 54 may comprise a gear step motor with an accuracy considerably less than the distinguishing features imaged by the high resolution optical imaging device or the digital image capture device, especially the aspects of blood cells. Since the location of the high resolution optical imaging device 24 is adjusted to locate the position of the optical objective in the width of the tape-format sample stream, the cell/particle view in the tape-format sample stream will be in focus . An autofocus pattern 44 may be located at an edge of a field of view of the high resolution optical imaging device or digital image capture device and does not interfere with viewing for that reason.
[00186] Furthermore, when the optical high resolution imaging device is moved along the shift distance and the auto focus pattern goes out of focus, the features that appear in focus are the blood cells instead of the auto focus pattern . In the mode of Figure 21, for example, the autofocus pattern is defined by shapes in the field of view. Shapes are relatively thin discrete shapes of a limited size and therefore, after moving the offset distance, shapes become substantially invisible in the digitized image when focused on the tape-shaped sample stream. A typical displacement distance might be, for example, 50 to 100 µm in a flow cell sized for hematology (blood cell) imaging applications. In some modalities, the auto focus feature keeps the high-resolution optical imaging device within 1 µm of the optimal focus distance.
[00187] The internal contour of the flow cell and the flow rates of PIOAL and the sample can be adjusted so that the sample forms a ribbon-shaped stream. The stream can be approximately as fine as or even finer than the particles that are encased in the tape-shaped sample stream. White blood cells can have a diameter of about 10 µm, for example. By providing a tape-shaped sample stream with a thickness of less than 10 µm, the cells can be oriented when the tape-shaped sample stream is extended by the sheath fluid or PIOAL. Surprisingly, extending the tape-shaped sample stream along a narrowing flow path in layers of PIOAL with a different viscosity than the tape-shaped sample stream, such as a higher viscosity, tends to advantageously align the non-spherical particles in a plane substantially parallel to the direction of flow and applying forces on the cells so as to enhance the in-focus contents of the intracellular structures of the cells. The optical axis of the high-resolution optical imaging device 24 is substantially normal (perpendicular) to the plane of the tape-shaped sample stream. The linear velocity of the tape-shaped sample stream at the imaging point can be, for example, 20 to 200 mm/second. In some embodiments, the linear velocity of the tape-format sample stream can be, for example, from 50 to 150 mm/second.
[00188] Tape format sample stream thickness can be affected by the relative flow rates and viscosities of sample fluid and PIOAL. Referring again to Figure 1, sample source 25 and/or PIOAL source 27, for example, which comprises precision displacement pumps, can be configured to deliver sample and/or PIOAL at controllable flow rates for optimize sample stream dimensions in tape format 32, more specifically as a thin tape at least as wide as the field of view of the high resolution optical imaging device 24.
[00189] In one embodiment, the PIOAL source 27 is configured to supply the PIOAL at a predetermined viscosity. Such viscosity may be different from the sample's viscosity and may be greater than the sample's viscosity. PIOAL viscosity and density, sample material viscosity, PIOAL flow rate, and sample material flow rate are coordinated to keep the tape-shaped sample stream at offset distance from the standard. autofocus and with predetermined dimensional characteristics, such as an advantageous tape-shaped sample stream thickness.
[00190] In a practical embodiment, the PIOAL has a linear velocity greater than the sample and a viscosity greater than the sample, thus extending the sample to form a flat ribbon. In some cases, the viscosity of PIOAL can be up to 0.01 Pa.s (10 centipoise).
[00191] In the mode shown in Figure 1C, the same digital processor 18 that is used to analyze the digital pixel image obtained through the photosensor array is also used to control the auto focus motor 54. 24 high optical resolution imaging is not automatically focused for all captured images. The autofocus process can be achieved periodically (at the start of the day or at the start of a shift) or, for example, when temperature or other process changes are detected through the appropriate sensors or when image analysis detects a potential need to refocus. In some cases, an automated autofocus process can be performed in a time duration of about 10 seconds. In some cases, an autofocus procedure can be performed before processing a rack of samples (eg 10 samples per rack). It is also possible, in other modalities, for the hematology image analysis to be performed by a processor and to have a separate processor, optionally associated with its own photosensor array, arranged to handle the autofocus steps to a fixed target 44 .
[00192] The digital processor 18 can be configured to perform auto focus at programmed times or under programmed conditions or upon user demand and is also configured to perform a categorization and subcategorization based on particle image. Exemplary particles include cells, white blood cells, red blood cells and the like.
[00193] In one embodiment, the digital processor 18 of Figure 1 or Figure 1C is configured to detect an auto focus reset signal. The auto focus reset signal can be triggered by a detected change in temperature, a decrease in focus quality as discerned through pixel image date parameters, passage of time or user input. Advantageously, it is not necessary to recalibrate in the measurement direction of the displacement distance 52 shown in Figure 1 to recalibrate. Optionally, autofocus can be programmed to recalibrate at certain frequencies/intervals between cycles for quality control and/or to maintain focus.
[00194] The displacement distance 52 varies slightly from one flow cell to another, however, it remains constant for a given flow cell. As a setup process when docking an image analyzer with a flow cell, the offset distance is estimated first and then during the calibration steps where the autofocus and imaging aspects are exercised, the offset distance exact displacement for the flow cell is determined and entered as a constant in the processor 18's programming.
[00195] Consequently, as shown in flowchart form in Figure 1D and with reference to the hematology analyzer of Figure 1 and/or Figure 1C, the process performed according to the disclosed methods and apparatus may involve calibrating once or rarely. Calibration may include focusing on the target and contrast 44, focusing on the tape-shaped sample stream 32, and indicating the displacement along the optical axis between these two locations, as indicated in step 110d. Such displacement can be indicated as a constant. Then, by controlling the motor 54 and analyzing the image data from the photosensor array, the processor 18 automatically focuses on the target 44 and displaces the high resolution optical imaging device 24 and/or the flow cell 22 relative to each other by the indicated offset distance as indicated in step 120d. The tape-shaped sample stream 32 is then in focus and its image can be collected (as indicated in step 130d) and processed (as indicated in step 140d) at regular intervals, specifically at intervals sufficient to collect substantially adjacent views non-overlapping portions of the tape-shaped sample stream passing through the viewing zone on the viewport 57. When self-monitoring (as indicated in step 150d) reveals a data anomaly or a temperature change it may have changed the relative positions of the optical high resolution imaging device 24 and the flow cell 22 due to differences in thermal expansion, then autofocus (as indicated in step 160d) is started, after which regular operation is continued. For this reason, an autofocus process can include detecting the autofocus reset signal and repeating the image capture and autofocus steps in response to the autofocus reset signal. In some embodiments, the auto focus reset signal may include or be based on a change in temperature, a decrease in focus quality, an elapsed time interval, or user input.
[00196] The linear velocity of the tape format sample stream can be limited enough to avoid blurring by moving the scanned image in the exposure time of the photosensor array image. The light source can optionally be a strobe light that is flashed to apply a high incident amplitude for a brief moment. As the autofocus pattern 44 and the image are in the same field of view, the light source is configured to illuminate the tape-shaped sample stream and the autofocus pattern simultaneously. However, in other modalities, the fields of view for imaging and for autofocusing may be different, for example, lit and/or imaged separately.
[00197] Matter developments have aspects of method as well as apparatus. A method for focusing a visual analyzer comprises focusing a high resolution optical imaging device 24, which may be a high resolution optical digital imaging device or the digital image capture device, into a fixed auto focus pattern 44 with respect to a flow cell 22, wherein the autofocus pattern 44 is located at an offset distance 52 with respect to the tape-format sample stream 32. The high-resolution digital optical imaging device 24 has an objective with an optical geometry axis that intercepts the tape-shaped sample stream 32. A relative distance between the objective and the flow cell 22 is varied through the operation of a motor drive 54, while the distance along the optical geometry axis between the high resolution optical imaging device and the ideal focus point is known. The high resolution optical digital imaging device is configured to resolve and collect a digitized image onto a photosensor array. The motor drive is operated to focus on the auto focus pattern in an auto focus process. The motor drive is then operated over the travel distance, thus focusing the high-resolution optical imaging device on the tape-shaped sample stream.
[00198] It is possible to use auto focus on the target and perform offset by the offset distance to get a suitable distance to focus on the tape format sample stream. Advantageously, however, performing autofocus is not required or repeated for each image capture. However, auto focus is initiated under certain conditions. An auto focus reset signal can be detected or generated so as to drive the refocusing steps in the autofocus pattern by operating the motor drive over the travel distance and refocusing the high imaging device. optical resolution in the sample stream in tape format. The auto focus reset signal can be generated by detecting a change, for example, in temperature, a decrease in focus quality, the passage of time, other process parameters or user input.
[00199] Figure 1E is a simplified block diagram of an exemplary module system that amply illustrates how the individual system elements for a 100e module system can be deployed in a separate or more integrated manner. The module system 100e may be a part of or be in connectivity to a particle analysis system to generate images of particles in a blood sample fluid, in accordance with embodiments of the present invention. The 100e module system is well suited for producing data or instructions related to focusing and imaging techniques, receiving inputs related to focusing and imaging techniques and/or processing information or data related to focusing and imaging techniques, as described elsewhere part of this document. In some cases, module system 100e includes hardware elements that are electrically coupled through a bus subsystem 102e, including one or more processors 104e, one or more input devices 106e, such as user interface input devices and/or one or more output devices 108e such as user interface output devices. In some cases, system 100e includes a network interface 110e and/or an imaging system interface 140e that can receive signals from and/or transmit signals to an imaging system 142e. In some cases, system 100e includes software elements, for example, shown in this document as currently located in a working memory 112e of a memory 114e, an operating system 116e, and/or other code 118e, such as a program configured to deploy one or more aspects of the techniques disclosed in this document.
[00200] In some embodiments, the module system 100e may include a storage subsystem 120e that can store basic programming and data constructs that provide the functionality of the various techniques disclosed in this document. For example, software modules that implement method aspects functionality as described in this document can be stored in storage subsystem 120e. Such software modules can be executed by one or more processors 104e. In a distributed environment, software modules can be stored on a plurality of computer systems and executed by processors from the plurality of computer systems. Storage subsystem 120e can include memory subsystem 122e and file storage subsystem 128e. Memory subsystem 122e may include a number of memories including a main random access memory (RAM) 126e for storing instructions and data during program execution and a read-only memory (ROM) 124e in which fixed instructions are stored. File storage subsystem 128e can provide persistent (non-volatile) storage for program files and data and can include tangible storage media that can optionally incorporate sample, patient, treatment, evaluation, or other data. The 128e file storage subsystem can include a hard disk drive, a floppy disk drive along with associated removable media, a Compact Disk Read Only Memory (CD-ROM) drive, an optical drive, DVD, CD- R, CD RW, removable solid state memory, other removable media cartridges or disks, and the like. One or more of the units may be located in remote locations on other computers connected in other locations coupled to the 100e module system. In some cases, systems may include a computer-readable storage medium or other tangible storage medium that stores one or more sequences of instructions that, when executed by one or more processors, can cause the one or more processors to perform any aspect of the techniques or methods disclosed in this document. One or more modules that implement the functionality of the techniques disclosed in this document may be stored by the 128e file storage subsystem. In some embodiments, the software or code will provide a protocol to allow the module system 100e to communicate with the communication network 130e. Optionally, these communications can include communications over a dial-up connection or an Internet connection.
[00201] It is noted that system 100e can be configured to perform various aspects of methods of the present invention. For example, the processor component or module 104e may be a microprocessor control module configured to receive temperature parameter signals and/or flow cell operating parameters from a sensor input device or module 132e, of a user interface input device or module 106e and/or an imaging system 142e, optionally through an imaging system interface 140e and/or a network interface 110e and a communication network 130e. In some cases, the sensor input device(s) may include or be a part of a particle analysis system that is equipped to image blood fluid samples. In some cases, the user interface input device(s) 106e and/or the network interface 110e may be configured to receive image parameter signals generated by a particle analysis system that is equipped to obtain image parameters. In some cases, the imaging system 142e may include or be a part of a particle analysis system that is equipped to obtain imaging parameters related to blood fluid samples.
[00202] The component or processor module 104e may further be configured to transmit particle analysis parameter signals or optionally processed image parameter signals, in accordance with any of the techniques disclosed herein, to the device or module of sensor output 136e, to user interface output device or module 108e, to network interface device or module 110e, to imaging system interface 140e, or any combination thereof. Each of the devices or modules in accordance with embodiments of the present invention may include one or more software modules on a computer-readable medium that is processed by a processor, or hardware modules, or any combination thereof. Any of a variety of commonly used platforms, such as Windows, MacIntosh, and Unix, along with any of a variety of commonly used programming languages, can be used to implement embodiments of the present invention.
[00203] User interface input devices 106e may include, for example, a touchpad, a keyboard, pointing devices such as a mouse, a trackball, a graphics tablet device, a scanner, a joystick, a touch screen embedded in a display, audio input devices such as voice recognition systems, microphones and other types of input devices. User input devices 106e may also download computer executable code from tangible storage media or communication network 130e, wherein the code incorporates any of the methods or aspects thereof disclosed herein. It will be understood that the terminal software may be updated from time to time and downloaded to the terminal as appropriate. In general, the use of the term "input device" is intended to include a variety of conventional and proprietary devices for entering information into the 100e module system.
[00204] User interface output devices 106e may include, for example, a display subsystem, a printer, a facsimile machine, or non-visual displays such as audio output devices. The display subsystem can be a cathode ray tube (CRT), a flat panel device such as a liquid crystal display (LCD), a projection device, or the like. The display subsystem can also provide a non-visual display, such as through audio output devices. In general, the use of the term "output device" is intended to include a variety of conventional and proprietary devices and ways of providing 600 module system information to a user.
[00205] The bus subsystem 102e provides a mechanism to allow the various components and subsystems of the module system 100e to communicate with each other as is intended or desired. The various subsystems and components of the module 100e system do not need to be in the same physical location, but can be distributed in multiple locations in a distributed network. Although the bus subsystem 102e is shown schematically as a single bus, alternative embodiments of the bus subsystem can utilize multiple buses.
[00206] The network interface 110e can provide an interface to an external network 130e or other devices. External communication network 130e can be configured to carry out communications as needed or desired with other participants. It can therefore receive an electronic packet from the module system 100e and transmit any information as needed or desired back to the module system 100e. As shown in this document, communication network 130e and/or imaging system interface 142e can transmit information to or receive information from an imaging system 142e that is equipped to obtain images or image parameters that correspond to the samples of blood fluid.
[00207] In addition to providing such infrastructure communications links internal to the system, the communications network system 130e may also provide a connection to other networks, such as the internet and may comprise a wired or wireless modem and/or another type of interface realization connection.
[00208] It will be apparent to the person skilled in the art that considerable variations can be used according to specific requirements. For example, custom hardware may also be used and/or specific elements may be implemented in hardware, software (including portable software such as applets), or both. Additionally, connection to other computing devices such as network input/output devices can be used. The module terminal system 100e itself may be of varying types, including a computer terminal, a personal computer, a laptop computer, a workstation, a network computer, or any other data processing system. Due to the constantly changing nature of computers and networks, the description of module system 100e depicted in Figure 1E is intended only as a specific example for purposes of illustrating one or more embodiments of the present invention. Many other configurations of module system 100e are possible with more or fewer components than the module system depicted in Figure 1E. Any of the modules or components of the module system 100e or any combinations of such modules or components may be coupled to or integrated into or otherwise configured to be in connectivity with any of the particle and/or particle analysis modalities. imaging system revealed in this document. Likewise, any of the hardware and software components discussed above can be integrated with or configured to interface with another medical evaluation or treatment system used elsewhere.
[00209] In some embodiments, the module system 100e may be configured to receive one or more image parameters of a blood fluid sample in an input module. Image parameter data can be transmitted to an evaluation module where diagnosis or other results can be predicted or determined based on analysis of the image data. Image or diagnostic data can be output to a system user through an output module. In some cases, the module system 100e can determine diagnostic results for a blood fluid sample, for example, using a diagnostic module. Diagnostic information can be output to a system user via an output module. Optionally, certain aspects of the diagnostics can be determined by an output device and transmitted to a diagnostic system or a sub-device of a diagnostic system. Any one of a variety of data relating to the blood fluid samples or the patients from whom the samples are taken can be entered into the module system, including age, weight, sex, treatment history, medical history and the like. The parameters of treatment regimens or diagnostic assessments can be determined based on these data.
[00210] Associatedly, in some cases, a system includes a processor configured to receive image data as an input. Optionally, a processor, storage medium, or both can be incorporated into a hematology or particle analysis machine. In some cases, the hematology machine can generate image data or other information for insertion into the processor. In some cases, a processor, storage medium, or both may be incorporated into a computer, and the computer may be in communication with a hematology device. In some cases, a processor, a storage medium, or both, can be incorporated into a computer, and the computer can be in remote communication with a hematology device over a network. flow cell
[00211] A practical embodiment of the flow cell 22 is further represented in Figures 2 and 3. As shown in this document, the flow cell 22 can be coupled to a source of sample 25 and also to a source 27 of material. PIOAL. Sample fluid is injected into flow cell 22 through cannula 29, for example, through a distal outlet port 31 of cannula 29. Typically, the PIOAL sheath fluid is not in a laminar flow state as the same if displaces through a curved channel section 41 in the flow cell from source 27 towards viewing zone 23. However, flow cell 22 can be configured so that the PIOAL sheath fluid is or becomes laminar or present a flat velocity profile as it flows through the distal outlet port 31 where the sample fluid is introduced into the flowing sheath fluid. Sample fluid and PIOAL may flow along flow cell 22 in a direction generally indicated by arrow A and then out of flow cell 22 through discharge 33. Flow cell 22 defines an internal flow path 20 that narrows symmetrically (eg in transition zone 21) in the flow direction A. The symmetry of the flow path contributes to a robust and centralized flow of the sample stream. The flow cell 22 is configured to direct a flow 32 of the sample wrapped with the PIOAL through a viewing zone 23 in the flow cell, more specifically behind the viewing port 57. An auto focus pattern 44 is associated with the viewing port. view 57. A flow cell 22 also has a rounded or recessed seat 58 that is configured to support or receive a microscope objective (not shown).
[00212] According to some embodiments, the auto focus pattern 44 may have a position that is fixed relative to the flow cell 22 and that is located at an offset distance from the plane of the tape-shaped sample stream. 32. In the embodiment shown in this document, the auto focus pattern (target 44) is applied directly to the flow cell 22 at a location that is visible in an image collected through the viewing port 57 by means of a high-end imaging device. optical resolution (not shown). A flow cell 22 can be constructed from a single piece of material. Alternatively, the flow cell 22 can be constructed from a first section or layer or an upper section or layer 22a and a second section or layer or a lower section or layer 22b. As shown in this document, a glass or transparent window panel 60 is attached to or forms an integral part with the first section 22a. Panel 60 can define at least a portion of the sample flow path within the flow cell. Light from light source 42 may travel through an aperture or passage of auto focus pattern 44 so as to illuminate sample particles flowing in flow stream 32.
[00213] In some cases, the thickness of panel 60 may have a value in a range from about 150 µm to about 170 µm. As noted above, panel 60 may define or form a portion of the flow path channel or sheath (e.g., PIOAL). Using a thin 60 panel, it is possible to place the microscope objective very close to the sample fluid strip and thus obtain highly magnified images of the particles flowing along the flow path.
[00214] Figure 3A depicts aspects of a flow cell modality, in which a distance between the imaging axis 355 and the distal transition zone portion 316 is about 8.24 mm. A distance between the distal transition zone portion 316 and the cannula outlet port 331 is about 12.54 mm. A distance between the cannula outlet port 331 and the sheath fluid inlet 301 is about 12.7 mm. A distance between the cannula outlet port 331 and a portion of the proximal transition zone 318 is about 0.73 mm. Figure 3B depicts aspects of a flow cell embodiment where the cannula outlet port has been moved more distally to the transition zone compared to the embodiment of Figure 3A. As shown in this document, the distal end of the cannula is advanced into the flow cell's narrowing transition zone and a distance between the imaging axis 355 and the distal transition zone portion 316 is in a range of about 16mm to about 26mm. In some cases, the distance between the imaging axis 355 and the distal transition zone portion 316 is about 21 mm.
[00215] Again with reference to Figure 1, the inner contour of the flow cell (eg in transition zone 21) and the flow rates of PIOAL and sample can be adjusted so that the sample forms a stream in the shape of a tape 32. The stream can be approximately as fine as or even finer than the particles that are encased in the tape-shaped sample stream. White blood cells can have a diameter of about 10 µm, for example. By providing a tape-shaped sample stream with a thickness of less than 10 µm, the cells can be oriented when the tape-shaped sample stream is extended by the sheath fluid or PIOAL. Surprisingly, extending the tape-shaped sample stream along a narrowing flow path within PIOAL layers of different viscosity than the tape-shaped sample stream, such as a higher viscosity, tends to advantageously align, the non-spherical particles in a plane substantially parallel to the flow direction and applying forces on the cells so as to enhance the in-focus contents of the cells' intracellular structures. The optical axis of the high-resolution optical imaging device 24 is substantially normal (perpendicular) to the plane of the tape-shaped sample stream. The linear velocity of the tape-shaped sample stream at the imaging point can be, for example, 20 to 200 mm/second. In some embodiments, the linear velocity of the tape-format sample stream can be, for example, from 50 to 150 mm/second.
[00216] Tape-format sample stream thickness can be affected by the relative flow rates and viscosities of sample fluid and PIOAL. Sample source 25 and/or PIOAL source 27, for example, which comprise precision displacement pumps, can be configured to deliver sample and/or PIOAL at controllable flow rates to optimize sample stream dimensions in tape format 32, more specifically as a thin tape at least as wide as the field of view of the high-resolution optical imaging device 24.
[00217] In one embodiment, the PIOAL source 27 is configured to supply the PIOAL at a predetermined viscosity. Such viscosity may be different from the sample's viscosity and may be greater than the sample's viscosity. PIOAL viscosity and density, sample material viscosity, PIOAL flow rate, and sample material flow rate are coordinated to keep the tape-shaped sample stream at offset distance from the standard. autofocus and with predetermined dimensional characteristics, such as an advantageous tape-shaped sample stream thickness.
[00218] In a practical embodiment, the PIOAL has a linear velocity greater than the sample and a viscosity greater than the sample thus extending the sample to form a flat ribbon. The viscosity of PIOAL can be up to 0.01 Pa.s (10 centipoise).
[00219] Still referring to Figures 2 and 3, the internal flow path of the flow cell narrows downstream from the injection point of the tape-shaped sample stream into the PIOAL to produce a stream thickness tape-format sample current, for example, up to 7 µm and/or the internal flow path produces a tape-format sample current width of 500 to 3000 µm. In exemplary embodiments, as depicted in Figure 1, the flow cell's internal flow path initiates the narrowing transition zone upstream from the sample stream injection point into the PIOAL.
[00220] In another embodiment, the internal flow path narrows to produce a tape-shaped sample stream thickness of 2 to 4 µm thick and/or the internal flow path results in the tape-shaped sample stream. 2000 µm wide tape. Such dimensions are particularly useful for hematology. The current thickness in this case is less than the diameter of some particles, such as red blood cells in their relaxed state. Consequently, such particles can become reoriented so that their widest dimension faces the geometric axis of imaging, which is useful for revealing distinguishing features.
[00221] The linear velocity of the tape format sample stream can be limited enough to avoid blurring by moving the scanned image in the exposure time of the photosensor array image. The light source can optionally be a strobe light which is flashed to apply a high incident amplitude for a brief moment. To the extent that the autofocus pattern 44 and the image are in the same field of view, the light source is configured to illuminate the tape-shaped sample stream and the autofocus pattern simultaneously. However, in other modalities, the fields of view for imaging and for autofocus may be different, eg lit and/or imaged separately.
[00222] Matter developments have aspects of method as well as apparatus. A method for focusing a visual analyzer comprises focusing a high resolution optical imaging device 24, which may be a high resolution optical digital imaging device or the digital image capture device, into a fixed auto focus pattern 44 with respect to a flow cell 22, wherein the autofocus pattern 44 is located at an offset distance 52 with respect to the tape-format sample stream 32. The high-resolution digital optical imaging device 24 has an objective with an optical geometry axis that intercepts the tape-shaped sample stream 32. A relative distance between the objective and the flow cell 22 is varied through the operation of a motor drive 54, while the distance along the optical geometry axis between the high resolution optical imaging device and the ideal focus point is known. The high resolution optical digital imaging device is configured to resolve and collect a digitized image onto a photosensor array. The motor drive is operated to focus on the auto focus pattern in an auto focus process. The motor drive is then operated over the travel distance, thus focusing the high-resolution optical imaging device on the tape-shaped sample stream.
[00223] The method may additionally include shaping the tape format sample stream into a tape format. The tape format is presented so that the optical axis of the optical high resolution imaging device is substantially perpendicular to the tape-shaped sample stream, more specifically normal to the plane of the tape-shaped stream.
[00224] Figure 4 represents aspects of a system 400 for imaging particles in a blood fluid sample. As shown in this document, system 400 includes a sample fluid injection system 410, a flow cell 420 and image capture device 430, and a processor 440. Flow cell 420 provides a flow path 422 that transmits a coating fluid flow, optionally in combination with the sample fluid. In accordance with some embodiments, sample fluid injection system 410 may include or be coupled to a cannula or tube 412. Sample fluid injection system 410 may be in fluid communication with flow path 422 (e.g. , through sample fluid inlet 402) and operable to inject sample fluid 424 through a distal outlet port 413 of cannula 412 and into fluent sheath fluid 426 within flow cell 420 so to provide a stream of sample fluid 428. For example, processor 440 may include or be in operational association with a storage medium that has a computer application that, upon being executed by the processor, is configured to cause the system to Injecting Sample Fluid 410 Inject the sample fluid 424 into the flowing coating fluid 426. As shown in this document, the coating fluid 426 can be introduced into the flow cell 4 20 through a coating fluid injection system 450 (eg, through coating fluid inlet 401). For example, processor 440 may include or be in operational association with a storage medium that has a computer application that, when run by the processor, is configured to cause sheath fluid injection system 450 to inject the fluid. of sheath 426 on flow cell 420. As depicted in Figure 4, the distal exit port 413 of the cannula 412 may be positioned at a central location along the length of the nip transition zone 419. Distal outlet may be positioned closer to the beginning (proximal portion) of transition zone 419. In some cases, the distal exit port may be positioned closer to the end (distal portion) of transition zone 419. In some cases, , the distal exit port 413 may be positioned completely outside the transition zone 419, for example, as shown in Figure 3A (where the distal exit port 331 is located. proximate to the transition zone of narrowing).
[00225] A sample fluid stream 428 has a first thickness T1 adjacent to the injection tube 412. The flow path 422 of the flow cell has a decrease in flow path size so that the thickness of the fluid stream of sample 428 decreases from the initial thickness T1 to a second thickness T2 adjacent to an image capture location 432. The image capture device 430 is aligned with the image capture location 432 so as to generate images of a first the plurality of particles of the first sample fluid at image capture site 432 of flow cell 420.
The processor 440 is coupled to the sample fluid injector system 410, the image capture device 430 and, optionally, the coating fluid injection system 450. The processor 440 is configured to stop injection of the first fluid of sample into the fluent coating fluid 426 and initiating an injection of the second sample fluid into the fluent coating fluid 426 so that sample fluid transients are initiated. For example, processor 440 may include or be in operational association with a storage medium that has a computer application that, when run by the processor, is configured to cause sample fluid injection system 410 to inject the second. sample fluid in the flowable sheath fluid 426 such that the sample fluid transients are initiated.
[00227] In addition, processor 440 is configured to begin capturing an image of a second plurality of particles of the second sample fluid at image capture location 432 of flow cell 420 after the sample fluid transients and the 4 seconds of imaging the first plurality of particles. For example, processor 440 may include or be in operational association with a storage medium that has a computer application that, when executed by the processor, is configured to cause image capture device 430 to initiate the capture of a imaging a second plurality of particles of the second sample fluid at image capture location 432 of flow cell 420 after the sample fluid transients and four seconds from imaging the first plurality of particles.
[00228] In some embodiments, processor 440 may include or be in operational association with a storage medium that has a computer application that, when executed by the processor, is configured to cause a cell motion control mechanism. The flow cell 442 adjusts the position of the flow cell 420, for example, relative to the image capture device 430. In some embodiments, the processor 440 may include or be in operational association with a storage medium that has a computer application. which, when executed by the processor, is configured to cause an image capture device motion control mechanism 444 to adjust the position of the image capture device 430, for example, relative to the flow cell 420. 442 and 444 motion control mechanisms may include motors, gimbals and other mechanical features that facilitate and produce motion in the flow cell and capture device of image, respectively. In some cases, the flow cell control mechanism 442 and/or image capture device control mechanism 444 may include a high-precision stepper motor control that provides automated motorized focusing of the image capture device. in relation to the flow cell. As shown in Figure 1, a processor can control the movement of the image capture device 24. Similarly, as shown in Figure 1B, a processor can control the movement of a flow cell conductor 55.
[00229] Therefore, embodiments of the present invention encompass particle analysis systems that perform combined viscosity and geometric hydrofocus to image particles in a blood fluid sample. Exemplary systems may include a flow cell that has a flow path with an injection tube and an imaging window with an imaging axis therethrough. The flow cell flow path may have a decrease in flow path size. In addition, analyzer systems may include a sheath fluid inlet in fluid communication with the flow path and a blood fluid inlet in fluid communication with the injection tube. The blood fluid inlet can be configured to inject the blood fluid sample into the flowing sheath fluid within the flow cell so that the blood fluid sample flows in a sample flow stream having a stream width of flux greater than a thickness of flux stream. The sheath fluid can have a viscosity that is greater than a blood fluid sample viscosity. In addition, the analyzer system can include an image capture device and a focusing mechanism that establishes a focal state of the image capture device with respect to the flow cell. In addition, the system may include an imaging target that has a fixed position relative to the flow cell, wherein the imaging target and sample stream stream define a displacement distance along the geometric imaging axis. The system may further include a processor and a focusing module having machine readable code embedding tangible media executed in the processor to operate the focusing mechanism to establish the focal state of the image capture device suitable for the characterization and counting of particles using displacement distance. The difference in viscosity between the sheath fluid and the blood fluid sample, in combination with the decrease in flow path size, can be effective to hydrofocus the first and second sample fluids on the imaging axis while maintaining the viability of cells in the blood fluid sample. In some cases, the focusing mechanism may include a drive motor configured to adjust a distance between the image capture device and the flow cell.
[00230] In some cases, an analyzer system 400 may include a thermal or temperature sensor 448 that is thermally coupled to the flow cell 420, as depicted in Figure 4. A focusing module, which may be operationally associated with the processor, may include machine readable code embedding tangible media that is executed in the processor to operate a focusing mechanism (e.g., flow cell control mechanism 442 or image capture device control mechanism 444) so to establish the focal state or focal plane of the image capture device, suitable for particle characterization and counting, in response to a change in temperature detected by the temperature sensor and a known relationship between the temperature and a desired focus.
[00231] Accordingly, embodiments of the present invention encompass a system 400 for imaging a plurality of particles in a blood fluid sample 424 that have a fluid sample viscosity. System 400 can be used with a coating fluid 426 that has a coating fluid viscosity that differs from the sample fluid viscosity by a viscosity difference within a predetermined range of viscosity difference. System 400 may include a flow cell 420 having a flow path 422 and a sample fluid injection tube 412. Flow path 422 may have a reduction in the size of the flow path or narrowing transition zone. In addition, system 400 may include a sheath fluid inlet 401 in fluid communication with flow path 422 of flow cell 420 so as to transmit a flow of sheath fluid along flow path 422 of flow cell 420 System 400 may further include a blood fluid sample inlet 402 in fluid communication with injection tube 412 of flow cell 420 so as to inject a flow or stream 428 of the blood fluid sample into the fluid. fluent coating 428 within flow cell 420. For example, sample fluid 424 may exit distal outlet port 423 of cannula 412 toward an envelope of fluent coating fluid 426 to form a sample tape 428 therein. .
[00232] As the coating fluid 426, together with the sample fluid strip 428 formed from the sample fluid 424, flows through a reduction 419 in the size of the flow path and towards an imaging location 432, a viscosity hydrofocus effect induced by an interaction between the coating fluid 426 and the sample fluid 424 associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the coating fluid 426 and the sample 424 associated with the reduction in flow path size, provides a target imaging state in at least a portion of the plurality of particles at imaging site 432. As shown herein, system 400 further includes an imaging device 430 which images the plurality of particles at the imaging site 432.
[00233] As shown in the flow cell modality depicted in Figure 4A, a decrease in the size of the flow path (for example, in the transition zone 419a) can be defined by opposing walls 421a, 423a of the flow path 422a. Opposite walls 421a, 423a may be angled radially inwardly along flow path 422a generally symmetrically about a transverse plane 451a that bisects sample fluid stream 428a. Plane 451a may bisect sample stream 428a where the sample stream has a first thickness T1 at a location where sample stream 428a exits a distal portion 427a of sample cannula or injection tube 412a. Similarly, plane 451a may bisect sample stream 428a where the sample stream has a second thickness T2, at a location where sample stream 428a passes image capture location 432a. According to some embodiments, the first thickness T1 has a value of about 150 µm and the second thickness T2 has a value of about 2 µm. In such cases, the compression ratio of the sample tape stream is 75:1. According to some embodiments, the first thickness T1 has a value in a range from about 50 µm to about 250 µm and the second thickness T2 has a value in a range from about 2 µm to about 10 µm. As the sample stream fluid flows through the flow cell, the ribbon thins as it accelerates and stretches. Two flow cell features can help to thin the sample fluid strip. First, a speed difference between the coating fluid envelope and the sample fluid strip can be operated to reduce the strip thickness. Second, the tapered transition zone geometry can be operated to reduce tape thickness. As depicted in Figure 4A, the distal outlet port 413a of the cannula 412a may be positioned at a central location along the length of the transition transition zone 419a. In some cases, the distal exit port may be positioned closer to the beginning (proximal portion 415a) of transition zone 419a. In some cases, the distal exit port may be positioned closer to the end (distal portion 416a) of transition zone 419a. In some cases, the distal exit port 413a may be positioned completely outside the transition zone 419a, for example as shown in Figure 3A (where the distal exit port 331 is disposed proximally to the transition zone of narrowing).
[00234] As depicted in Figure 4A (as well as Figures 4 and 4B-1), the transition zone 419a can be defined by angular transitions at the proximal 415a and distal 416a portions. It is further understood that transition zone 419a may instead have smooth or curved transitions at proximal 415a and distal 416a portions, similarly to smooth or curved transitions as depicted in Figures 1, 3, 3A, 3B and 4B-2).
[00235] Typically, the first thickness T1 is much larger than the size of the sample particles and therefore the particles are completely contained within the sample tape stream. However, the second thickness T2 can be smaller than the size of certain sample particles and, for that reason, such particles can extend out of the sample fluid and into the surrounding sheath fluid. As shown in Figure 4A, the sample tape current can generally flow along the same plane as it exits the cannula and travels toward the imaging site.
[00236] The flow cell may further provide a separation distance 430a between the distal cannula portion 427a and the image capture site 432a. In accordance with some embodiments, the distal portion 427a of the sample fluid injection tube 412a may be positioned an axial separation distance 430a from the image capture location 432a, where the axial separation distance 432a has a value of about 21 mm. In some cases, the axial separation distance 430a has a value in a range from about 16 mm to about 26 mm.
[00237] The axial separation distance 430a between the cannula exit port and the image capture location can impact the transition time for the sample fluid as the fluid moves from the exit port to the image capture location . For example, a relatively smaller axial separation distance 430a can contribute to a shorter transition time and a relatively larger axial separation distance 430a can contribute to a longer transition time.
[00238] The position of the outlet port in the distal portion of cannula 427a relative to the flow path transition zone 419a or relative to the proximal portion 415a of the flow path transition zone 419a, can also infer the transition time to the sample fluid as the fluid moves from the exit port to the imaging site. For example, the sheath fluid may have a relatively slower velocity at the proximal portion 415a and a relatively faster velocity at a location between the proximal portion 415a and the distal portion 416a. For this reason, if the cannula outlet port at the distal portion 427a is positioned at the proximal portion 415a, it will take a longer amount of time for the sample fluid to reach the image capture site, not just due to the fact that the travel distance is longer, but also due to the fact that the initial velocity of the sample fluid after it exits the distal cannula port is slower (due to the slower sheath fluid velocity). In other words, the longer the sample fluid is present in the thicker portion (eg, near the proximal portion 415a) of the flow cell, the longer the sample takes to reach the image capture site. On the other hand, if the cannula outlet port at distal portion 427a is positioned distal to proximal portion 415a (e.g., at a central location between proximal portion 415a and distal portion 416a, as shown in Figure 4A ), it will take a smaller amount of time for the sample fluid to reach the image capture site, not only because the displacement distance is shorter, but also because the initial fluid velocity of sample after it exits the distal cannula port is faster (due to the faster sheath fluid velocity). As discussed elsewhere in this document, the sheath fluid is accelerated as it flows through transition zone 419a, due to the narrowing cross-sectional area of zone 419a.
[00239] According to some arrangements, with a shorter transition time, there will be more time available for image collection at the image capture site. For example, as the duration of the transition time from the cannula distal tip to the imaging area decreases, it is possible to process more samples in a specific amount of time and, consequently, it is possible to obtain more images in a specific amount of time (per example, images per minute).
[00240] Although there are advantages associated with positioning the cannula distal portion outlet port 427a closer to the image capture location 432a, it is also desirable to maintain a certain distance between the port and the capture location. For example, as depicted in Figure 3, an optical objective or front lens of an imaging device can be positioned on the seat 58 of the flow cell 22. If the outlet port 31 of the cannula is too close to the seat 58, then the sample fluid may not be sufficiently stabilized after being injected into the coating fluid so as to provide the desired imaging properties at the image capture site. Similarly, it may be desirable to keep the tapered transition region 21 at a distance from the viewing zone 23 so that the tapered region does not interfere with the positioning of the seat 58 that receives the objective of the image capture device.
[00241] Still referring to Figure 4A, the downstream end 427a of the sample fluid injection tube 412a may be positioned distally to the proximal portion 415a of the flow path transition zone 419a. In addition, the downstream end 427a of sample fluid injection tube 412a may be positioned proximally to the distal portion 416a of flow path transition zone 419a. For this reason, in some embodiments, sample fluid can be injected from the injection cannula 412a and into the flow cell at a location within the transition zone 419a.
[00242] According to some embodiments, symmetry in decreasing the size of the flow path (for example, in the flow path transition zone 419a) operates to limit particle misalignment in the blood fluid sample. For example, such symmetry can be effective to limit the misalignment of imaging orientation of red blood cells in the blood fluid sample to less than about 20%.
[00243] According to some embodiments, the methods disclosed in this document are operable for signaling rate during blood count analysis to below 30%, 29%, 28%, 27%, 26%, 25%, 24 %, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6% or 5% of samples.
[00244] According to some embodiments, the image capture site 432a has a field of view 433a between about 150 μm x 150 μm and 400 μm x 400 μm. In some cases, the 432a image capture site has a 433a field of view of about 275 µm x 275 µm. In some cases, the field of view can be defined in terms of length times width. If expressed as surface area, a field of view of 275 μm x 275 μm has an area of 75,625 μm2. According to some modalities, the field of view can be determined by the objective of the imaging device and its magnification. In some cases, the field of view may correspond to the extent of the field (area) that is imaged by the optical collection elements (eg, objective, tube lens, and camera). In some cases, the field of view is much smaller than the viewport of the transparent area at the image capture location.
[00245] Figures 4A-1 and 4A-2 illustrate the effects of hydrofocusing on the sample stream as it travels from the cannula outlet port to the image capture site. As shown in Figure 4A-1, the sample stream can have a height H(S) of about 150 µm and a width L(S) of about 1350 µm. Furthermore, the PIOAL coating stream can have a height H(P) of about 6,000 µm and a width L(P) of about 4,000 µm. After hydrofocusing, as shown in Figure 4A-2, the sample stream can have a height H(S) of about 2 µm and a width L(S) of about 1350 µm. Furthermore, the PIOAL coating stream can have a height H(P) of about 150 µm and a width L(P) of about 4,000 µm. In one embodiment, the cross-sectional area of the PIOAL coating stream at the cannula outlet is 40 times greater than the cross-sectional area near the image capture site.
[00246] According to some embodiments, it may be useful to determine the cross section of the flow cell channel at the image capture site. It can correspond to a PIOAL H(P) sheath current height of about 150 µm and a width L(P) of about 4,000 µm, as depicted in Figure 4A-2. It may further be useful to determine the volumetric flow rate of the combined sample and coating fluids that flow continuously through the flow cell at the image capture site. When the cross-sectional area and flow rate are known, it is possible to determine the velocity of the combined sample and coating fluids at the image capture site.
[00247] According to some embodiments, the flow of sample and coating fluids through the flow cell can be approximated through a parallel plate profile model. Combined, the flow rate at the center of the sample fluid stream (for example, as depicted in Figure 4A-2), can be about 1.5 times the average flow rate of the combined sample and coating fluid stream. .
[00248] According to some embodiments, the cross-sectional area of the sample stream at the cannula outlet (for example, L(S) x H(S) in Figure 4A-1) is 40 times greater than the cross-sectional area cross-section of the sample stream at the imaging site (eg, L(S) x H(S) in Figure 4A-2). The volumetric flow rate of the sheath fluid in the imaging area can be about 45 µL/second. The volumetric flow rate of the sample fluid in the imaging area can be about 0.232 µL/second. In some cases, the cross-sectional area of the combined coating and sample streams at the imaging site is 600,000 μm2. In some cases, the average flow current velocity at the imaging site is 75 mm/second.
[00249] The flow rate or velocity can be determined as the rate that results in sharp and focused cellular images. Exemplary flow rates and velocities were found based on the flow rates of the two samples that were observed to achieve certain sample tape flow shapes and current characteristics at the imaging site. For example, at a flow rate of about 75 mm/sec (or in a range of 20 to 200 mm/sec), cells do not flow so slowly so that there are cell overlaps in consecutive images and cells do not flow as well. fast so that ghosting effects are created (blurry image). Additionally, by avoiding excessively high flow rates, it is possible to conserve more reagent and sample. According to some modalities, an ideal or desired linear velocity can be achieved by changing both the volumetric flow (pumping rate) and the shape of the cannula.
[00250] The flow rate of the sample stream through the image capture zone can also be related to the performance of the image capture device in relation to the flow cell function. For example, if the sample stream flows too fast, it can be difficult to get sharp images of particles contained in the sample (for example, the shutter speed of the image capture device can be too slow, thus producing a blurry image). Similarly, if the sample stream flows too slowly, the image capture device can take consecutive images of the same particle (for example, the same particle remains in the capture frame during two image captures). In some embodiments, the speed of the sample tape can be modulated (eg by adjusting any of a variety of flow cell operating parameters) against the image capture rate so that there is minimal flow between frame captures and for that reason a high percentage of the sample is imaged.
[00251] According to some embodiments, the particle analysis system and associated components can be configured so that the coating fluid and fluid sample flow through the flow cell, the coating fluid can flow at a fluid volumetric rate of 45 μL/s coating and fluid sample can flow at a volumetric fluid sample flow rate of 0.232 μL/s (or in a range of 0.2 to 0.35 μL/s). In some cases, the ratio of the coating fluid flow rate to the sample fluid flow rate is about 200. In some cases, the ratio of the coating fluid flow rate to the fluid flow rate of sample fluid has a value in a range of about 70 to 200. In some cases, the ratio of the coating fluid flow rate to the sample fluid flow rate is about 193. In some cases, the ratio of the sheath fluid flow rate to the sample fluid flow rate is about 70. In some cases, a ratio of sheath fluid volume to fluid sample volume flowing within the flow cell may be in a range of 25:1 to 250:1.
[00252] Under some embodiments, the system and associated components can be configured so that, as the coating fluid and fluid sample flow through flow cell 420, the coating fluid can flow at a fluid velocity of 75 mm/sec coating before the imaging area and the fluid sample can flow at a fluid sample velocity of 130 mm/sec before the imaging area. In some cases, a ratio of sheath fluid volume to fluid sample volume flowing within the flow cell may be in a range of 100:1 to 200:1.
[00253] In some cases, a flow cell may have a minimum compression ratio of about 50:1 and a maximum compression ratio of about 125:1. In some cases, the minimum compression ratio may be around 30:1 or 20:1. Such compression ratio refers to the ratio of flow stream thicknesses H(S):H(S) when comparing Figure 4A-1 with Figure 4A-2. This compression ratio can be influenced by a combination of geometric compression (for example, the ratio of sheath fluid thicknesses H(P):H(P) when comparing Figure 4A-1 with Figure 4A-2, which also can generally correspond to the dimensions of the tapered transition zone of flow cell narrowing 419a shown in Figure 4A) and a hydrodynamic compression (e.g., which also corresponds to a difference in velocity). Under some embodiments, the geometric compression ratio is about 40:1.
[00254] The decrease in the size of the flow path, which corresponds to the transition zone, can be defined by a proximal portion of the flow path that has a proximal height or thickness and a distal portion of the flow path that has a height or distal thickness that is less than the proximal height or thickness. For example, as shown in the partial views of Figures 4B-1 and 4B-2, the transition zone 419b of the flow path may have a length C between a proximal portion 415b and a distal portion 416b, where the proximal portion 415b has a proximal height 417b and the distal portion 416b has a distal height 418b. As depicted in Figure 4B-2 and as noted elsewhere in this document, the shape or contour of the transition zone can be curved or smooth and, for example, it can be provided in the shape of an S curve, a sigmoidal curve, or a tangent curve. Under some embodiments, the proximal height 417b has a value of about 6,000 µm. In some cases, the proximal height 417b has a value in a range from about 3000 µm to about 8000 µm. In some embodiments, the distal height 418b has a value of about 150 µm. In some cases, the distal height 418b has a value in a range from about 50 µm to about 400 µm.
[00255] The geometry of the transition zone 419a can provide a first angle α1 between the first flow path contour 403b and the transverse plane of bisection 451b and a second angle α2 between the second flow path contour 404b and the transverse plane of bisection 451b. In some cases, angle α1 is about 45 degrees and angle α2 is about 45 degrees. In some cases, angle α1 has a value in a range from about 10 degrees to about 60 degrees. In some cases, angle α2 has a value in a range from about 10 degrees to about 60 degrees. According to some modalities, angles α1 and α2 have the same value. Angles α1 and α2 can be selected to maintain laminar flow or minimize sample fluid turbulence as it moves from proximal portion 415b to distal portion 416b, which can, in turn, enhance particle alignment inside the sample along the transverse plane 451b. As noted above with reference to Figure 4A, the distal and proximal contours or portions of the transition zone can be curved or smooth rather than angled.
[00256] Figure 4C represents features of an exemplary cannula or sample feed tube 400c, in accordance with embodiments of the present invention, wherein the cannula has a length C. Figure 4D represents a longitudinal cross-section of cannula 400d. As shown in this document, cannula 400d includes a distal flat section 410d, a central tapered section 420d, and a proximal tubular portion 430d. As depicted in Figure 4C-1, an exemplary sample feed cannula or tube 400c-1 may have a distal portion 410c-1 and a proximal portion 430c-1. In some cases, the distal portion 410c-1 has a length of about 1.359 mm and a width of about 1.43 mm. In some cases, the distal end outlet port has an outlet width L(E) of about 1.359 mm. Under some embodiments, a cannula may have an internal flow path geometry that is different from what is depicted in Figures 4C and 4D. For example, as illustrated in Figure 4D-1, the 400d-1 cannula does not include a tapered center section that has an expanded flow area cross-section. As depicted in Figure 4D-1, cannula 400d-1 has a distal section 410d-1, a central tapered section 420d-1 that has a tapered inner diameter, and a proximal section 430d-1. Corresponding to the tapered inner diameter of the center section 420d-1, the inner cross-sectional area of 410d-1 is smaller than the inner cross-sectional area of 430d-1.
[00257] A hematology system, in accordance with the embodiments of the present invention, can process a blood sample having a volume of about 150 µL. The volume of blood aspirated can be around 120 to 150 μL. In some cases, the minimum blood volume available in the sample tube is about 500 µL for an automatic sampling mode and about 250 µL for a manual sampling mode. The 400d injection tube or tube shown in Figure 4D has an internal volume of about 13 µL. Under some modalities, the cannula or injection tube has an internal volume of less than about 30 uL.
[00258] Figure 4E illustrates a cross-section of a distal flat section 410e. As shown in this document, the distal section 410e has an inner width L(I) and an inner height H(I), through which a sample stream flows. Furthermore, the distal section 410e has an outer width L(O) and an outer height H(O). As depicted in Figures 4D and 4E taken together, the distal portion 410e of the sample fluid injection tube has an outlet port P that has a height H(I) and a width L(I), where the height H (I) is less than width L(I). According to some embodiments, the height H(I) of the outlet port P of the distal portion 410e (or the inner height of the distal portion 410d) may have a value of about 150 µm. In some cases, the height H(I) may be in a range from about 50 µm to about 250 µm. According to some embodiments, the width L(I) of the output port P of the distal portion 410e (or the inner width of the distal portion 410d) may have a value of about 1350 µm. In some cases, the width is around 1,194 µm. In some cases, the width L(I) may have a value in a range from about 500 µm to about 3000 µm. In some cases, the distal flat section 410d can be produced by applying a clamping force over a tube or conduit.
[00259] Figure 4F illustrates a cross-section of a central tapered section 420f. As shown in this document, the center tapered section 420f has an inside diameter D(I) through which a sample stream flows. In addition, the 420f tapered center section has an outside diameter D(O). Figure 4G illustrates a cross-section of a proximal section 430g. As shown in this document, the proximal section 430g has an inside diameter D(I) through which a sample stream flows. In addition, the 430g distal section has an outside diameter D(O).
[00260] As depicted in Figure 4D, the injection tube or cannula 400d may have a proximal portion 430d that has a first cross-sectional area of flow (eg π*(D/2)2 shown in Figure 4G), a portion distal 410d that has a second flow cross-sectional area (e.g., L(I)*H(I) shown in Figure 4E) that is smaller than the first flow cross-sectional area and a third portion 420d disposed between the proximal portion 430d and distal portion 410d. The third portion 420d may have a third flow cross-section (eg, π*(D/2)2 shown in Figure 4F) that is larger than the first and second flow cross-sections. In some cases, the outer diameter D(O) of the proximal portion 430g is about 1067 µm and the inner diameter D(I) of the proximal portion 430g is about 813 µm.
[00261] According to some embodiments, a proximal portion of an injection tube may be coupled to a sample port of a sample inlet fitting. For example, as shown in Figure 4H, a proximal 405 hr portion of a 400 hr cannula can be attached directly to a 410 hr sample port at an output of a 420 hr sample inlet fitting.
[00262] A flow cell of a system for imaging particles in a blood fluid sample can be oriented at any desired angle or direction relative to the direction of the force of gravity. For example, a flow cell can be oriented in an upward direction so that fluid flowing inside the flow cell (eg sheath fluid, optionally in combination with the sample fluid) can move in a an upward direction against the force of gravity. Similarly, a flow cell can be oriented in a downward direction so that fluid flowing inside the flow cell (eg, sheath fluid, optionally in combination with sample fluid) can move. in a downward direction in favor of the force of gravity. Figure 4I depicts a flow cell 420i oriented in an upward direction such that sample fluid 424i and sheath fluid 426i flowing within flow cell 420i flow against gravity G. Figure 4J depicts a cell flow cell 420j oriented in a downward direction, so that the sample fluid 424j and sheath fluid 426j flowing within the flow cell 420j do not flow against gravity G, but instead flow in favor of gravity G.
[00263] As shown in Figure 4K, a sample tape stream R flowing through a 432k image capture site of a 420k flow cell can have a thickness T of about 2 µm. In some cases, the thickness T of the sample tape stream can be up to about 3 µm. Typically, cells or particles that are smaller than the sample stream thickness will be contained within the tape. An exemplary red blood cell (red blood cells) may be present as a biconcave disk and may have a diameter D between about 6.2 µm and about 8.2 µm. Furthermore, an exemplary red cell may have a maximum thickness T1 between about 2 µm and about 2.5 µm and a minimum thickness T2 between about 0.8 µm and about 1 µm. In some cases, red blood cells can be up to about 3 µm thick. Exemplary human platelets can vary in size and can further have a thickness or diameter of about 2 µm. Although not shown to scale in this document, the flow cell can define a flow path thickness F that has a value of about 150 µm at the image capture location. In some cases, the flow path thickness F has a value between 50 µm and 400 µm. Such flow path thickness F may further correspond to the distal height 418b of the distal portion 461b depicted in Figures 4B-1 and 4B-2.
[00264] As shown in Figure 4K, the ratio of the thickness T of the sample fluid stream to the particle thickness (RBC) is about 1:1. Under some embodiments, a ratio of the thickness T of the sample fluid stream at the image capture site to a size of one of the particles is in a range of 0.25 to 25. In some cases, the thickness T may be a value in a range of 0.5 µm to 5 µm. A viscosity differential between the coating fluid and the sample fluid can be selected in order to achieve a desired positioning of the current sample tape within the flow cell.
[00265] Viscosity differences between the R sample tape fluid and the coating fluid can operate to align or orient particles in the sample stream, eg red blood cells, along the direction of flow. When aligned in such a way, as shown in Figure 4K, the imaging device or camera can image the red cells so that they appear rounded due to the fact that the main surface of the blood cell is facing towards the camera. Thus, the red blood cell assumes an alignment that has a low resistance to the flow. For this reason, the relative viscosity characteristics of the coating fluid and the sample fluid can contribute to a high percentage or amount of red cells facing the camera, thus enhancing the evaluability of the particle analysis system.
[00266] According to some embodiments, the sheath fluid viscosity characteristics operate to limit particle misalignment in the blood fluid sample. For example, viscosity differentials can be effective to limit the red cell imaging orientation misalignment in the blood fluid sample to less than about 10%. That is, 90 or more RBCs out of 100 RBCs in a sample can be aligned so that their main surfaces are facing the imaging device. A symmetric narrowing transition zone can provide a value of 20%. As discussed elsewhere in this document, for example with reference to Figure 4R, it is possible to compare the alignment results obtained using an analyzer setup involving a flowcell having a narrow symmetrical flowcell transition zone and a viscous sheath fluid for alignment results obtained through an analyzer setup involving a flow cell that has a symmetrical narrow flow cell transition zone without the use of a viscous sheath fluid. Using a viscous sheath fluid can reduce the percentage of misaligned cells. In some embodiments, the sheath fluid has a refractive index similar to that of water (i.e., n = 1.3330). In some cases, the coating fluid has a water content of around 89%. In addition to the alignment effects observed as a result of the viscosity differential, the alignment effects are also observed as a result of a bilateral tapered transition zone. In some cases, a bilateral tapered transition zone (i.e., symmetrical) is found to be twice as effective for aligning particles compared to an asymmetric tapered transition zone model.
[00267] The effective alignment of red blood cells can contribute to improve the diagnosis. In some cases, the shape of the imaged RBCs can be used to determine whether a patient in that obtained sample has a specific physiological condition or disease. For example, patients with sickle cell disease have blood cells that are abnormally shaped (that is, shaped like a sickle). For this reason, by obtaining high-quality images of aligned RBCs, it is possible to guarantee an accurate diagnosis. Other shape variations in red cells, for example, red cells that have a thin peripheral area and a large flat central area, because of which the red cell appears to have the profile of a bicycle tire, can be imaged effectively using the techniques of instant alignment. Similarly, red cells that have a small central portion and a thick peripheral area, because of which the red cell appears to have the profile of a truck tire, can be imaged for diagnostic purposes. The improved imaging techniques disclosed in this document are also useful to assess other characteristics of red blood cells, such as hemoglobin content, iron content, and the like.
[00268] Without being limited to any specific theory, it is believed that a viscosity differential between the coating fluid viscosity and the sample fluid viscosity produces a modified parabolic profile, where the profile is generally parabolic and has a central relief that corresponds to a central area of the flow where acceleration is increased and the central relief contributes to the alignment of sample particles or intraparticle organelles. Under some embodiments, the speed difference between the coating and the sample tape and the viscosity difference generate shear forces to increase the alignment of intracellular organelles or particles. Exemplary aspects of the sheath fluid parabolic profile are discussed in co-pending U.S. Patent Application, the contents of which are incorporated herein by reference.
[00269] White blood cells are typically larger than red cells and platelets. For example, exemplary neutrophils and eosinophils can have a diameter between about 10 µm and about 12 µm. Exemplary basophils can have a diameter between about 12 µm and about 15 µm. Exemplary (small) lymphocytes can be between about 7 µm and about 8 µm in diameter, and exemplary (large) lymphocytes can be between about 12 µm and about 15 µm in diameter. Exemplary monocytes can have a diameter between about 12 µm and about 20 µm. The Particle Analysis System setup, including the interaction between the coating fluid and the fluid sample tape as they pass through the flow cell, can operate to compress white blood cells as they travel through the capture site. of 432l imaging, as indicated in Figure 4L. Hence, for example, a central portion of the white blood cell (WBC) may be positioned within the sample fluid strip R and the peripheral portions of the white blood cell may be positioned in the sheath fluid. For this reason, as the white blood cell is transported through the flow cell by the tape, the sides of the white blood cell may extend into the sheath fluid. The numerical values or ranges for the thickness T of the sample tape stream R and the thickness F of the flow path, as discussed above in relation to Figure 4K, are similarly applicable to Figure 4L.
[00270] Under some embodiments, viscosity differences between the coating fluid and the sample fluid can operate to align organelles or other intracellular features that are present in cells, such as white blood cells. Without being limited to any specific theory, it is believed that the shear forces associated with the viscosity differential between the coating fluid and the sample fluid can act on the white blood cells to align the intracellular resources. In some cases, shear forces associated with velocity differentials between the coating fluid and the sample fluid can contribute to such alignment. These alignment effects can also be impacted by a size differential between the particles and the sample fluid strip. For example, where portions of the particles extend out of the sample fluid strip and into the surrounding sheath fluid, the shear forces associated with the difference in viscosity can have a marked effect on intracellular resource alignment.
[00271] As depicted in Figure 4L, portions of a cell such as a white blood cell may extend into the sheath fluid. Embodiments of the present invention encompass those sheath fluid compositions that do not lyse or fragment the cell or otherwise damage the integrity of the outer cell membrane when the cell is exposed to the sheath fluid. A viscosity agent in the sheath fluid can be operated to maintain cell viability in the sample fluid stream so as to leave the structure (e.g., shape) and contents (e.g., core) of the cells intact when membrane or cell wall crosses an interface between the sample fluid strip and the sheath fluid envelope or otherwise extends from the sample fluid stream to the fluent sheath fluid.
[00272] Often there are compressive forces acting on the cells or particles as they flow within the sample fluid strip along the flow cell. For this reason, cells can come into contact with the sheath fluid while the cells are in a compressed state or are otherwise subjected to compressive forces as a result of a narrowing transition zone. The sheath fluid viscosity agent can operate to protect the compressed cells so that they are not fragmented or destroyed when they emerge from the thin strip of sample fluid and become exposed to the viscous sheath fluid, at least until the cells reach the site. of image capture. For this reason, the sheath fluid viscosity agent composition can act as a cell protector, while also enhancing particle alignment or intraparticle content.
[00273] Referring to Figures 4K and 4L, in some cases, portions of the cell or particle may extend out of the thin strip of sample fluid R and into the surrounding sheath fluid. As discussed in co-pending U.S. Patent Application, the sheath fluid may contain cell protectors that inhibit or prevent the sheath fluid from rupturing or lysing the cells or particles. For example, the sheath fluid may contain cell protectors that preserve the structural integrity of the cell walls as the cells are exposed to the chemical environment of the sheath fluid. Similarly, cell protectors can further operate to preserve the structural integrity of the cell walls as the cells experience any shear forces induced by the flow cell geometry and a difference in velocity and/or viscosity between the sample fluid and the coating fluid. Associatedly, shields can protect cells or particles against forces resulting from the difference in velocity between the sample fluid and the coating fluid. In this way, the cells maintain their viability as they reach the image capture site.
[00274] Shear forces can be significant at the interface between the sample fluid strip and the coating fluid envelope. According to some embodiments, the flow within the flow path of the flow cell can be characterized by a parabolic flow profile. Figure 4L-1 represents exemplary aspects of the parabolic flux profile 400l-1a and 400l-1b. The 400l-1a parabolic profile on the top panel is a typical velocity profile found in flows within certain flow cell embodiments of the present invention (e.g., where there is little or no viscosity differential between a flow-flow fluid. that is enveloped within a stream of sheath fluid flow). As can be seen, a higher linear velocity is observed in the middle of the fluid stream and lower linear velocities are observed near the flow cell wall. The 400l-1a profile can also be seen in the fluid stream with a slight difference in viscosity between the coating and sample fluids. In a case where there is a high viscosity differential between the coating and the fluid streams, a central relief is observed, as shown in profile 400l-1b, in which a central area with amplified linear velocities is located. Under some embodiments, particles that are sufficiently large in size will be subjected to a certain amount of shear force, even where such particles are completely contained within a single fluid phase (i.e., both within the envelope coating fluid or alternatively inside the sample fluid strip).
[00275] In some cases, the velocity of the coating fluid may differ from the velocity of the sample fluid. For example, coating fluid can travel at 80 mm/second and sample fluid can travel at 60 mm/second. For this reason, in some cases, sample fluid exits the distal cannula port at a sample fluid velocity that is even slower than the surrounding envelope coating fluid velocity. For this reason, the sheath fluid can operate to drag the sample fluid along the flow path of the cannula, thereby accelerating the sample fluid and reducing the thickness of the sample fluid strip. The sample fluid strip maintains the overall volume and mass, so as it travels faster it becomes thinner. In some embodiments, both the coating fluid and the sample fluid have a velocity between about 20 and 200 mm/second at the image capture site.
[00276] Typically, the velocity of the sample fluid increases as the sample fluid moves from the cannula exit port to the image capture site. In some cases, the velocity of the sample fluid at the image capture site is 40 times the velocity of the sample fluid as it exits the cannula port in the distal portion of the cannula. Under some embodiments, the decrease in cross-sectional area of the sample tape is linear with respect to the increase in speed. According to some embodiments, if the coating speed at the cannula output is higher than the sample tape speed this will also increase the final sample tape speed in the imaging area.
[00277] The coating fluid can operate to apply significant shear forces on the sample fluid strip and on particles within the sample fluid strip. Some forces are parallel to the flow direction and particles can also encounter forces that are perpendicular to the flow direction. Often, as the coating fluid and sample fluid reach the image capture location or zone, the coating fluid and sample fluid travel at the same or close speeds. For this reason, the contour or interface between the coating and sample fluids, as they pass through the image capture site, may have lower shear forces compared to the contour or interface at the distal cannula outlet port or in the area of tapered transition. For example, in the tapered transition zone, the contour or interface between the coating fluid envelope and the sample fluid tape may be in transition so that the sample tape that is initially slower and thicker becomes thicker. faster and finer and the particles in the sample fluid become more aligned. In other words, shear forces can be prominent in the tapered transition zone and can dissipate towards the image capture location. The shear forces at the image capture site can be represented by a parabolic profile and can be much less than the shear forces at the tapered transition zone. For this reason, cells or particles may experience higher shear forces as they pass through the transition zone and lower shear forces as they pass through the image capture site. Under some embodiments, the difference in viscosity between the coating and sample fluids can bring the red cells into alignment and therefore into focus. Under some embodiments, the difference in viscosity between the coating and sample fluids can bring the white blood cell organelles into alignment and therefore into focus. Additionally, improved imaging results can be obtained for cellular and organelle components that are aligned and placed in focus, resulting from the geometric narrowing of the current and the velocity difference between the coating and sample fluids.
[00278] As noted elsewhere in this document and with reference to Figures 4K and 4L, as the sheath fluid and sample fluid R flow through a reduction in the size of the flow path or transition zone of a flow cell and towards a 432k or 432l imaging site, a viscosity hydrofocus effect induced by an interaction between the coating fluid and the sample fluid R associated with a viscosity difference between the coating fluid viscosity and the viscosity of sample fluid, in combination with a geometric hydrofocus effect induced by an interaction between the sheath fluid and the sample fluid R associated with a reduction in the size of the flow path or transition zone, provides a target-imaged state in atlas. minus a part of the plurality of particles at the 432k or 432l imaging site.
[00279] In some cases, the target imaging state is a target orientation relative to a focal plane F at the imaging site. For example, as depicted in Figure 4K-1, the particle (red blood cells) can be shifted a distance from the focal plane F. In some cases, the target orientation involves a target particle orientation with respect to the focal plane F at the 432k-1 imaging site. The particle can be a blood cell, such as a red blood cell, a white blood cell or a platelet. As shown in this document, the flow path at the 432k-1 imaging site may define a plane P that is substantially parallel to or coplanar with respect to the focal plane F. In some cases, a portion of the particle may be positioned along the plane focal F, however, the central portion of the particle may otherwise deviate from the focal plane F. In some cases, target orientation involves a target position relative to the focal plane F at the 432k-1 imaging site. For example, the target position may involve positioning the particle so that at least a portion of the particle is disposed along the focal plane F. In some cases, the target position may involve positioning the particle such that a distance between the particle and the focal plane F does not exceed a certain threshold. In some cases, the target position involves a target particle position that is related to the focal plane F at the 432k-1 imaging site. In some cases, the target position is at focal plane F or closer than distance D to focal plane F, where distance D corresponds to a position tolerance. A viscosity differential between the coating fluid and the sample fluid can be selected in order to achieve a desired positioning of the current sample tape within the flow cell (for example, with respect to plane P and/or focal plane F of the flow path). In some cases, the viscosity differential can be selected so as to achieve a target particle position that is in the D position tolerance or less.
[00280] In some cases, the focal plane F has a thickness or depth of field as indicated in Figure 4K-2 and the particle (red blood cells) has a target-imaging state relative to the focal plane thickness. For example, the target position for the particle may be in the focal plane F or at least partially in the focal plane F. In some cases, an imaging device or high-resolution optical camera may have a focal plane depth of field or thickness. of about 7 µm. In some cases, the depth of field or focal plane thickness has a value with a range from about 2 µm to about 10 µm. In some cases, the camera's depth of field is similar to or equal to the sample tape thickness at the image capture location.
[00281] In some cases, target orientation may involve target alignment in relation to the focal plane F at the imaging site. For example, target alignment may indicate that a plane defined by the particle is aligned with the focal plane F, so as not to exceed a certain angle α with respect to the focal plane F at the 432k-3 image capture location, as shown in Figure 4K-3. In some cases, the target imaging state may involve a limitation on the amount or percentage of misaligned particles in a sample. For example, a difference in viscosity between the sheath fluid and the R sample fluid may be effective to limit the red cell imaging orientation misalignment in the blood fluid sample to less than about 10%. That is, 90 or more RBCs out of 100 RBCs in a sample can be aligned so that their main surfaces are facing towards the imaging device (as depicted in Figures 4K-1 and 4K-2) or so that the alignment of such 90 or more RBCs is at 20 degrees with respect to the plane substantially parallel to the direction of flow (for example, the red blood cell alignment angle α is 20 degrees or less). As discussed elsewhere in this document, in some cases at least 92% of non-spherical particles such as RBCs may be aligned in a plane substantially parallel to the direction of flow. In some cases, at least between 75% and 95% of non-spherical particles such as RBCs may be substantially aligned, more specifically within 20 degrees of a plane substantially parallel to the direction of flow (eg the α angle of alignment is 20 degrees or less). According to some embodiments, 90% or more of certain particles (e.g., red cells and/or platelets) may be oriented transverse to the imaging axis of the imaging device.
[00282] In some instances, embodiments of the present invention include compositions for use with a hematology system as described herein, such as a sheath fluid or intracellular organelle and particle alignment fluid (PIOAL). Such sheath fluids or PIOALs are suitable for use in a combined geometric and viscosity hydrofocal visual analyzer. PIOAL can operate to direct or facilitate the flow of a blood sample fluid of a certain viscosity through a narrow flow cell transition zone of the visual analyzer. PIOAL can include a fluid that has a viscosity greater than the viscosity of the sample fluid. A viscosity hydrofocus effect induced by an interaction between the PIOAL fluid and the sample fluid associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the PIOAL fluid and the sample fluid associated with the Narrow flow cell transition zone may be effective to provide a target-imaging state on at least a portion of the plurality of particles at an imaging site of the visual analyzer, while maintaining the viability of the cells in the blood sample fluid.
[00283] Figure 4M depicts an exemplary 400m neutrophil (a type of white blood cell) that has internal organelles such as 410m lobes. As a result of the viscosity differential between the sample fluid and the sheath fluid, the inner organelles may line up inside the cell, as indicated in Figure 4N. For this reason, intracellular organelles can be imaged effectively with a 430m image capture device, without the organelles overlapping one another. That is, instead of the lobes being stacked on top of each other, as shown in Figure 4M, when viewed from the imaging or optical axis of the image capture device, the lobes are aligned and seated side by side, as shown in Figure 4N. For this reason, the lobes can be visualized in the captured images more effectively. The internal alignment of organelles is a surprising and unexpected result of the viscosity differential between sample and coating fluids. Consequently, improved imaging results that match the alignment of cells and cell in focus are achieved using viscosity differential, hydrodynamic flow, and geometric compression capabilities.
[00284] As noted elsewhere in this document and with reference to Figures 4M and 4N, as the sheath fluid and sample fluid R flow through a reduction in the size of the flow path or transition zone of a flow cell and towards an imaging site of an image capture device 430m or 430n, a viscosity hydrofocus effect induced by an interaction between the coating fluid and the sample fluid R associated with a viscosity difference between the viscosity of sheath fluid and sample fluid viscosity, in combination with a geometric hydrofocal effect induced by an interaction between the sheath fluid and sample fluid R associated with a reduction in the size of the flow path or transition zone, provides a target imaging state in at least a portion of the plurality of particles at the imaging site. According to some embodiments, the target imaging state may correspond to a distribution of imaging states.
[00285] In some cases, the target imaging state may involve an intraparticle target structure orientation (eg alignment and/or position) relative to a focal plane at the imaging site. For example, as depicted in Figure 4N, internal 410 m structures (eg, intracellular structure, organelle, lobule or the like) can be oriented relative to the focal plane F. In some cases, target alignment involves a frame alignment intraparticle-target relative to a focal plane F at the imaging site similar to the particle alignment relationship depicted in Figure 4K-3. In some cases, the target position involves an intraparticle target structure position relative to a focal plane at the imaging site similar to the particle position relationship depicted in Figure 4K-1. In some cases, the target orientation of the intraparticle structure may include both a target alignment in relation to the focal plane and also a target position in relation to the focal plane. In some cases, the target imaging state may involve a target deformation at the imaging site. For example, as depicted in Figure 4N, the 400m particle has a compressed shape compared to the particle shape depicted in Figure 4M. For this reason, it can be seen that the flow cell operation can produce a lateral compression effect on the particle shapes. Associatedly, the intraparticle features can be oriented positionally or directionally (eg, aligned relative to the focal plane F and/or tape flow plane) as the particle itself is compressed into shape. Under some embodiments, a velocity difference between the coating and sample fluids can produce friction in the flow stream and a viscosity difference between the coating and sample fluids can amplify such hydrodynamic friction. Examples
[00286] Any of a variety of hematology or blood particle analysis techniques can be performed using images of sample fluid flowing through the flow cell. Image analysis can often involve determining certain cell or particle parameters or measuring, detecting or evaluating certain cell or particle features. For example, image analysis may involve evaluating cell or particle size, cell nucleus resources, cell cytoplasm resources, intracellular organelle resources, and the like. In combination, analysis techniques may encompass certain methods of counting or grading or diagnostic testing including white blood cell differentials (WBC). In some cases, images obtained using the flow cell can support a 5-part WBC differential test. In some cases, images obtained using the flow cell can support a 9-part WBC differential test. Associatedly, with reference to Figure 4, processor 440 may include or be in operational association with a storage medium that has a computer application that, when executed by the processor, is configured to cause system 400 to differentiate different types of cells based on images obtained through the image capture device. For example, diagnostic or testing techniques can be used to differentiate various cells (eg, neutrophils, lymphocytes, monocytes, eosinophils, basophils, metamyelocytes, myelocytes, promyelocytes and blastulae).
[00287] The examples provided in this document are for illustrative purposes only and the invention is not limited to such examples; rather, it encompasses all variations that are evident as a result of the teaching provided in this document.
[00288] Prior to the experiments described in this document, there was no published protocol enabling the development and use methods that comprise PIOAL to align particles and reposition intracellular content, as disclosed in this document. This is useful for image-based analysis and categorization and subcategorization of particle differentials in body fluid samples (eg blood). The methods and compositions disclosed in this document may optionally stain and/or lyse particles in an appropriate manner to achieve white blood cell staining, reticulocyte staining, and platelet staining that mimics Wright's stained cells visualized in a single smear of whole blood.
[00289] The exemplary compositions described herein allow staining to occur at a relatively low blood-to-reagent dilution and staining can occur rapidly (eg, within 30 sec). If desired, the exemplary method can employ the use of a surfactant in combination with heat to be able to lyse red cells. Exemplary formulations can be modified to maintain red blood cell integrity and still achieve WBC, reticulum and platelet staining efficacy.
[00290] Aspects and modalities of the present disclosure are based on the surprising and unexpected finding that certain compositions of PIOAL have unexpected properties in aligning cells and repositioning intracellular structures when used to perform image-based particle/cell analysis .
[00291] By way of example, several exemplifying PIOAL formulations and methods for using them have been developed. The following are some examples of PIOAL formulations with the desired properties.
[00292] Figure 4O shows a comparison between images obtained using PIOAL versus images obtained using a non-PIOAL coating fluid. The use of PIOAL resulted in more focused cell contents, such as lobules, cytoplasm and/or granules. In this example, a PIOAL comprising a viscosity agent (about 30% glycerol) was used to process the sample. The pH was adjusted to a pH of about 6.8 to 7.2 and the sample mixture became isotonic (0.9% sodium chloride). The results shown in this document demonstrate the effectiveness of an exemplary PIOAL used in an image analyzer to align cells and intracellular organelles.
[00293] Figures 4P and 4Q show a comparison between images obtained using a standard coating fluid (top and bottom panels of Figure P) versus images obtained using an exemplary PIOAL fluid (top panels and bottom of Figure 4Q). As shown in this document, the use of PIOAL has resulted in improved red blood cell alignment, for example, orienting the main surfaces of the red cells so that they are facing towards the camera or imaging device. The sample was analyzed using an instrument focusing protocol (on an exemplary target as depicted in Figure 1) and the target was brought into focus using a visual analyzer. The focusing system was then compensated by the displacement distance 52, resulting in the fact that the particles in the tape-shaped sample stream are in focus. The blood sample was previously diluted using a sample diluent. The sample flowed through a cannula and along a flow path of a flow cell, thereby generating a tape-shaped sample stream (eg, 2 microns thick) that sits between two layers of PIOAL or coating - default (on controls). The visual analyzer then generates focused images of the particles in the sample stream in a tape format (eg, at about 60 frames per second) to be used for analysis. The blood sample is obtained from an individual and processed for analysis by the blood analyzer. Images of RBCs in a flow cell are captured while the sample is processed using a standard sheath fluid or a PIOAL. Relative percentages demonstrate a significant improvement in the number of RBCs aligned, based on imaging data (eg, 4P and 4Q). The result demonstrated that PIOAL was effective in increasing the percentage of red blood cell alignment during flow in the ribbon-shaped sample stream using the focusing instrument/protocols as described in this document.
[00294] It is further noted that the implementation of PIOAL results in improved alignment based on the use of increasing levels of glycerol (gly) in symmetrical and asymmetrical flow cells.
[00295] The graph in Figure 4R shows the percentage of non-aligned cells obtained using 0% to 30% glycerol in PIOAL with symmetric vs. flow cells. asymmetric. Using 30% glycerol in the PIOAL and a symmetrical flow cell results in a reduction in the percentage of misaligned cells to only 8%. It is observed that without the glycerol in the PIOAL and with an asymmetrical cell, the percentage of misaligned cells increased to 87%. For this reason, such a graph demonstrates the effect of glycerol percentage and flow cell geometry on particle alignment (eg, red blood cells). The addition of glycerol decreases the percentage of misaligned red blood cells using both symmetrical and asymmetrical flow cell geometry. The percentage (%) of unaligned RBCs was reduced from 87% to 15% in asymmetric cells and from 46% to 8% in symmetrical cells. As such, the graph provides a comparison between the misalignment results (8%) obtained using an analyzer setup involving a flow cell that has a symmetrical narrow flow cell transition zone and a viscous sheath fluid, and misalignment results (46%) obtained from an analyzer setup involving a flow cell that has a symmetrical narrow flow cell transition zone without the use of a viscous sheath fluid.
Such results provide evidence for the surprising and unexpected finding that certain compositions of PIOAL have unexpected properties in aligning cells and repositioning intracellular structures when used to perform an image-based particle/cell analysis.
[00297] By way of example, several exemplifying PIOAL formulations and methods for using them have been developed. The following are some examples of PIOAL formulations with the desired properties. PIOAL comprises a diluent and at least one viscosity modifying agent.
[00298] Exemplary PIOAL formulation A includes a 30% (v/v) glycerol solution that has 300 mL of glycerol and QS (sufficient amount or to raise the final volume) to 1 L with a diluent that contains 9, 84 g of sodium sulphate, 4.07 g of sodium chloride, 0.11 g of Procaine HCl, 0.68 g of monobasic potassium phosphate, 0.71 g of dibasic sodium phosphate and 1.86 g of disodium EDTA. The initial mix was followed by QS to 1 L with deionized water while adjusting the pH to 7.2 with sodium hydroxide.
[00299] Exemplary PIOAL formulation B includes a 6.5% (v/v) glycerol solution that has 65 mL of glycerol and QS to 1 L with a suitable exemplary diluent that contains 9.84 g of sodium sulfate , 4.07 g of sodium chloride, 0.11 g of Procaine HCl, 0.68 g of monobasic potassium phosphate, 0.71 g of dibasic sodium phosphate and 1.86 g of disodium EDTA. The initial mix was followed by QS to 1 L with deionized water while adjusting the pH to 7.2 with sodium hydroxide.
[00300] Exemplary PIOAL formulation C includes a 5% (v/v) glycerol solution with 1% PVP (weight to volume) in buffer that has 50 ml glycerol, 10 g PVP (molecular weight: 360,000 ), 1 packet of Sigma PBS powder, at a pH of 7.4 (0.01 M phosphate buffered saline; 0.138 M sodium chloride; 0.0027 M potassium chloride) and QS to 1 L with water deionized.
Exemplary PIOAL formulation D includes a 1.6% (weight to volume) PVP solution that has 16 g of PVP (molecular weight: 360,000) and 1 packet of Sigma PBS powder, at a pH of 7.4 (0.01 M phosphate buffered saline; 0.138 M sodium chloride; 0.0027 M potassium chloride) and QS to 1L with deionized water. Performance
[00302] Figure 5 represents a timeline 500 that corresponds to the injection of one or more sample fluids into a flow cell. As shown in this document, injection of a first sample fluid can be initiated into a flow cell as indicated by step 510. The particles of the first sample fluid can then be imaged in the flow cell as indicated by step 515. Under some embodiments, the first sample fluid may have a volume in a range of about 5 µL to about 150 µL. In some cases, the flow is 0.232 μL/sec (or in a range of 0.2 μL/sec to 0.35 μL/sec) in the imaging area. For 20 seconds of imaging, the flow value can be in a range of 5 µL to 15 µL. Injection of the first sample fluid may be stopped as indicated by step 520 and injection of a second sample fluid may be started into the flow cell as indicated by step 530. Sample fluid transients may be initiated as indicated by indicated by step 535 as a result of stopping the injection of the first sample fluid and starting the injection of the second sample fluid. Subsequently, the sample fluid transients in the flow cell may dissipate as indicated by step 445. Particles from the second sample fluid may be imaged in the flow cell as indicated by step 550. Injection of the second sample fluid can be stopped as indicated by step 560. In some cases, the injection and flow procedures are performed at temperatures in a range of about 18°C to about 40°C.
[00303] Typically, the sheath fluid current still flows within the flow cell as the sample is injected and as the injection is stopped. Therefore, in some embodiments, a continuous flow of coating fluid is maintained while sample fluid injections are pulsed into the flowable coating. The continuous flow of coating fluid can contribute to preserving a ribbon shape in the sample fluid as the sample fluid flows through the flow cell.
[00304] According to some modalities, the image capture associated with step 550 can be performed within four seconds of the image capture associated with step 515. According to some modalities, the time between injections of the first and second fluid of sample (for example, between steps 510 and 530) is about 30 seconds. Associatedly, in some embodiments, the time between initialization of imaging of the first and second sample fluids (e.g., between initialization of step 515 and initialization of step 550) is about 30 seconds. In this way, it is possible to process 120 sample fluids per hour. In some cases, an image capture device operates at a frame rate of 180 frames per second (FPS) thus producing multiple consecutive images or single frames at a high frequency or rate. As shown in this document, the duration of an imaging step (eg, 515 or 550) can be 15 seconds, thus producing 2,700 images per sample fluid.
[00305] In some cases, the first sample fluid reaches a stabilized state in about 1 to 3 seconds after injection (for example, step 510) of the first sample fluid from the sample fluid injection tube into the fluent coating. In some cases, the first sample fluid reaches a stabilized state in less than 1 second after injection (eg, step 510) of the first sample fluid from the sample fluid injection tube into the flowing coating fluid. Injecting the sample into the flow cell can be a two-step process. According to this modality, a first step is a high-speed pulse which clears all the diluent from the cannula and after the initial pulse, the sample flow rate is significantly reduced. Transition time can be defined as the time it takes the sample (eg a cell) to move from the cannula output to the imaging area under imaging flow conditions (slower sample flow rate). In some cases, the first sample fluid reaches a stabilized state and about 1.8 seconds from the injection (eg step 510) of the first sample fluid from the sample fluid injection tube into the fluent coating fluid. In some cases, the sample fluid has a transit time through the flow cell (eg, from a cannula outlet port to an image capture location) in a range of about 2 to 4 seconds.
[00306] According to some modalities, it takes about 5 seconds for the flow to stabilize or move from a distal exit port of the cannula to the imaging area. In some cases, an image capture duration period may be about 20 seconds.
[00307] A hematology system, in accordance with the embodiments of the present invention, can process a blood sample that has a volume of about 150 µL. The volume of blood aspirated can be around 120 to 150 μL. In some cases, the minimum blood volume available in the sample tube is about 500 µL for an automatic sampling mode and about 250 µL for a manual sampling mode. The 400d injection tube or cannula shown in Figure 4D has an internal volume of about 13 ul. In some embodiments, the cannula or injection tube has an internal volume less than about 30 µl. The blood sample volume is effective for purging the cannula before starting image collection and thus can avoid extended periods of time when the sample flow is not stable. For example, using a cannula that has an internal volume of about 13 uL can correspond to a sample flow instability period of about 2 to 3 seconds. Under some embodiments, the internal cannula volume may not impact sample flow stability. Under some embodiments, the cannula internal volume can impact the cell concentration stability in the sample strip itself if the initial high velocity sample pulse is insufficient to replace all of the diluent inside the cannula. Additionally, the cannula can be cleaned between samples in a small amount of time with the use of a small amount of diluent. In this way, it is possible to achieve a stable sample flow that facilitates the capture of a high quality image and, at the same time, achieve a high yield with a low residue persistence. Under some embodiments, a cannula with a high internal volume may require an initial high-speed, high-volume sample pulse to clear all the diluent in the lines and cannula. Embodiments of the present invention encompass the implantation of lower internal cannula volumes, which are suitable for hematology applications where available sample volumes are low and where a lower volume pulse can be achieved in a lesser amount of time.
[00308] According to some embodiments, hematology systems can be configured to limit sequential and transient sample cross-contamination in order to accelerate the image capture of blood fluid samples. Cell structure, content and alignment
[00309] According to some modalities, to achieve the coloration and visualization of white blood cells, it is useful to lyse red blood cells in the sample and permeabilize the white blood cells so as to allow the pigment to be incorporated into the white blood cells. It is often desirable to obtain white blood cell staining with little or no change in cell morphology. Furthermore, it is often desirable to obtain coloring properties that resemble a Wright's stain. In addition, it is often desirable to achieve high red cell alignment (eg, target >90%).
[00310] Figure 5A represents results obtained using a pigment formulation that does not include glutaraldehyde. It was observed that the cells deteriorated as a result of shear forces found in the flow cell. Although good staining of the nucleus has been obtained, the nucleus itself appears deformed and the cell membrane appears damaged. Briefly, when imaged, the cell appears to be destroyed due to disruption of cell content and structure.
[00311] Figure 5B represents WBC results obtained using a pigment formulation that includes glutaraldehyde. As shown in this document, cell membranes are intact and cells are rounded. For this reason, the non-gluteraldehyde version of the pigment (for example, shown in Figure 5A) was observed to result in weakened WBCs. Although the WBCs are more intact in Figure 5B, the core portions are damaged.
[00312] The sheath fluid (PIOAL) used to obtain the images in Figure 5B includes 30% glycerol. On the other hand, the sheath fluid (PIOAL) used to obtain the images in Figure 5C includes 6.5% glycerol. The lower concentration of glycerol resulted in better morphology, with the core mostly unchanged. For this reason, it was observed that the cell membrane in Figure 5C is even more intact than the cell membrane in Figure 5B. The lower concentration of glycerol in Figure 5C can operate to reduce the viscosity difference, thus reducing the shear force. If a shear force is present, the force can destroy cell membranes. Glycerol can have some properties that are incompatible with cells and therefore a higher concentration of glycerol can also destroy cell membranes. For this reason, it can be concluded that the core damage depicted in Figure 5A may be the result of 30% glycerol in the sheath fluid.
[00313] However, when the glycerol concentration was lowered to 6.5% as represented in Figure 5C it was observed that the alignment of red blood cells in the sample fluid decreased.
[00314] Several alternative formulations of PIOAL were used in an attempt to obtain improved alignment in red cells, however, such alternative formulations did not provide satisfactory results. For example, several different viscosity enhancers were tested, however, many of them exhibited similar behavior to the glycerol formulation greater than 30%, so the cell contents were damaged.
[00315] It was found that through the use of polyvinylpyrrolidone (PVP) and 5% glycerol as a viscosity agent component, it was possible to obtain a coating fluid that has a viscosity compatible with the viscosity of the 30% glycerol formulation (and for that reason, improved alignment results were achieved) without the negative effects of destroying the core. Figure 5D represents results obtained using a PIOAL with 5% glycerol and 1% PVP. For this reason, it can be seen that the viscosity agent in the sheath fluid maintains cell viability in the sample fluid stream so as to leave the structure and contents of the cells intact, for example, when cells flow through. of the flow cell and are exposed to the flowing sheath fluid. Under some embodiments, the percentage of glycerol concentration is expressed in terms of (v/v) and the percentage of PVP concentration is expressed in terms of (weight per volume).
[00316] Figure 5E represents image capture results based on a traditional microscope wet mounting technique (left column) compared to a flow cell technique, according to embodiments of the present invention (right column). The wet mounting procedure can be considered as a target standard for image clarity and quality. Techniques involving sheath fluids and designed flow cell as disclosed herein were found to be effective in achieving clarity and image quality equivalent to the wet mounting procedure.
[00317] According to some embodiments, a flow stream tape may split when the viscosity differential between the sample fluid and the coating fluid exceeds a certain threshold. Under some embodiments, a flow-stream ribbon split was observed when using a sheath fluid containing 60% glycerol. Methods
[00318] Figure 6 depicts aspects of an exemplary method 600 for imaging a plurality of particles using a particle analysis system configured to perform combined viscosity and geometric hydrofocus, in accordance with embodiments of the present invention. Particles can be included in a blood fluid sample 610 that has a sample fluid viscosity. As shown in this document, the method may include flowing a coating fluid 620 along a flow path of a flow cell as indicated by step 630. The coating fluid 620 may have a different coating fluid viscosity. of the sample fluid viscosity by a viscosity difference over a predetermined range of viscosity difference. The method may further include injecting the blood fluid sample 610 into the flowing sheath fluid within the flow cell as indicated by step 630 so as to provide a stream of sample fluid surrounded by the sheath fluid. In addition, the methods may include flowing the sample fluid stream and coating fluid by reducing the size of the flow path toward an imaging location as indicated by step 640. Conforming to the sample fluid stream and passing through the reduction in size of the flow path or narrowing transition zone, a viscosity hydrofocus effect induced by an interaction between the coating fluid and the sample fluid stream associated with the viscosity difference (as depicted in step 650), in combination with a geometric hydrofocal effect induced by an interaction between the sheath fluid and the sample fluid stream associated with the reduction in flow path size (as depicted in step 660), is effective to provide a target imaging state in at least a portion of the plurality of particles at the imaging site as a viscosity agent in the f coating fluid maintains cell viability in the sample fluid stream so as to leave the structure and contents of the cells intact as the cells extend from the sample fluid stream to the flowing coating fluid as represented by step 670. The methods may further include imaging the plurality of particles at the imaging site as represented by step 680.
[00319] Figures 6A and 6B represent exemplary flow stream characteristics related to shear force, lateral compression, orientation, viscosity differential, relative movement between coating and sample fluids, and the like.
[00320] Figure 6C depicts aspects of an exemplary method 6000 for generating particle images in a blood fluid sample, in accordance with embodiments of the present invention. As shown herein, blood sample 6010 includes particles and may be divided into portions into one or more sample fluids, such as a first sample fluid 6012 that contains particles and a second sample fluid 6014 that contains particles. The method may include flowing a sheath fluid along a flow path of a flow cell as indicated by step 6020. In addition, the method may include injecting first sample fluid 6012 from a fluid injection tube of to a fluent sheath fluid within the flow cell as indicated by step 6030 to provide a stream of sample fluid having a first thickness adjacent to the injection tube. The flow path of the flow cell may have a decrease in flow path size such that a thickness of the sample fluid stream decreases from the initial thickness to a second thickness adjacent and relative to an image capture location. Method 6000 may further include imaging a first plurality of particles from the first sample fluid at the flow cell image capture site, as indicated by step 6040.
[00321] Method 6000 may further include initiating sample fluid transients. For example, sample fluid transients can be initiated by interrupting the injection of the first sample fluid into the flowing coating fluid and by injecting the second sample fluid into the flowing coating fluid as indicated by step 6050. , method 6000 may include imaging a second plurality of particles of the second sample fluid at the flow cell image capture location as indicated by step 6060. Under some embodiments, imaging the second plurality of particles may be performed substantially after the sample fluid transients and within 4 seconds after imaging the first plurality of particles. Shear strain rate
[00322] Figures 7 and 8 represent aspects of shear strain rate values for certain flow conditions in a flow cell, according to embodiments of the present invention. In each such design, a 30% glycerol coating fluid is used. In some cases the viscosity may have a value of 2.45 x 10-3. A shear stress value can be equal to the product obtained by multiplying a viscosity value by a strain rate value. Referring to Figure 7, the sample can have a flow rate of 0.3 µL/sec and the sheath fluid can have a flow rate of 21 µL/sec. Referring to Figure 8, the sample can have a flow rate of 1 µLl/sec and the sheath fluid can have a flow rate of 70 µL/sec. In each of these Figures, it can be seen that the flow has a lower effort value towards the center (C) and a higher effort value towards the periphery (P). Such effort values may correspond to an asymmetrical flow cell configuration in some modalities.
[00323] As depicted in Figure 7, according to some embodiments, the lower strain rate towards the center portion (C) of the flow stream may have a value of about 500 (1/s) or less and the higher strain rate towards the periphery (P) of the flow stream may have a value of about 3,000 (1/s) or higher. As depicted in Figure 8, according to some embodiments, the lower strain rate towards the center portion (C) of the flow stream may have a value of about 1,000 (1/s) or less and the strain rate higher towards the periphery (P) of the flux current can have a value of about 9,000 (1/s) or higher.
[00324] For this reason, it can be seen that lower sample and coating fluid rates (eg Figure 7) correspond to lower strain rates and higher sample and coating fluid rates (eg Figure 8 ) correspond to higher effort rates. It is understood that embodiments of the present invention encompass the use of sample and/or coating fluids corresponding to various viscosity values, various strain rate values and/or various shear stress values. auto focus target
[00325] The PIOAL can be introduced into a flow cell and transport the sample through the imaging area, then towards the discharge. The sample fluid stream can be injected through a cannula with a flat slit to establish a flow path of considerable width. For example, PIOAL can have a relatively higher viscosity relative to the sample fluid, adequate density and flow rates at the sample injection point are such that the sample fluid is flattened into a thin ribbon format. The sample fluid tape is transported along with the PIOAL to pass in front of a viewing port where a high resolution optical imaging device and a light source are arranged to view the sample stream in tape format.
[00326] The tape-formatted sample stream is transported together with the PIOAL to pass in front of a viewing port on which a high-resolution optical imaging device and a light source (eg, UV, visible or IR ) are arranged to view the sample stream in tape format. The high-resolution optical imaging device and light source can be placed on opposite sides of the flow cell to obtain back-illuminated images of particles such as blood cells. The high resolution optical imaging device captures images of sample pixel data through a viewing port in the flow cell. For example, the high-resolution optical imaging device captures images at a repetition rate consistent with the velocity of the sample stream so that sections of the tape-format sample stream are imaged without substantial spacing or overlapping.
[00327] The embodiments of the present invention provide several unique structural and functional features deployed in the design and operation of a system to collect images of a tape-shaped sample stream flowing through a flow cell. Exemplary modalities are configured to obtain sufficiently focused images of the particles, with sufficient clarity and resolution to reveal the different features of the various particles, such as blood cells, that allow particle and/or cell types to be distinguished from one another. of others.
[00328] To bring the tape-format sample stream into focus, the distance between the high-resolution optical imaging device and the tape-format sample stream can be established, so that the tape-format sample stream. tape is at a desired distance (eg, the focusing distance) from the optical high-resolution imaging device along the optical axis.
[00329] A focusing distance is a characteristic of optical high resolution imaging device lenses used to resolve the image into a photosensor array, more specifically defined by the material, shape and dimensions of the lens elements and their configuration and placement to the along the optical geometric axis. The dimensions of the area of the sample that is imaged and the depth of field that is in focus in the sample are determined by the lens setting.
[00330] Aperture adjustments and zoom adjustments are possible, however, for the purposes of simplicity, certain examples in this disclosure are such that the focusing of the high-resolution optical imaging device on the particles in the tape-shaped sample stream it simply requires relatively positioning the high-resolution optical imaging device and the tape-shaped sample stream in the flow cell at a correct distance, more specifically the distance that a focused image resolves in the photosensor array (eg, a charge-coupled device array) of particles in the tape-shaped sample stream. The high resolution optical imaging device may include a camera which records or transmits still images or video images for display and/or processing and/or transmission.
[00331] In one aspect, the symmetrical nature of the flow cell and the manner of injection of the sample fluid and PIOAL provide a repeatable position in the flow cell for the tape-shaped sample stream in the PIOAL. However, the relative positions of the flow cell and the high-resolution optical imaging device undergo change and require occasional position adjustments to maintain the optimal distance between the high-resolution optical imaging device and the shaped sample stream. tape thus providing a quality in-focus image.
[00332] Embodiments of the present invention encompass automated visual analyzer systems and methods for blood and/or other biological fluids that incorporate an autofocus device/apparatus to provide reliably focused images of the sample through very accurate establishment of the distance between currents. tape format sampler and the high resolution optical imaging device. In one aspect, the modalities of the autofocus system disclosed in this document can very precisely establish the distance between the tape-format sample stream and the high-resolution optical imaging device and reliably capture focused images of the sample. In some modalities, algorithms are used to establish the distance that achieves good focus results.
[00333] It is an objective to employ a flow cell that provides a stable and highly repeatable position for a tape-shaped sample stream encased in a PIOAL stream, in combination with a high resolution optical imaging device and device/apparatus auto focus that maintains the ideal distance between the high resolution optical imaging device and the tape-format sample stream, thus providing a focused, quality image.
[00334] Such apparatus and methods are disclosed and claimed in this document. A symmetrical flowcell is provided which has been found to produce a repeatable tape-shaped sample stream position within the flowcell. Focusing involves establishing a precisely correct relative position of the high-resolution optical imaging device with respect to the tape-format sample stream so as to maintain focus on the tape-format sample stream.
[00335] Advantageously, the flow cell and/or the optical high resolution imaging device can be moved relative to each other in an autofocus process using an autofocus pattern such as a high contrast pattern or similar focusing target, preferably a flat target with strongly contrasting features, such as edges, where the auto focus pattern is fixed in position relative to the flow cell and used as a focusing material instead of the sample in themselves. The tape-shaped sample stream is a thin tape at a fixed distance from the autofocus pattern along the line parallel to the optical axis of the high-resolution optical imaging device. The offset distance between the auto focus pattern and the position of the tape-format sample stream is a constant distance, which is initially determined and programmed in the auto focus procedure. The exemplifying technique further comprises automatically focusing on the autofocus pattern, then shifting the high resolution optical imaging device and/or flow cell relative to one another by the predetermined known and constant distance, whereby the distance between the device optical resolution and the location of the tape format sample stream is the ideal distance to provide a focused quality image of the tape format sample stream. For example, first, an autofocus algorithm focuses the position of the high-resolution optical imaging device on the autofocus pattern located at a fixed distance from the tape-shaped sample stream. After focusing on the auto focus pattern, the processor operates the motor drive over the fixed distance so as to thereby bring the tape-shaped sample stream into focus of the high-resolution optical imaging device.
[00336] An exemplary high-resolution optical imaging device comprises an objective lens and an associated pixel image sensor that can capture an image that reveals particles at a sufficient magnification and resolution to provide sufficient detail to resolve the particles' visual capabilities. In certain modalities, the magnification is higher by a factor of at least 2x (thus providing a 2x image area for each image taken) thus generating more detailed information for each particle compared to traditional hematology analyzers.
[00337] The PIOAL flow path can be arranged symmetrically so that equal amounts of PIOAL flow above and below the tape-shaped sample stream that extends and locates the tape-shaped sample stream as a thin tape at a fixed distance from the autofocus pattern along the line parallel to the optical axis of the high-resolution optical imaging device. In one embodiment, the autofocus pattern comprises an opaque rim around a slit that admits light from a backlight source and the distance of the autofocus pattern is ready and unambiguously housed via the autofocus controls. Then, the tape-shaped sample stream is brought into focus by displacing the high resolution optical imaging device with respect to the flow cell over the predetermined distance and the constant displacement distance. There is no need to automatically focus directly on the sample image content, although additional autofocus is possible.
[00338] An automated focusing configuration includes a motor drive that adjusts the relative position of the flow cell and a high-resolution optical imaging device along the optical axis responsive to control signals from a processor that evaluates one or more measures focus quality over a range of distances and seeks an optimal distance. For example, the processor can evaluate a contrast measure and operate the motor drive to automatically focus. In normal operation, the processor operates the motor drive to automatically focus on the target and then adjusts the distance between the high-resolution optical imaging device and the flow cell by the recorded displacement of the target to set the sample current. in tape format in focus. As long as the device continues to move the tape-shaped sample stream in the same direction and thermal expansion or similar factors that may cause confusion do not arise, the image of the tape-shaped sample stream will remain in focus.
[00339] A preliminary setup or calibration process can be used to determine and record the displacement distance between the target and the position of the sample stream in tape format in the flow cell. The exact displacement distance which may differ slightly for different flow cells is established through preliminary tests, such as automatically focusing alternatively on the target and a sample stream in test tape format several times, and recording the average result as a constant associated with the flow cell.
[00340] Consequently, a sample to be imaged, such as a prepared blood sample or other type of sample, is directed along a defined flow path through a viewing zone in a flow cell. The PIOAL flow path is preferably symmetrical and the sample is injected into the center of the PIOAL flow with which the sample is enveloped. The flow rates and viscosity and density characteristics of the sample and the coating material, such as a PIOAL, along with the contour of the flow cell, cooperate to shape the tape-shaped sample stream into a flat tape that consistently flows through the viewing zone in a repeatable position.
[00341] The sample can be imaged by a camera component of the high resolution optical imaging device and digital images collected to be analyzed by at least partially automated image analysis processes, including an autofocus process as described in this document.
[00342] One objective is to distinguish, categorize, subcategorize and/or count particles, such as blood cells in blood samples as well as other biological samples described in this document, that may be associated with specific conditions. In one aspect, the particle contrast agent compositions of this disclosure can be combined with a visual analyzer such as the analyzer described herein in a method for providing surprisingly high quality focused images of flow cells. Cells can be captured and processed automatically.
[00343] The images allow for automated imaging based on differential WBC counts, as well as automated identification of morphological anomalies useful in determining, diagnosing, prognosing, predicting and/or sustaining a diagnosis to determine whether an individual is healthy or has a disease, condition, abnormality and/or infection and/or to determine or monitor whether the individual is responsive or non-responsive to treatment. Cell category and/or subcategory counts in blood samples are used in this disclosure as non-limiting examples of the types of fluids that can be analyzed.
[00344] In one aspect, image analyzers for use with the compositions of this invention can reliably capture focused images of the sample by very accurately establishing the distance between the tape-format sample stream and the high-resolution optical imaging device of the optical system. In some embodiments, visual analyzers can be used in combination with the compositions of this invention and algorithms to establish said distance that can achieve good focus results. The sample is arranged in the flow cell and illuminated for viewing through a viewing port. Individual cells or particles appear clearly in the pixel data image with enough feature detail to reveal attributes that are then compared and contrasted with parameters known to distinguish cell categories and subcategories from each other.
[00345] It is an object to employ a flow cell in combination with the exemplary particle contrast agent compositions described in this document and an exemplary PIOAL that provides images of optimal quality and detail for particle recognition. In addition, the PIOAL and instrument provide a stable and highly repeatable position for an enveloped tape-format sample stream in a PIOAL stream. This, in combination with a high resolution optical imaging device and the auto focus device/apparatus that maintains the optimum distance of the high resolution optical imaging device from the tape format sample stream provides a focused quality image . auto focus target
[00346] Again referring to Figure 1, particle imaging systems can include an autofocus pattern or target 44 that is fixed relative to the flow cell 22. The autofocus target 44 can be used to achieve focused images of particles of blood fluid flowing through the flow cell.
[00347] Figure 9A represents an exemplary autofocus target 900, in accordance with embodiments of the present invention. As shown in this document, target 900 includes an opaque annular band 910 and a transparent aperture or center 920. During operation, the imaging device focuses on band 910 and captures the image through the aperture. As discussed elsewhere in this document and in co-pending U.S. Patent Application, an image capture process may involve first focusing (or automatically focusing) on band 910 and then adjusting a distance between the capture device. and the sample fluid stream before imaging through aperture 920. Consequently, band 910 can present a target on which an autofocus system of the image capture device can detect and focus, and certain portions of the target (eg edges or segments) can be included in the image. In some cases, the target can be provided as a chrome disk that has a central opening. An exemplary target may be provided with a central microhole, having a diameter of about 0.5 mm, which is glued or attached to the flow cell. The size of the central microhole or aperture 920 can be selected so that only four edge portions 930 of the opaque annular band 910 are visible in the captured image 940, as illustrated in Figure 9B. Therefore, the annular band 910 does not interfere with cell image capture (for example, light can pass through the aperture 920 so as to illuminate the sample particles and the field of view is substantially unhindered by the annular band. ). In this way, band 910 appears only in the corners of the image.
[00348] Figure 10 represents an exemplary autofocus target 1000, according to embodiments of the present invention. Target 1000 includes a band or rim 1010 and a central aperture 1020. Figure 11 shows another exemplary autofocus target 1100, in accordance with embodiments of the present invention. Target 1100 includes a band or rim 1110 and a center aperture 1120. Under some embodiments, auto focus target 1100 provides an image that has 50 pixels of black at the top and bottom. In some cases, the 1100 auto focus target provides a flow cell focus offset (FCFO) of about 65.3 µm. Aspects of the FCFO are further discussed in co-pending U.S. Patent Application, the contents of which are incorporated herein by reference.
[00349] Figure 12A represents an exemplary autofocus target 1200, according to embodiments of the present invention. Target 1200 is shown as a mailbox design and includes a first rim or upper rim 1210 and a second rim or lower rim 1220. Target 1200 further includes a transparent opening or passageway 1230 between the first and second rims. According to some embodiments, the target has a diameter of about 4 mm and the height of the mailbox is 265 µm. In some cases, the upper and lower edges may be present as half circles and may be produced from a deposited metal such as chromium oxide or some other opaque material.
[00350] Figure 12B shows a close-up view of the central portion of the auto focus target 1200. As shown in this document, the first bead 1210 includes a negative/positive numerical scale with a centered zero value. The second rim 1220 includes a similar scale. In some cases, the scale increments are 100 µm. In some embodiments, scales can be used to facilitate the positioning of the flow cell so that the field of view of the imaging device or camera can be centered on the sample stream. As shown in this document, sample stream 1240 flows in a direction perpendicular to the scales of the first and second lips. As a part of a focusing protocol, the image capture device may operate to focus on numbers or other imageable characters or objects present on the edges 1210 and 1220.
[00351] The embodiments of the present invention encompass techniques to solve the thermal slip associated with the use of the particle analysis system, whereby such thermal effects can otherwise understand the quality of images obtained with the imaging device. Figure 13A is a partial side view of a flow cell 1320 that has a thermal sensor 1370, a reflector 1380, and an autofocus target 1344. During operation of a particle analysis system, thermal effects can cause the sample stream slowly slides out of focus of the imaging device. For example, thermal effects can be caused by thermal expansion of the flow cell through radiated heat from the lamp. Furthermore, thermal effects can be caused by thermal expansion of the flow cell assembly and the optical bank assembly (OBA) through conduction heating and radiation. In some modalities, certain OBA components can expand, which can contribute to targeting errors. For example, such components can include metal plates that hold the camera 24 together, a metal plate that holds or is connected to the flow cell, or a metal plate that holds both the flow cell and camera 24 together. Figure 13B represents a partial perspective view of flow cell 1320 having thermal sensor 1370 and auto focus target 1344. In addition, Figure 13C represents another perspective view of flow cell 1320 having thermal sensor 1370, the 1380 reflector and the 1344 auto focus target.
[00352] Figure 13B represents a partial perspective view of the flow cell 1320 having the thermal sensor 1370 and the autofocus or imaging target 1344. According to some embodiments of the present invention, an image capture device can be focused on the sample flow stream using a temperature that is sensed through a thermal sensor associated with the analyzer. For example, the temperature can correspond to a sample fluid temperature, a sheath fluid temperature, a flow cell temperature, or an image capture device temperature. In some cases, temperature is a temperature at the imaging site of a flow cell. In some cases, temperature is a temperature at a location downstream of the imaging site. In some cases, temperature is a temperature at a location upstream of the imaging location. In accordance with some embodiments of the present invention, an image capture device can be focused on the sample flow stream using a rate of change temperature associated with the analyzer. For example, the temperature change rate corresponds to a sample fluid temperature change rate, a coating fluid temperature change rate, a flow cell temperature change rate, or a temperature change rate of image capture device.
[00353] Figure 13C represents another perspective view of the flow cell 1320 that has a thermal sensor 1370, a reflector 1380 and autofocus or imaging target 1344. The reflector 1380 can operate to reduce or limit the amount of heat absorbed by the flow cell 1320. For example, reflector 1380 can block heat radiated by a flash lamp 1342, as indicated in Figure 13A. For this reason, the 1380 reflector can minimize the thermal impact of the lamp. The 1342 reflector can further reduce glare and scattering of light generated by the lamp, thus resulting in improved image quality. The 1370 thermal sensor is positioned close to the fluid flow channel and adjacent to the imaging location so that accurate temperature readings can be obtained. Information from the temperature sensor can be used to focus the image capture device on the sample fluid tape stream. The exemplary autofocus techniques disclosed in this document may be based on temperature fluctuations that occur within certain elements of the analyzer.
[00354] As depicted in Figure 13D, a flow cell 1320d may include a flow path 1322d that has a port or vent 1301d through which bubbles 1302d can be released or removed. As shown in this document, a tube 1303d, through which vacuum can be applied, can be brought into contact with port 1301d in order to withdraw bubbles 1302d from the flow stream. Such a bubble removal mechanism is suitable for removing bubbles from fluid flowing within the flow cell and can operate to prevent bubbles or microbubbles from being housed or trapped within the flow cell.
[00355] In accordance with some embodiments, a method for imaging particles in a blood fluid sample may include flowing a sheath fluid along a flow path of a flow cell and injecting the blood fluid sample. blood in the sheath fluid flows within the flow cell, so that the blood fluid sample flows in a sample flow stream with a flow stream width greater than a flow stream thickness, so that the flow cell has an associated temperature. Furthermore, the method may include focusing an image capture device, along an imaging geometric axis, in the flow stream to a first focal state while the temperature associated with the flow cell is at a first temperature and acquiring a first image focused of a first subset of the particles within the flux stream with the image capture device in the first focal state. In addition, the method may include determining that the temperature associated with the flow cell has undergone a change from the first temperature to a second temperature and automatically adjusting the image capture device's focus from the first focal state to a second focal state in response. to the change in temperature and a known relationship between flow cell temperature and desired focus. Furthermore, the method may include acquiring a second focused image of a second subset of the particles within the flow stream with the image capture device in the second focal state.
[00356] In some cases, the process of adjusting the focus of the image capture device includes adjusting a distance between the image capture device and the flow cell using the change in temperature and the known relationship between the temperature of flow cell and the desired focus. In some cases, the process of adjusting the focus of the image capture device includes adjusting a focal length of the image capture device using the change in temperature and the known relationship between the flow cell temperature and the desired focus. dynamic range extension
[00357] Figure 14 is a block diagram showing additional aspects of systems and methods for achieving detection range extension or dynamics for particle analysis in blood samples, in accordance with embodiments of the present invention. As shown in this document, at least one digital processor 18 is coupled to operate the motor drive 54 and to analyze the scanned image from the photosensor array as collected at different focus positions relative to the auto focus target pattern 44 The processor 18 is configured to determine a focus position of the auto focus pattern 44, that is, to automatically focus on the auto focus target pattern 44 and thus establish an optimal distance between the optical high resolution imaging device. 24 and the autofocus pattern 44. This can be achieved through image processing steps, such as applying an algorithm to assess the contrast level in the image at a first distance, which can be applied to the entire image or by the less on an edge of the auto focus pattern 44. The processor moves the motor 54 to another position and evaluates the contrast at that position or edge and after two or more interactions determines an optimal distance that maximizes focus accuracy in autofocus pattern 44 (or optimizes focus accuracy if moved to such a position). The processor relies on the fixed spacing between the auto focus pattern of the auto focus target 44 and the tape format sample stream, the processor 18 then controls the motor 54 to move the high resolution optical imaging device 24 to the correct distance to focus on the 32 tape format sample stream. More specifically, the processor operates the motor to shift the distance between the high resolution optical imaging device and the 32 tape format sample stream by the distance of offset 52 (see Figure 1) by which the tape-shaped sample stream is shifted from the auto focus target pattern 44. In this way, the high-resolution optical imaging device is focused on the tape-shaped sample stream. ribbon.
[00358] According to some embodiments, the visual analyzer 17 is an exemplary analyzer 17 of Figure 1. The visual analyzer 17 may comprise at least one flow cell 22 and at least one imaging device 24, such as an imaging device High resolution optical that has an imaging sensor, just like a digital camera. Visual analyzer 17 may further comprise a sample injector 29. Sample injector 29 is configured to deliver sample 12 within at least one flow cell 22. A flow cell 22 defines an internal PIOAL flow path which narrows, for example, symmetrically in the direction of flow. A flow cell 22 is configured to direct a flow 32 of sample through a display zone in flow cell 22.
[00359] Figure 14 illustrates the auto focus and another aspect of digital imaging, as described. Such techniques can be employed in conjunction with the non-imaging-based blood cell apparatus or perhaps less image-related than the modalities described, such as Coulter blood cell counters, also known as cytometers flow. Such counters are known to detect and count blood cells and particles in fluid, but not usually through imaging. In such a counter, a flow cell is arranged to transport a stream of particles surrounded by a fluid. The flow cell narrows to force particles into the flow path in a single row. A pair of electrodes or other detectors that span the flow path produce a count by detecting a pulsed change in electrical impedance or obstruction of a light path between a light source and a photo detector as cells pass.
[00360] Flow cytometers are advantageous due to the fact that a large amount of cells or other particles can be counted, much greater than the amount of cells that can be practically imaged on a visual counter. However, flow cytometers are not as effective at distinguishing between cells based on type or at making distinctions between normal and abnormal cells or at distinguishing clustered cells, such as platelet nodules, from distinct blood cells. By operating an analyzer, for example, the visual analyzer, as described, across a statistically significant amount of image frames of a tape-shaped sample stream, a proportional distribution or ratio of blood cell types can be measured . Proportional ratios determined from a visual analyzer or a function thereof, are applied to blood cell counts and large amounts of blood cells counted through the cytometer, although with less discrimination or no discrimination as to cell type, to provide an accurate whole blood count that exploits the unique advantages of both types of analyzers.
[00361] According to some embodiments, particle counts can be inferred by applying an algorithm, for example, an algorithm based on a proportional ratio of particle counts. Figure 14 illustrates an exemplary apparatus adapted for analyzing blood. In some embodiments, the particle counter 15 and the visual analyzer 17 can be connected in series as well as parallel. The particle counter 15 can be, for example, a Coulter blood cell counter, which detects and counts blood cells and particles in fluids. In such a counter, a flow path (not shown) is arranged to carry a stream of particles enveloped in a fluid. The flow path narrows to force particles on the flow path into a single row. A pair of electrodes or other detectors that span the flow path produce a count by detecting a pulsed change in electrical impedance or obstruction of a light path between a light source and a photo detector when cells pass. Particle counter 15 is configured to count a large number of cells or other particles. However, the particle counter 15 may not have the ability to distinguish between members in subcategories of cells and/or to distinguish between normal and abnormal cells or to distinguish clustered cells such as platelet nodules from distinct blood cells.
[00362] The visual analyzer 17 may further comprise at least one contact chamber 25 configured to provide at least one chemical that comprises at least one of a diluent, a permeabilizing agent, a contrast agent effective to generate visual distinctions for the categorization and/or subcategorization of particles. For example, as shown with reference to Figures 1 and 14, contact sample is introduced into the flow cell through sample injector 29 and a coating alignment reagent or intracellular organelle is introduced from injector 27. A diluent can be used to dilute the sample to a suitable concentration. A contrast agent and/or permeabilizing agent is used to generate visual distinctions to categorize and/or subcategorize particles. PIOAL is used to align certain cell types or cell structures in one direction for better imaging. In some embodiments, the at least one chemical can be applied to contact a sample first and then the treated sample is delivered to the visual analyzer 17. Sample treatment with the addition of at least one chemical can be carried out at room temperature. In some embodiments, such treatment may be carried out at a temperature such as 10, 15, 20, 25, 30, 35, 36, 37, 38, 38, 39, 40, 45, 46, 47, 48, 49 or 50° Ç. Treatment at a selected temperature can be conducted in an incubator that is separate from the visual analyzer 17 or in a visual analyzer 17 that is temperature controlled.
[00363] In some embodiments, the visual analyzer may have a contrast agent injector to bring the sample into contact with a contrast agent and/or permeabilizing agent or surfactant. In other embodiments, the sample may be placed in contact with the contrast agent in order to permeabilize the agent prior to injection into the visual analyzer. In other embodiments, the visual analyzer contains heating elements to heat the sample while in contact with the contrast agent and/or permeabilizing agent, at a controlled temperature for a controlled time. The visual analyzer may also have a cooling element to cool the sample mixture after the heating step. Contrast agent compositions and exemplary methods that can be used to process blood fluid samples are disclosed in copending U.S. Patent Application, the contents of which are incorporated herein by reference.
[00364] By operating the visual analyzer 17 as described, through a statistically significant amount of image frames of a sample stream in tape format, a proportional ratio of cells into cell categories and/or subcategories can be determined through of processor 18. The proportional ratios determined from the visual analyzer 17 are applied to the blood cell counts and the larger amounts of blood cells counted by the particle counter 15, although it has less discrimination or no discrimination as to members in a category and/or cell subcategory, to provide an accurate whole blood count that exploits the unique advantages of both the particle counter 15 and the visual analyzer 17.
[00365] In addition to providing accurate results, the apparatus comprising a particle counter 15 and a visual analyzer 17 offers significant advantages to improve analysis speed. In Figure 14, accurate counting results of different blood cells can be output via display 63. During an analysis process, an operator can interact with processor 18 via a terminal 65. Previously, from about 25% to about 30% of the results were manually reviewed by producing slides with a contrast agent, which were examined under a microscope by an operator. In comparison, an exemplary method using the apparatus of this invention comprises a CBC in a particle counter and categorizes and/or subcategorizes blood cells according to some modalities. By operating the instrument as described in this disclosure, images can be reviewed on the visual analyzer and samples will require less frequent manual review.
[00366] The engine 54 can comprise a gear step motor with a precision considerably less than the distinguishing features imaged by the high resolution optical imaging device or the digital image capture device, especially the aspects of blood cells. Since the location of the high resolution optical imaging device 24 is adjusted to locate the position of the optical objective in the width of the tape-format sample stream, the cell/particle view in the tape-format sample stream will be in focus . The auto focus pattern may be located at an edge of a field of view of the high resolution optical imaging device or digital image capture device and does not interfere with viewing for that reason.
[00367] Furthermore, when the optical high resolution imaging device is moved along the shift distance and the auto focus pattern goes out of focus, the features that appear in focus are the blood cells instead of the auto focus pattern . According to some modalities, the auto focus pattern can be defined by formats in the field of view. Shapes are relatively thin discrete shapes of a limited size and therefore, after moving the offset distance, shapes become substantially invisible in the digitized image when focused on the tape-shaped sample stream. A typical displacement distance might be, for example, 50 to 100 µm in a flow cell sized for hematology (blood cell) imaging applications. In some modalities, the auto focus feature keeps the high-resolution optical imaging device within 1 µm of the optimal focus distance.
[00368] The internal contour of the flow cell and the flow rates of PIOAL and sample can be adjusted so that the sample forms a ribbon-shaped stream. The stream can be approximately as fine as, or even finer than, the particles that are encased in the tape-shaped sample stream. White blood cells can have a diameter of about 10 µm, for example. By providing a tape-shaped sample stream with a thickness of less than 10 µm, the cells can be oriented when the tape-shaped sample stream is extended by the sheath fluid or PIOAL. Surprisingly, extending the tape-shaped sample stream along a narrowing flow path in layers of PIOAL with a different viscosity than the tape-shaped sample stream, such as a higher viscosity, tends to advantageously align the non-spherical particles in a plane substantially parallel to the direction of flow and applying forces on the cells so as to enhance the in-focus contents of the intracellular structures of the cells. The optical axis of the high-resolution optical imaging device 24 is substantially normal (perpendicular) to the plane of the tape-shaped sample stream. The linear velocity of the tape-shaped sample stream at the imaging point can be, for example, 20 to 200 mm/second. In some embodiments, the linear velocity of the tape-format sample stream can be, for example, from 50 to 150 mm/second.
[00369] Tape-format sample stream thickness can be affected by the relative flow rates and viscosities of sample fluid and PIOAL. Sample source 25 and/or PIOAL source 27, for example, which comprise precision displacement pumps, can be configured to deliver sample and/or PIOAL at controllable flow rates to optimize sample stream dimensions in tape format 32, more specifically as a thin tape at least as wide as the field of view of the high-resolution optical imaging device 24.
[00370] In one embodiment, the PIOAL source 27 is configured to supply the PIOAL at a predetermined viscosity. Such viscosity may be different from the sample's viscosity and may be greater than the sample's viscosity. PIOAL viscosity and density, sample material viscosity, PIOAL flow rate, and sample material flow rate are coordinated to keep the tape-shaped sample stream at the offset distance from the standard autofocus and with predetermined dimensional characteristics, such as an advantageous tape-shaped sample stream thickness.
[00371] In a practical embodiment, the PIOAL has a linear velocity greater than the sample and a viscosity greater than the sample, thus extending the sample to form a flat ribbon. The viscosity of PIOAL can be up to 0.01 Pa.s (10 centipoise).
[00372] In the mode depicted in Figure 14, the same digital processor 18 that is used to analyze the digital pixel image obtained from the photosensor array is also used to control the auto focus motor 54. Meanwhile, the imaging device 24 high optical resolution is not automatically focused for all captured images. The autofocus process can be achieved periodically or, for example, when temperature changes or other process changes are detected by the appropriate sensors or when image analysis detects a potential need to refocus. It is also possible, in other modalities, to have the hematology image analysis performed by a processor and to have a separate processor, optionally associated with its own photosensor array, arranged to handle the autofocus steps to a fixed target 44.
[00373] In Figure 14, the at least one said digital processor 18 is configured to automatically focus on scheduled times or on scheduled conditions or on demand by the user, and is also configured to perform categorization and subcategorization based on images of the particles. Exemplary particles include cells, white blood cells, red blood cells and the like.
[00374] In one embodiment, said at least one digital processor 18 is configured to detect an auto focus reset signal. The auto focus reset signal can be triggered through a detected change in temperature, a decrease in focus quality as discerned by the parameters of pixel image date, passage of time or user input. Advantageously, it is not necessary to recalibrate in the displacement distance measurement direction 52 to recalibrate. Optionally, autofocus can be programmed to recalibrate at certain frequencies/intervals between cycles for quality control and/or to maintain focus.
[00375] The displacement distance 52 varies slightly from one flow cell to another, however, it remains constant for a given flow cell. As a setup process, when docking an image analyzer with a flow cell, the offset distance is estimated first and then during the calibration steps where the autofocus and imaging aspects are exercised, the distance Exact displacement for the flow cell is determined and entered as a constant in the processor 18's programming.
[00376] Referring to Figure 15, an exemplary apparatus 10 for analyzing a sample 12 that contains particles includes a particle counter 15 that has at least one detection range, an analyzer 17 and a processor 18, in accordance with some embodiments . The block diagram in Figure 15 is for illustrative purposes. Particle counter 15, analyzer 17 and processor 18 may or may not be connected to each other. In some embodiments, the processor may be coupled to the particle analyzer and/or counter. In other embodiments, the processor can be a component of the particle analyzer and/or counter.
[00377] The particle counter 15 comprises at least one channel and is configured to provide a particle count for at least one category and/or subcategory of particles. In some embodiments, a particle counter 15 comprises at least two channels for different categories and/or subcategories of particles. In some embodiments, particles are counted by detecting the electrical impedance or light scattering of the sample. An example of a suitable particle counter 15 includes, but is not limited to, a flow cytometer. In some embodiments, detection can occur in each of a plurality of channels responsive to different physical properties, either simultaneously or sequentially.
[00378] The analyzer 17 is configured to differentiate different categories and/or subcategories and corresponding members of each category and/or subcategory of particles. Examples of a suitable analyzer 17 include, but are not limited to, a visual analyzer, a digital camera, or any other pixel data analyzer that can capture pixel data and is programmed to discriminate among attributes represented in a pixel file. Processor 18 and analyzer 17 are configured to apply an algorithm such as determining a proportional ratio of the counts of two categories or two corresponding subcategories of particles and applying such proportional ratio to the counts of particles of at least one category and/or subcategory of particles obtained in at least one channel of particle counter 15. After data analysis, processor 18 provides, at output 20, an accurate measure of the concentration of each category and each corresponding subcategory of particles in sample 12.
[00379] In some embodiments, in sample 12, at least a first category and/or subcategory of particles may be present at a concentration outside a detection range applicable to the first category and/or subcategory of particles, while at least a second category and/or subcategory of particles is present at a concentration in a detection range applicable to the second category and/or subcategory of particles. The concentration of the second category and/or subcategory of particles is determined in particle counter 15. A proportional ratio of the first category and/or subcategory to the second category and/or subcategory of particles is determined in analyzer 17. The concentration of particles in the The first category and/or subcategory is calculated in processor 18, at least in part, by applying such a ratio proportional to the concentration of the second category and/or subcategory of particles.
[00380] In some embodiments, a category and/or subcategory of particles detected in the at least one channel of the particle counter 15 may comprise at least two classes of particles. And each class of particles can comprise a plurality of subclasses. Particle counter 15 is configured to detect a plurality of particles that satisfy one or more selection criteria, e.g., based on a predetermined size range, and to provide a count of particles therefrom. Selection criteria cover members of at least two classes of particles. Analyzer 17 and processor 18 are programmed to distinguish between members of the at least two categories and/or subcategories of particles. A distribution of each of the members across at least two categories and/or subcategories is determined at processor 18. Processor 18 uses such distribution to correct the particle count for members of at least one of the at least two categories and/or subcategories obtained in the particle counter 15.
[00381] More specifically, the apparatus 10 can be used to identify and quantify different blood cells including RBCs, WBCs, PLTs and other blood cells, fetal cells or bacterial cells, viral particles, parasites, cysts, including parasitic cysts, crystals or fragments thereof or other cell fragments in a sample.
[00382] Figure 15A represents aspects of an exemplary counter or counting module 1500a, in accordance with embodiments of the present invention. Such counters can operate to control or perform various mechanical functions as well as electronic and photometric measurement functions for counting WBC cells, red blood cells and PLT and hemoglobin measurements. Exemplary counters can be used to prepare samples for CBC analysis and to generate CBC parameter measurements through aperture bath assemblies (eg, WBC bath 1510a and red blood cell bath 1520a). In some embodiments, counter 15 of Figure 15 may be represented by counter 1500a of Figure 15A. Similarly, in some embodiments, counter 15 of Figure 14 may be represented by counter 1500a of Figure 15A. In some embodiments, counter 722 of Figure 16 may be represented by counter 1500a of Figure 15A.
Cellular elements of the blood (eg, red blood cells, white blood cells, and platelets) can be counted using electrical impedance methods. For example, an aspirated whole blood sample can be divided into two aliquots and mixed with an isotonic diluent. The first dilution can be delivered to the opening bath of red blood cells 1520a and the second can be delivered to the opening bath of WBC 1510a. In the red blood cell chamber, red blood cells and platelets can be counted and discriminated by electrical impedance as cells pass through the sensor openings. For example, particles between 2 and 20 fL can be counted as platelets, and those larger than 36 fL can be counted as red blood cells. For processing the white blood cell chamber, a red cell lysis reagent can be added to the white blood cell dilution aliquot to lyse the red cells and release hemoglobin, and then the white blood cells can be counted by impedance at the sensing openings of the bath. of white blood cells. In some cases, baths can include multiple openings. Thus, for example, a blood cell count used in a blood cell enumeration technique can be obtained by using a triple opening red blood cell bath.
[00384] An exemplary blood count sample preparation technique can include two processes, sample collection and sample placement. Sample capture can occur when 165 uL of patient sample is aspirated and directed to a Blood Sampling Valve (BSV). The BSV can operate to direct specific volumes of patient sample with processing reagents for delivery to the two triple opening baths. Patient sample and processing reagents can be delivered to the bottom of the opening baths at an angle that, with a rounded design, allows the sample and reagents to mix thoroughly without showing mixing bubbles. The sample can then be prepared for measurement and analysis. According to some modalities, in the WBC bath, 6.0 mL (± 1.0%) of diluent and 28 uL of sample can be combined with 1.08 mL (± 1.0%) of DxH cell lysate to a final dilution of 1:251. Under some modalities, in the red blood cell bath, 10 mL (± 1.0%) of diluent and 1.6 uL of sample can be combined for a final dilution of 1:6250. After the patient sample and reagents are mixed, vacuum and opening current can be applied to the openings for cell count and cell volume measurements. RBC and platelet counts may also include the application of drag flow to prevent cell recirculation near the opening. In certain modalities, data capture for red blood cells and platelets can be a maximum of 20 seconds and a maximum of 10 seconds for white blood cells. In certain modalities, all analog pulses generated by the aperture sets can be amplified by a "preamp" card and then sent to a blood count signal conditioning analyzer card for analog to digital conversion and parameter extraction. Under some embodiments, a system can be used to measure multiple parameters for each cellular event and a digital parameter extraction process can be used to provide digital measurements such as time, volume (pulse attributes including amplitude and pulse width ), counting and counting rate and waiting time. Such measurements can be used for pulse editing, coincidence correction, count voting, histogram generation for WBC, red blood cells and PLT, histogram voting, pattern analysis and interface correction, and the like.
[00385] Figure 16 represents aspects of systems and methods for measuring an amount of a first cell type in a blood fluid sample, wherein the sample further includes a second cell type, according to embodiments of the present invention. As shown herein, method 700 may include obtaining a first sample volume 720 and a second sample volume 730 from blood fluid sample 710. As indicated in step 724, the method may include determining a population of the second type of cell in the first volume 720 of the sample by flowing the first volume through a hematology cell counter 722. Often, the cell counter 722 is suitable for accurately counting cells when there is a sufficient amount of an electrically discernible type of cell in the sample and not when the number of cell types exceeds a certain threshold or threshold. Cell counters can be used to count red blood cells or the total amount of other components (eg, large components) in a blood sample in a small amount of time. In some cases, cell counters may encounter challenges when discriminating between white blood cells and other components (eg, large components) in the blood, or of which there may be several different species with a relatively small amount of each.
[00386] In addition, method 700 may include capturing images of a first quantity of the first type cells and a second quantity of the second cell types, as indicated by step 732, by injecting the second volume 730 of the sample into a fluid of coating that flows within a flow cell to provide a sample stream that has a thickness and a width greater than the thickness, where the captured images are captured along an image path that traverses the thickness of the stream. of sample. In some cases, image capture 732 can be performed using an analyzer 17, as depicted in Figure 14 and/or Figure 15. In some cases, analyzers can effectively discriminate between white blood cells, giant platelets, and others large components in the blood fluid sample. However, there can be challenges when using such analyzers to obtain a complete particle count in a sample. Furthermore, in some cases, it may not be desirable to use the analyzer to obtain certain counts (for example, a count of all red cells) due to the fact that such counting procedures may also involve performing a particle characterization as well. in addition to getting the count. Under some embodiments, the analyzer is used to image only a percentage or portion of the sample that is processed through the analyzer.
[00387] As depicted in Figure 16, method 700 may include determining a ratio of the first amount of the first cell type 734 to the second amount of the second cell type 736 using the captured images as indicated in step 738. The methods further include calculating a measure of cell quantity of the first cell type in the sample using ratio 738 and population of second cell type 724 as indicated in step 740.
[00388] According to some embodiments, the cell quantity measure calculated in step 740 is a cell concentration for the first cell type in the blood fluid sample 710. In some cases, the cell quantity measure calculated in the step 740 is a cell count for the first cell type in blood fluid sample 710. In some cases, cell counter 722 has a first accuracy associated with counting the first cell type and a second accuracy associated with counting the second cell type, where the second accuracy is greater than or greater than the first accuracy. In some cases (see, for example, Figures 19A and 19B) the 722 hematology cell counter has a desired accuracy range and the desired accuracy range extends between a minimum population of cells in the first volume 720 and a population maximum number of cells in the first volume 720, where the population of the second cell type in the volume determined in step 724 is in the desired accuracy range and where the cell quantity measure of the first cell type of the sample calculated in step 740 is outside the desired accuracy range.
[00389] As further depicted in Figure 16 (and still referring to Figures 19A and 19B), the methods may include optionally determining a population of the first cell type 726 in the first volume of the sample as a result of flowing the first volume through the 722 hematology cell counter. The determined population of the first cell type 726 in the first volume may be above or below a desired accuracy range for the first cell type and may also be different from the measured quantity of cell of the first cell type as calculated in step 740. In some cases (for example, Figure 19A), the determined population of the first cell type 726 is zero. In some cases (for example, Figure 19B), the determined population of the first cell type 726 is greater than zero.
[00390] In accordance with some embodiments of the present invention, the 722 hematology cell counter may include a sensor mechanism that detects a change in electrical impedance in response to a second cell type flowing through the cell counter. In some embodiments, hematology cell counter 722 includes a sensor mechanism that detects an obstruction of a light path in response to a second cell type flowing through the cell counter.
[00391] In some cases, the 722 hematology cell counter has a minimum detectable concentration limit and a maximum detectable concentration limit for the first cell type and a minimum detectable concentration limit and a maximum detectable concentration limit for the second type of cell. The determined population of the second cell type 724 can be based on a detected concentration parameter for the second cell type that is above a lower threshold and below the upper threshold for the second cell type. The first cell type can be present at a concentration that is either below the lower limit or above the upper limit for the first cell type.
[00392] In some cases, the 722 hematology cell counter has a minimum detectable volume limit and a maximum detectable volume limit for the first cell type and a minimum detectable volume limit and a maximum detectable volume limit for the second cell type. The determined population of the second cell type 724 can be based on a sensed volume parameter for the second cell type that is above the lower threshold and below the upper threshold for the second cell type. The first cell type can be present in a volume parameter that is either below the low limit or above the high limit for the first cell type.
[00393] In some cases, the 722 hematology cell counter has a minimum detectable size limit and a maximum detectable size limit for the first cell type and a minimum detectable size limit and a maximum detectable volume size for the second cell type. The determined population of the second cell type 724 can be based on a detectable size parameter for the second cell type that is above the lower threshold and below the upper threshold for the second cell type. The first cell type can be present in a size parameter that is either below the minimum limit or above the maximum limit for the first cell type.
In accordance with some embodiments of the present invention, (see Figures 13b and 13c), determining the population of the second cell type 724 in the first sample volume includes grouping the cells of the first cell type and cells of the second cell type. In some cases, the methods may even include calculating a measure of cell quantity of the second cell type in the sample using the ratio and population of the second cell type. In some cases (for example, as depicted in Figure 19D), determining the population of the second cell type 724 in the first sample volume includes grouping cells of the first cell type and cells of the second cell type and determining a population of the first cell type 726 in the first volume of the sample which results in flowing the first volume through the hematology cell counter 722. The measure of cell quantity of the first cell type in the sample as calculated in step 740 can use ratio 738, population of second cell type 724, and population of first cell type 726.
[00395] In other aspects, for example, as depicted in Figure 17 and/or Figures 19A and 19B, a method is provided for analyzing a sample that contains particles. In such a method, a sample is provided in a particle counter that has detection limits as indicated in step 72 in method 70 of Figure 17. At least a first category and/or subcategory of particles may be present in the sample at a concentration outside a detection range applicable to the first category and/or subcategory of particles and at least one second category and/or subcategory of particles is present in the sample within the detection range applicable to the second category and/or subcategory of particles. The concentration of the second category and/or subcategory of particles in the sample is determined in the particle counter as indicated in step 74. The sample is also provided in an analyzer to determine a proportional ratio of the first category and/or subcategory of particles to the second category and/or subcategory of particles as indicated in step 76. The concentration of particles in the first category and/or subcategory can then be calculated at least in part by applying the ratio proportional to the concentration of the second category and/or subcategory of particles as indicated in step 78. Figure 19A shows the detection of particles in a sample below the detection range and Figure 19B shows the detection of particles present in the sample above the detection range.
[00396] Figure 17 thus illustrates an exemplary method 70 for determining the concentration of the first category of particles that are present in a sample at a concentration outside a detection range in a particle counter, according to some modalities. In step 72, also referring to Figures 15 and 17, a sample 12 is provided in a particle counter 15 which has at least one detection range. Sample 12 includes particles that can be dispersed in a fluid. In some embodiments, the first category of particles is present in the sample at a concentration above an upper limit of a detection range applicable to the first category of particles. The second category of particles is present in the sample in a detection range applicable to the second category of particles. For example, the first category and/or subcategory of particles might include WBCs. The second category of particles can include platelets.
[00397] In some embodiments, the first category of particles is present in the sample at a concentration below a lower limit of a detectable range applicable to the first category of particles. The second category of particles is present in the sample in a detection range applicable to the second category of particles. For example, the first category of particles comprises platelets. The second category of particles comprises white blood cells.
[00398] In step 74 of Figure 17, the concentration of the second category of particles in sample 12 is determined in particle counter 15. The particle counter may comprise at least one channel. The second category of particles is measured in one of the channels in some modalities. The particle counter may comprise at least two channels in some embodiments. The first category of particles can be counted in another channel if the concentration is in a detection range applicable to the first category of particles.
[00399] In step 76 of Figure 17, sample 12 is provided in an analyzer, such as a visual analyzer 17 (for example, as depicted in Figures 14 or 15), to determine a proportional ratio of the first category of particles to the second category of particles. In some embodiments, visual analyzer 17 comprises a flow cell 22 connected to an imaging device as described above. The proportional ratio of the first category of particles to the second category of particles can be determined according to the method described in this document. For example, at least one chemical that includes at least one of a diluent, a permeabilizing agent, and a contrast agent can be introduced into the sample. Exemplary chemicals, compositions, contrast agents, and related compositions that can be used to process blood fluid samples are discussed in copending U.S. Patent Application, the contents of which are incorporated herein by reference. The contrast agent can be effective in generating visual distinctions that differentiate the first categories and/or subcategories and the second categories and/or subcategories of particles. The prepared sample 12B shown in Figure 14 can be applied to at least one flow cell 22 in some embodiments. Particle images of the prepared 12B sample are captured. An image analysis is performed by the analyzer which may be a visual analyzer 17 and/or processor 18. A proportional ratio of the first category of particles to the second category of particles is then determined by analyzing the plurality of images of the stream. sample in tape format.
[00400] In step 78 of Figure 17, the concentration of particles in the first category can then be calculated by processor 18 (for example, as depicted in Figure 15), at least in part by applying the ratio proportional to the concentration of the second category of particles.
[00401] The present disclosure further provides methods for analyzing a sample that contains particles. Figure 18 illustrates an exemplary method 80 for determining the concentration of two subcategories of particles, such particles cannot be distinguished by the particle counter according to some embodiments. In step 82, a sample (eg sample 12 of Figure 15) is provided in a particle counter (eg particle counter 15 of Figure 15), which has detection criteria that are satisfied by at least two categories or subcategories of particles, which you want to be distinguished. The particle counter results cover such categories or subcategories in a single count in step 84 of Figure 18.
[00402] In step 86, the sample is provided in the analyzer (such as a visual analyzer) to determine a proportional ratio of the first category or subcategory of particles to the second category or subcategory of particles. In some embodiments, for example as depicted in Figures 14 and/or 15, a visual analyzer 17 includes a flow cell 22 connected to an imaging device.
[00403] The proportional ratio of the first category or subcategory of particles to the second category or subcategory of particles can be determined according to the methods described in this document. At least one chemical which comprises at least one of a diluent, a permeabilizing agent and a contrast agent is introduced into the sample. The contrast agent is effective in generating visual distinctions for the categorization and subcategory of particles that differentiate the first category or subcategory from the second category or subcategory of particles. As depicted in Figure 14, prepared sample 12B can be applied to at least one flow cell 22 in some embodiments. Particle images of the prepared 12B sample are captured. An image analysis is performed by the visual analyzer and/or processor 18. A proportional ratio of the at least first subcategory of particles to the second subcategory of particles is then determined by analyzing the plurality of images.
[00404] In step 88 of Figure 18, the concentration of particles in the first category or subcategory can then be calculated by processor 18, as depicted in Figures 14 or 15, at least in part, by applying the ratio proportional to the single counting (for example, step 84 of Figure 18) obtained from the particle counter.
[00405] In some embodiments, the first category and/or subcategory of particles is present in the sample at a concentration above an upper limit of a detection range applicable to the first category and/or subcategory of particles. The second category and/or subcategory of particles is present in the sample in the detection range applicable to the second category and/or subcategory of particles. For example, the first category of particles comprises white blood cells. The second category of particles comprises platelets. As illustrated in Figure 19B, the analyzer particle count of this disclosure can be used to correct inaccurate particle counts associated with at least one detection range used by the particle counter, such as particle concentration, volume and/or size . By operating the apparatus as described in the present disclosure, particles present in amounts above the upper limit of the detection range can be detected and measured accurately.
[00406] In some embodiments, the first category and/or subcategory of particles is present in the sample below a lower limit of a detectable range of some parameters, for example, concentration, applicable to the first category and/or subcategory of particles as per illustrated in Figure 19A. The second category and/or subcategory of particles is present in the sample in the detection range applicable to the second category and/or subcategory of particles. As illustrated in Figure 19A, the proportional ratio of particle counts in the two analyzer categories and/or subcategories of this disclosure can be used to correct inaccurate particle counter counts for at least one category and/or subcategory. By operating the apparatus as described in the present disclosure, particles present below the detection limit range that are not detected by the particle counter can be accurately measured.
[00407] As shown in Figure 19A, the particle counter provides a particle count for category 2. The analyzer provides a proportional ratio of particle counts for categories 1 and 2. Multiplying the proportional ratio by the particle count for category 2, the process arrives at the particle count for category 1. The first category and/or subcategory of particles can comprise, for example, platelets. The second category and/or subcategory of particles comprise white blood cells. Under some embodiments, the detection range extension systems or dynamics and method disclosed in this document can be used to obtain accurate platelet counts when the amount of platelet contained in the sample is low.
[00408] In some embodiments, the analyzer includes an imaging device and a flow cell connected to the imaging device to determine a proportional ratio of the first category and/or subcategory of particles to the second category and/or subcategory of particles. At least one of a diluent, a permeabilizing agent, a contrast agent is introduced to the sample. The at least one chemical is effective in generating visual distinctions that differentiate the first and second categories and/or subcategories of particles. In one step to determine such proportional ratio, the sample is applied to at least one flow cell present in some modalities. A plurality of sample particle images are captured to provide a statistically significant estimate of a proportional count or ratio. A proportional ratio of the at least first category and/or subcategory of particles to the second category and/or subcategory of particles is then determined by counting the particles in each of the first and second categories and/or subcategories of particles.
[00409] In another aspect, as depicted in Figure 18 and/or Figure 19D, a method 80 for analyzing a sample containing particles is provided to correct the particle count obtained in a particle counter. For example, the analyzer results, eg the relative count, of this disclosure can be used to obtain accurate particle counts from categories and/or subcategories of particles that cannot be differentiated by the detection criteria or criteria used by the particle counter by myself.
[00410] In another embodiment shown in Figure 19C, the counter can provide a substantially accurate count for a plurality of particles. The plurality of particles comprises members of at least two subcategories, however, the count does not distinguish between the subcategories. A distribution of each of the members of the at least two subcategories can be determined in an analyzer. The distribution of subcategories is the proportional ratio of the counts of the respective subcategories to the total. A processor is programmed to distinguish members of at least two subcategories. Using the analyzer distribution and total particle count from the particle counter, for example, as depicted in Figure 19C, the particle count for members of at least one of the at least two subcategories can then be determined by the processor using each member's distribution.
[00411] According to some modalities, as represented in Figure 19D, the sample can have two categories of particles present. In such a context, categories can be constructed to include the possibility of multiple categories and/or multiple subcategories. By operating the apparatus as described in this disclosure, correction can be made to the particle count in which at least some of the members of at least one additional particle category are incorrectly categorized or subcategorized by the particle counter as members of a first category of particles. In such a method, the count for a plurality of particles can be determined using a predetermined range, e.g., size and/or volume range to provide particle counts of the same in a particle counter. The predetermined range groups members of a first category of particles and at least some members of at least a second category of particles in the particle count. Particles in one or more categories or subcategories that are incorrectly counted as another particle category in an instrument channel can be measured separately and accurately using the analyzer configured to distinguish a distribution of particles along the first category of particles and the at least one second category of particles in the sample. The distribution of categories and/or subcategories is the proportional ratio of the counts of the respective categories and/or subcategories to the total. The processor then uses the distribution to calculate the particle count for the members of the first category and at least one second category and/or subcategory of particles. In such embodiments, as illustrated in Figure 19D, the apparatus and methods of this disclosure and counting particles in each category and/or subcategory can be corrected.
[00412] As shown in Figure 19D, the particle counter can provide a substantially accurate total count that comprises two categories. Such a count may include assumed counts for categories 1 and 2. However, the assumed count is imprecise in the sense that the particle counter has misclassified at least one member of category 2 with category 1. The analyzer provides a distribution of counts of particle based on a smaller sample than used in the particle counter for categories 1 and 2, however, the analyzer produces an accurate distribution. The processor uses this information to arrive at an accurate count for both categories. This same process can be used for samples that contain more than two categories and/or subcategories of particles.
[00413] For example, members of different categories or subcategories of particles with similar size or morphology may not be accurately categorized or subcategorized by the particle counter. For example, aggregates of PLTs, "giant" PLTs, nodules, multiple platelets, and nucleated RBCs can be mistakenly counted as WBCs, resulting in a higher WBC count than actually exists in the sample. As another example, microcytic red cells, cell fragments, artifacts, and even electronic noise can be erroneously counted as platelets, resulting in an erroneously high PLT count.
[00414] In some embodiments, the analyzer is a visual analyzer comprising an imaging device and a flow cell. As an example, at least one chemical which comprises at least one of a diluent, a permeabilizing agent, a contrast agent is introduced into the sample. The at least one chemical is effective in generating visual distinctions that differentiate the first category and/or subcategory and the second category and/or subcategory of particles. In a step to determine such distribution, the sample is applied to at least one flow cell present in some modalities.
[00415] In a step to determine a distribution of each of the members of at least two categories and/or subcategories of particles, at least a part of the sample is applied in the at least one flow cell. The at least one chemical is effective in generating visual distinctions that differentiate members of particle categories and/or subcategories. A plurality of particle images of the sample are captured. A plurality of sample particle images are captured to provide a statistically significant estimate of a proportional count or ratio. A proportional ratio of the at least first category and/or subcategory of particles to the second category and/or subcategory of particles is then determined by counting the particles in each of the first and second categories and/or subcategories of particles.
[00416] A proportional ratio of the members of each of the two or more subcategories of particles in a category and/or subcategory of particles and/or a proportional ratio of the members of a first category and/or subcategory of particles to the fur members at least one other category and/or subcategory of particles can be determined based on the plurality of sample particle images. A count or concentration value for each category and/or subcategory of particles can then be calculated, estimated, inferred and/or derived. As an example, the concentration of subcategories of particles can be determined based on the proportional ratio of each subcategory of particles in the analyzer and the count of the total amount of particles in the category of the particle counter. In some embodiments, members of the at least two subcategories comprise at least one type of particles selected from a group consisting of subcategories of white blood cells, platelets, and red blood cells.
[00417] Consequently, in some embodiments, the method further comprises determining a proportional ratio of counting particles in a category and/or subcategory of particles present at a concentration outside a detection range applicable to a category of particles of the counter of particles as a function of counting particles in a second category and/or subcategory of particles that are in a detection range applicable to the second category and/or subcategory of particle based on the plurality of sample particle images from the analyzer and /or processor. The concentration in the sample of the category and/or subcategory of particles outside the detection range of the particle counter can then be determined by applying the ratio proportional to the particle count obtained in the particle counter. For example, in some embodiments, the first category and/or subcategory of particles is present in the sample at a concentration above an upper limit of the detection limit range applicable to the first category and/or subcategory of particles. The second category and/or subcategory of particles is present in the sample in the detection range of the particle counter (below an upper limit and above the lower limit of the detection range) applicable to the second category and/or subcategory of particles. As another example, where the detection criteria or criteria used by the particle counter erroneously categorizes particles by grouping particles from a first category and/or subcategory with particles from at least a second category and/or subcategory, the particle count for the first and second categories and/or subcategories can be corrected from proportional particle ratios determined from the plurality of images of the sample particles from the visual analyzer and/or processor.
[00418] The measurement detection range can be limited in an individual 15-particle counter in Figure 15. For example, the upper detection limit for WBCs can be less than 100,000 to 200,000 per μL in a 15-particle counter. lower detection limit for PLTs can be greater than 10,000 per µL. With the use of the apparatus described in this document, the effective measurement detection range can be extended, for example, the upper detection limit for WBCs can be extended to about 300,000, 350,000, 400,000, 410,000, 420,000, 430,000, 440,000, 450,000, 460,000, 470,000, 480,000, 490,000, 500,000, 510,000, 520,000, 530,000, 540,000, 550,000, 560,000, 570,000, 580,000, 590,000, 600,000, 610,000, 620,000, 630,000, 640,000, 650,000, 670,660,000 700,000, 710,000, 720,000, 730,000, 740,000, 750,000, 760,000, 770,000, 780,000, 790,000, 800,000, 810,000, 820,000, 830,000, 840,000, 850,000, 860,000, 870,000, 880,000, 890,000, 9,000,000, 910,000, 910,000 950,000, 960,000, 970,000, 980,000, 990,000, or 1,000,000, 1,000,000, 1,010,000, 1,020,000, 1,030,000, 1,040,000, 1,050,000, 1,060,000, 1,070,000, 1,080,000 , 1,090,000, 1,100,000, 1,110,000, 1,120,000, 1,130,000, 1,140,000, 1,150,000, 1,160,000, 1,170,000, 1,180,000 or about 1,190,000 cells per µL or any range between any two such values in some modalities. The lower detection limit for PLTs can be extended downwardly up to 10,000, 9,500, 9,000, 8,500, 8,000, 7,500, 7,000, 6,500, 6,000, 5,500, 5,000, 4,500, 4,000, 3,500, 3,000, 2,500, 2,000, 1,500 or 1,000 or 500, 400, 300, 200 or 100 cells per μL in some modalities.
[00419] The analyzer preferably comprises a visual analyzer 17 is operable to determine a proportional ratio of the first category and/or subcategory of particles to the second category and/or subcategory of particles. In such an embodiment, the proportional ratio as described above can be determined by analyzing the plurality of images of particles in the sample obtained in the visual analyzer 17.
[00420] The visual analyzer 17 can be configured to introduce into the sample at least one chemical that comprises at least one of a diluent, a permeabilizing agent and/or a contrast agent to generate visual distinctions for the categorization and subcategorization of particles . Such visual distinctions differentiate members of at least two categories. Particle images of the sample are captured. Visual analyzer 17 and processor 18 are configured to determine a proportional ratio of each category or subcategory of particles by discriminating among the sample particle images. The concentration of each category or subcategory of particles is then calculated. For example, the accurate results of giant WBCs, PLTs and NRBCs can be determined. In a particle counter, due to similar size or morphology, the giant PLTs and NRBc are counted with the WBCs. By operating the device as described, the particle count or concentration of giant PLTs and nRBCs can be accurately reported.
[00421] In some embodiments, the sample may comprise particles whose size is outside a detection size range of the particle counter 15. The visual analyzer 17 and processor 18 are configured to detect the particles and determine a proportional ratio of the particles outside a detection size range for particles in the detection size range of the particle counter 15, based on the sample particle images. The concentration of the category and subcategory of particles outside the detection size range of the particle counter 15 can then be calculated.
[00422] Generally speaking, methods for analyzing a sample containing particles are provided to correct the particle count obtained in a particle counter. An exemplary method can be used to differentiate different categories of particles, including corresponding subcategories, which belong to the same category and/or subcategory of particles in particle counter 15, for example, as depicted in Figures 14 and 15. The method can be used to correct the particle counts obtained in the particle counter 15. In some embodiments, for example, the first category and/or subcategory of particles comprises one or more types of abnormal blood cells, immature blood cells, blood cells in abnormally sized nodules or blood cells. The second category and/or subcategory of particles comprises white blood cells. By operating the apparatus as described in this document, particles in subcategories can be distinguished by the analyzer and the particle category and/or subcategory counts obtained from the particle counter can be corrected.
[00423] A sample or portion thereof is provided in particle counter 15 to detect particles and provide particle counts based on one or more selection criteria that may cover subcategories of at least two categories of particles. For example, the Particle Counter's erroneous WBC category may also contain a small number of giant PLTs and NRBCs. Such a particle counter category may further comprise white blood cell subcategories which cannot be distinguished by the particle counter. Another portion of the sample can also be analyzed on the visual analyzer as described below, to resolve such erroneous categorizations and/or subcategorize the undistinguished WBC subcategories.
[00424] The distribution of each one among the at least two subcategories or categories can be determined in the analyzer 17 as represented in Figure 14. Such distribution can be presented in a numerical ratio, proportional ratio and/or other function of the relative counts. In some embodiments, such distribution can be determined in accordance with the methods disclosed herein on a visual analyzer 17 comprising a flow cell 22 and an imaging device 24. As described, sample 12A, which may be a portion of a sample, is applied to at least one flow cell 22. At least one chemical that comprises at least one of a diluent, a permeabilizing agent, and a contrast agent is introduced into sample 12A. The at least one chemical that comprises at least one of a diluent, a permeabilizing agent and/or a contrast agent is effective to generate visual distinctions that differentiate the at least two categories of particles and differentiate the at least two subcategories of the skin. minus one category of particles. A plurality of particle images of sample 12B are captured. An image analysis is performed on the visual analyzer 17 and/or processor 18.
[00425] In some embodiments, processor 18 is programmed to distinguish members of at least two categories and/or subcategories. A proportional ratio of particle counts in each of the at least two subcategories or categories of particles can be determined based on the plurality of sample particle images. The particle count for the subcategories of at least one of the at least two categories obtained from the particle counter 15 can then be corrected in processor 18 using the distribution of each of the subcategories. The concentration of each subcategory of particles can be calculated in processor 18 based on the proportional ratio of each subcategory of particles and the particle count of the particle category obtained from the particle counter.
[00426] The methods disclosed in this document can also be used to differentiate one or more types of particles outside a detection range in the particle counter 15, according to some modalities. For example, such particles can be blood cells or other fragments that are too large or too small to be detected in particle counter 15. In visual analyzer 17, a proportional ratio of counts of a type of particle outside of a detection range in the particle counter for another type of particle in the detection range of the particle counter can be determined based on the plurality of images of the particles in the sample. The concentration of the type of particles outside the detection range in the sample can then be determined by applying, at least in part, the ratio proportional to the particle count obtained in the particle counter 15. focused images
[00427] Figures 20A and 20B provide cross-sectional side views illustrating aspects of imaging systems and methods, according to embodiments of the present invention. Referring to Figure 20A, a particle analysis system 1400a such as a hematology analyzer can be configured to perform combined viscosity and geometric hydrofocus, for example, using flow cell and sheath fluid techniques. viscous, such as those described in co-pending US Patent Applications, the contents of which are incorporated herein by reference. An exemplary method of imaging particles in a blood fluid sample using the particle analysis system may include flowing a sheath fluid 1410a along a flow path 1420a of a flow cell 1430a of the blood system. particle analysis. Flow path 1420a may be defined, at least in part, by opposing flow cell walls 1422a, 1424a of the flow cell. Sheath fluid 1410a may have a viscosity that is different from a blood fluid sample viscosity. The imaging method may additionally include injecting the blood fluid sample into the flowable sheath fluid 1410a within the flow cell 1430a so that the blood fluid sample fluid flows in a sample flow stream 1440a. Sample stream stream 1440a may have a stream stream width greater than a stream stream thickness. Sample flow stream 1440a may further flow through a decrease in flow path size and traverse an imaging axis 1450a. In the illustration in Figure 20A, the flow direction is left to right.
[00428] Additionally, the imaging method may include focusing an image capture device 1460a by imaging an imaging target 1470a that has a fixed position relative to the flow cell 1430a. For example, as depicted herein, imaging target 1470a may have a fixed position relative to an illumination window 1480a of the flow cell. In some cases, the 1470a imaging target may be embedded or fixed over the 1480a window. The methods may further include capturing a focused image of the sample fluid particles (e.g., particle 1490a disposed at least partially in flow stream 1440a) with image capture device 1460a. Focused image is suitable for particle characterization and counting.
[00429] The image capture device 1460a can be focused on the sample stream stream 1440a with the use of an offset distance. For example, the offset distance can correspond to a distance D between sample stream 1440a and imaging target 1470a. The difference in viscosity between the sheath fluid 1410a and the blood fluid sample, in combination with the decrease in flow path size, is effective to hydrofocus the sample fluid into the sample flow stream 1440a on the geometric axis. of 1450a imaging while maintaining cell viability in the blood fluid sample. For example, a viscosity hydrofocus effect induced by an interaction between the coating fluid 1410a and the sample fluid stream 1440a associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the coating fluid 1410a and the sample fluid stream 1440a associated with the reduction in size of the flow path, can be effective to provide a target imaging state in at least a portion of the fluid sample particles on the imaging axis 1450a as an imaging agent. viscosity in coating fluid 1410a maintains cell viability in sample fluid stream 1440a so as to leave cell structure and contents intact when cells extend from sample fluid stream 1440a to coating fluid fluent 1410a.
[00430] As the image capture device 1460a is focused on the sample stream stream 1440a using the displacement distance, the image capture device 1460a can image particles or cells in the sample stream stream 1440a at the imaging axis 1450a or at an image capture location associated with imaging axis 1450a. In some cases, the particles can be illuminated with a 1426a light source or lamp. Images of the sample flow stream 1440a can be obtained as the particles reach the imaging axis 1450a, as the particles traverse the imaging axis 1450a, and/or as the particles flow in the opposite direction to the imaging axis 1450a.
[00431] Figure 20B depicts aspects of an alternative flow cell configuration, wherein the imaging target 1470b has a fixed position relative to a viewport window 1482b of the flow cell 1430b. For example, imaging target 1470b may be embedded or fixed over window 1482b. As shown in this document, the imaging method can include focusing an image capture device 1460b by imaging an imaging target 1470b that has a fixed position relative to flow cell 1430b. Furthermore, the image capture device 1460b can be focused on the sample stream stream 1440b using an offset distance. For example, the offset distance can correspond to a distance D between sample stream 1440b and imaging target 1470b.
[00432] Figure 20C is an end cross-sectional view of a flow cell 1430c illustrating several alternative placement locations for an autofocus target or imaging target. For example, an imaging target 1472c may be located in a viewport window 1482c of flow cell 1430c. Optionally, an imaging target 1474c may be located in an illumination window 1480c of flow cell 1430c. Additionally, optionally, an imaging target 1476c may be located on a flow cell sidewall (e.g., 1432c and/or 1434c). The image capture device 1460c can be focused on a stream of sample stream 1440c that is enveloped in a sheath fluid 1410c using the displacement distance. In some embodiments, the offset distance may correspond to or be defined by a distance D1 along the geometric imaging axis 1450c between sample stream stream 1440c (or a center plane 1441c defined by stream stream 1440c) and the target image of the viewport window 1472c. In some embodiments, the offset distance may correspond to or be defined by a distance D2 along the geometric axis of imaging between sample stream stream 1440a (or center plane 1441c) and illumination window imaging target 1476c . In some embodiments, the offset distance may correspond to or be defined by a distance D3 along the geometric axis of imaging between sample stream 1440a (or center plane 1441c) and the cell sidewall imaging target flow 1474c. In some cases, distance D3 has a value greater than zero. In some cases, distance D3 has a value of zero; That is, where sample stream 1440a (or center plane 1441c) is coplanar with respect to imaging target 1474c. In some cases, it is possible to define an offset distance that is not calculated based on distance D1, distance D2, or distance D3. For example, an offset distance can be a predetermined number or value that is provided by a flow cell manufacturer or hematology analyzer.
[00433] According to some embodiments, the sample stream stream 1440c may have a thickness T1 on the geometric axis of imaging in a range from about 2 µm to about 10 µm. In some cases, the flow path or sheath fluid 1410c may have a thickness T2 of about 150 µm on the imaging axis. As shown in this document, an imaging target 1472c may be located in a viewport window 1482c disposed between the sample stream stream 1440c and the image capture device 1460c. In some cases, an imaging target (eg 1474c) may be located between an illumination window 1480c and a viewport window 1482c. As discussed elsewhere in this document, the process of capturing a focused image may include setting a distance between the image capture device 1460c and the flow cell 1430c using the offset distance. In some cases, as discussed elsewhere in this document, the process of capturing a focused image may include adjusting a focal length of the image capture device 1460c using the offset distance. In some cases, the process of capturing a focused image may include adjusting the distance between the image capture device 1460c and the flow cell 1430c and the process of adjusting the distance includes moving the flow cell 1430c, for example, to a position closer to the image capture device 1460c or to a position furthest away from the image capture device 1460c.
[00434] As depicted in Figure 20D, a first focal length of the image capture device 1460d may correspond to a distance D1 (for example, along the imaging axis 1450d) between the image capture device 1460d and the target of imaging 1470d and a second focal length of image capture device 1460d may correspond to a distance D2 (e.g., along imaging axis 1450d) between image capture device 1460d and sample stream 1440d (or a center plane defined by the sample flow stream). In some cases, the imaging target may be located elsewhere in the flow cell, for example, as depicted in Figure 20C. According to some modalities, the displacement distance can correspond to a distance difference between the first focal length (or D1 distance) and the second focal length (or D2 distance). The image capture device 1460d can be focused on the sample stream 1440d using such a displacement distance (eg, the difference between D1 and D2).
[00435] Figure 21 represents an elevation view showing the modalities of an auto focus pattern (or imaging target) which, for example, may be located in windows or lighting holes, in a window or viewing portal or elsewhere in the flow cell. The target may fade as the distance or position of the high-resolution optical imaging device is moved relative to the tape-format sample stream. As depicted in Figures 9 through 12B, a focus target (auto focus pattern) or imaging may be situated at the periphery of the viewing area where the sample should appear. Again with reference to Figure 21, it can be seen that it is also possible that the focus target may be defined by contrasting shapes that are situated in the field of view.
[00436] When the imaging device is in focus in the auto focus pattern (target) (panel B in Figure 21), the formats as imaged by the device are well defined and can be used for auto focus as described in this document, more specifically to seek the distance between the target and the imaging device where shapes produce the greatest contrast in amplitude between adjacent pixels located along lines that cross over the shapes, such as lines shown as arrowheads. The focus configuration depicted in panel B corresponds to an analogous focus configuration depicted in Figure 22A. As illustrated in Figure 22A, the focal plane of the image capture device is aligned with the auto focus target and therefore the image capture device is in a position to obtain sharp images of the auto focus target.
[00437] Again with reference to Figure 21, when the workplace (eg, imaging device focal plane) is moved in the opposite direction to the auto focus pattern (shown in panels A and C, shown on the left and right of the autofocus pattern in Figure 21), for example, by adjusting the objective working distance or the distance between the objective and its focal plane, the shapes of the focus target then go out of focus, and in the position where the high resolution optical imaging device is focused on the sample stream in tape format, the focus target shapes are no longer discernible (see panel D in Figure 21). The focus configuration depicted in panel D may correspond to an analog focus configuration depicted in Figure 22B. As illustrated in Figure 22B, the focal plane of the image capture device is aligned with the sample fluid stream and, therefore, the image capture device is in position to obtain sharp images of particles in the flow stream. sample. The focal plane of Figure 22A is separated from the focal plane of Figure 22B by a distance D. As shown in Figure 22B, by moving the image capture device a distance D, it is also possible to move the focal plane by a distance D and therefore move the focal plane of the auto focus target to the sample stream stream. In some cases, the focal plane can be moved from the auto focus target to the sample stream stream by internally adjusting the focal length of the image capture device while keeping the image capture device in a fixed position at relation to the flow cell. In some cases, the focal plane can be moved from the auto focus target to the sample stream stream by internally adjusting the focal length of the image capture device in combination with adjusting the position of the image capture device in relation to to the flow cell. Autofocus formats can be provided in any location that is in plain view and is fixed in relation to the flow cell, such as at the lighting or window opening or at the front or rear of the viewing port or window through which the device A high resolution optical imaging device is directed or in an accessory attached to the photocell to hold a target in position to be imaged.
[00438] According to some embodiments, when the optical high resolution imaging device is moved along the displacement distance and the auto focus pattern goes out of focus, the features that appear in focus are the blood cells instead of the auto focus pattern. In the mode of Figure 21, the auto focus pattern is defined by shapes in the field of view. Shapes are relatively thin discrete shapes of a limited size and therefore, after moving the offset distance, shapes become substantially invisible in the digitized image when focused on the tape-shaped sample stream. A typical displacement distance might be, for example, 50 to 100 µm in a flow cell sized for hematology (blood cell) imaging applications. In some modalities, the auto focus feature keeps the high-resolution optical imaging device within 1 µm of the optimal focus distance.
[00439] Consequently, the features described in Figure 21 provide an exemplary technique for determining an offset distance. For example, a method for determining an offset distance may include an autofocus process that involves injecting a test fluid sample into a sheath fluid to form a test sample flow stream in a flow cell and obtain a first focused image of the imaging target using an image capture device. The first focused image can correspond to panel B in Figure 21, where the focused imaging target and the image capture device define a first focal length. As depicted in this document, the focal plane or working distance/location of the image capture device is positioned on the imaging target. The autofocus process may further include obtaining a second focused image of the test sample stream stream using the image capture device. The second focused image can correspond to panel D in Figure 21, where the focused test sample stream stream and the image capture device define a second focal length. As depicted in this document, the focal plane or working distance/location of the image capture device is positioned on the imaging target. Autofocus processes can additionally include obtaining the offset distance by calculating a difference between the first focal length and the second focal length. In some cases, the test fluid sample is equal to the blood fluid sample and the test sample flow stream is equal to the sample flow stream. In some cases, the autofocus process establishes a focal plane associated with the image capture device and the focal plane remains stationary relative to the image capture device. In some cases, the image capture device's autofocus process includes determining an optimal focus position from a plurality of focus positions.
[00440] According to some embodiments, the image capture device can be focused on the sample stream stream without using temperature data. For example, an image capture device focusing process on the sample stream stream can be performed independently of an image capture device temperature. In some cases, an imaging target may include a scale (for example, as depicted in Figure 12B) for use in positioning the imaging axis of the image capture device in relation to the sample stream stream. In some cases, the imaging target may include an iris aligned with respect to the imaging axis, so that the imaged particles are arranged in an aperture defined by the iris and one or more iris edge portions are imaged during autofocus .
[00441] In the exemplary modalities, autofocus techniques can position the flow cell at ± 1 μm from the ideal focus position of the sample stream. In some cases, the modalities encompass autofocus techniques that can automatically focus the imaging system without the need for a separate focus liquid or solution or any user intervention. Exemplary autofocus techniques can also be considered as mechanical causes of sub-optimal focusing performance, such as slippage or thermal expansion that can generate fluctuations in the distance between the imaging device objective and the flow cell. In some cases, it has been observed that the location of the sample flow in the flow cell can be very stable and independent of temperature. For this reason, exemplary imaging techniques may involve focusing on an imaging target in the flow cell and using a fixed offset to achieve optimal focus in the sample stream.
[00442] According to some embodiments, the microscope objective that is used in an imaging system has a numerical aperture of 0.75, which results in a theoretical depth of field (DoF) of ± 0.5 μm. In certain experimental tests, it was observed that good image quality can be obtained s ± 1.25 μm from the ideal focal point. It is also noted that a practical or experimental depth of field may be different from a theoretical depth of field. For example, in certain experimental tests it was observed that the depth of field was about 2.5 to 3 µm. Based on certain experimental studies, it has been determined that the autofocus performance to position the flowcell at ±1.25 µm can ensure good image quality. In some embodiments, an autofocus system can operate to position the flowcell within ± 1 µm of an optimal focus position of the sample stream. In certain experimental tests, it has been observed that autofocus techniques as disclosed in this document can repeatedly locate a target in a flow cell with a standard deviation of less than 0.3 µm. In some cases, autofocus system test cycles demonstrated excellent repeatability (standard deviation < 0.23 µm) and were able to determine the focus position of the sample stream at <0.6 µm relative to an optimized metric position which is within a position tolerance of ± 1 µm. The additional autofocus test cycles in a variety of temperature conditions also exhibited excellent positioning performance (eg flow cell positioning within a required tolerance of ± 1 µm and optimal focus position). This degree of accuracy in an automated analyzer system is well suited to consistently and reliably obtaining high-quality particle images from a blood fluid sample flowing in a thin-strip flow stream, as revealed elsewhere of this document, over an operating temperature range that corresponds to normal laboratory conditions.
[00443] Figure 23 represents aspects of 2300 sample processing methods, according to embodiments of the present invention. As shown in this document, sample processing methods may include drawing a sample into a shear valve as indicated by step 2305. This step may be performed through a CBC module. Methods can further include dispensing sample and reagent into a reaction chamber as depicted in step 2310. This step can be performed through a CBC module and a first fluid system (eg, BBL1 Fluids). In addition, methods may include incubating the reaction mixture for a desired length of time at a desired temperature (eg, for 40 seconds at 47.5 °C) as indicated by step 2315. Methods may further include dispensing a quench reagent in the reaction chamber as indicated by step 2320, aspirate the reaction mixture into the imaging preparation section as indicated by step 2325 and shear the air/liquid interfaces and drive the sample to the interior of the flow cell as indicated by step 2330. Under some embodiments, steps 2315, 2320, 2325, and 2330 may be performed by a fluid system (e.g., BBL Fluids). Under some embodiments, the methods may include collecting images as indicated in step 2335. For example, an image collection process may include collecting 5,000 to 7,000 frames and the images may be stored in a video file. In some cases, step 2335 can be performed by a video system (eg BBL Video). In addition, the methods may include performing a patch extraction for each frame to generate a collection of images as indicated by step 2340, generate a 5-part differential or other diagnostic result file as indicated by step 2345, and sort each patch/cell as indicated by step 2350. In some cases, steps 2340, 2345, and 2350 can be performed with offline processing using automated particle recognition (APR) hematology software.
[00444] PIOAL has a suitable viscosity and density and the flow rates at the point of introduction into the sample flow cell are such that the sample fluid is flattened into a thin ribbon. The tape-shaped sample stream is transported together with the PIOAL to pass in front of a viewing port where an objective lens and a light source are arranged to allow viewing of the tape-shaped sample stream. Sample fluid is introduced, for example, injected at a point where the PIOAL flow path narrows symmetrically. As a result, the sample fluid stream is flattened and extended into a thin ribbon format. A PIOAL of this disclosure can be used as the sheath fluid with any visual analyzer of this disclosure. In one embodiment, PIOAL can be introduced at one end of the flow cell to transport the sample fluid towards the discharge.
[00445] The dimension of the tape-shaped sample stream in the viewing zone is affected by the geometric thinning of the PIOAL flow path and linear differential velocity of the sample fluid and PIOAL, which results in the thinning and stretching of the sample stream in tape format. The initial differential linear velocity of the sample for the PIOAL can vary in the range from 0.5:1 to 5:1. The cross section of the PIOAL flow path can be fine-tuned by reducing the depth by a factor of about 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1 , 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 105 :1, 110:1, 115:1, 125:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1 or 200:1. In one modality, the geometric thinning is 40:1. In one modality, the geometric thinning is 30:1. The factors considered are the transit time through the flow cell, the desired rate of sample throughput, achieving a tape-shaped sample stream thickness comparable to the particle size, achieving the alignment of particles and organelles, achieving the focusing on particle content, balancing pressure, flow and viscosity within operational limits, optimizing sample stream thickness in tape format, achieving a desired linear velocity, manufacturing capability considerations and required sample and PIOAL volumes.
[00446] The length and volume of the cannula and the flatness of the cross section can be selected to reduce the period of sample flow instability, thus increasing throughput. In some embodiments, the period of flux instability may be less than about 3, 2.75, 2.5, 2.25, 2, 1.75, 1.5, 1.25 or less than about 1 second . A smaller cannula volume can also reduce the time and volume of diluent required to clean the cannula between sample cycles. In some embodiments, the transit time through the flow cell is 1, 2, 3, or 4 seconds or any range between any two such times. In some modalities, the transit time can be less than 4, 3 or 2 seconds.
[00447] The viscosities and flow rates of the sample fluid and the PIOAL and flow cell contour are arranged so that the PIOAL flow flattens and extends the sample flow in a flat ribbon consistently along the zone of view in a trusted location that matches an image capture location. The sample fluid stream can be compressed to approximately 2 to 3 µm in fluid flow thickness. Several types of blood cells have diameters greater than the current thickness. Shear forces in the direction parallel to the direction of flow cause an increase in an image projection of particles under imaging conditions in the focal plane of the high-resolution optical imaging device and/or cause intraparticle structures, e.g. intracellular, organelles or lobules, are positioned, repositioned and/or better positioned so that they are substantially parallel to the direction of flow. The depth of field of optical high resolution imaging device is up to 7 µm, eg 1 to 4 µm.
[00448] The flow cross-section of the PIOAL, with the tape-shaped sample stream carried together, is constant along the viewing zone in front of a viewing port through which the objective lens is directed. The objective lens can be the objective component of a high resolution optical imaging device or digital image capture device. The tape-shaped sample stream follows a trajectory through the viewing zone at a known and repeatable position within the flow cell, for example, at a known and repeatable distance from two flow cell walls, so as to be discharged downstream.
[00449] The optical information of the particles in the sample is detected by a detection section in the analyzer when the tape-shaped sample stream is transported through the viewing zone in front of the viewing port, thus generating particle data/ cells contained in the sample. The use of such an analyzer allows for the capture, processing, categorization and subcategorization and counting of cells and/or particles contained in the samples. PIOAL liquid can be prepared by adding viscosity modifying agent, buffering agent, pH adjusting agent, antimicrobial agent, ionic strength modifier, surfactant and/or a chelating agent. Exemplary components and/or functional features of the analyzer in the present disclosure may include, for example, the ability to acquire and/or process image analysis data, sample color processing, image processing, and/or particle image identification. , counting and/or categorization and subcategorization of particles.
[00450] In one embodiment, this disclosure was based on the surprising and unexpected finding that the addition of an adequate amount of a viscosity agent to PIOAL significantly improves particle/cell alignment in a flow cell, so as to lead at a higher percentage of aligned cells or cellular components in focus and high quality images of cells and/or particles in flow. A viscosity differential in combination with a geometric focusing effect of a narrowing transition zone can achieve improved alignment and focusing results. The addition of the viscosity agent increases shear forces on cells such as RBCs, which improves the alignment of cells in a plane substantially parallel to the flow direction, resulting in image optimization. This further results in the positioning, repositioning and/or better positioning of intraparticle structures, such as intracellular structures, organelles or lobes substantially parallel to the flow direction, which results in image optimization. The viscosity agent further reduces cell misalignment generally, but not limited to cells having a diameter smaller than the flow stream.
[00451] The alignment of cells that have a diameter smaller than the flow stream, for example, the red blood cells, can be obtained by, for example, increasing the viscosity of the PIOAL or by increasing the flow velocity ratio. This results in the alignment of the RBCs parallel to the flow direction and the FP focal plane (eg, as depicted in Figure 4K). In some embodiments, a reduction in red blood cell alignment and/or an increase in red blood cell alignment is achieved by increasing the viscosity of PIOAL.
[00452] Tape-format sample stream thickness can be affected by the relative flow rates and viscosities of sample fluid and PIOAL. The sample source and/or the PIOAL source, for example, which comprise precision displacement pumps, can be configured to deliver the sample and/or the PIOAL at controllable flow rates to optimize the dimensions of the formatted sample stream. of tape, more specifically as a thin tape at least as wide as the field of view of the high resolution optical imaging device or the digital image capture device.
[00453] The flow cross section of the PIOAL, with the tape-format sample stream carried, is constant along a viewing zone in front of a viewing port through which the high-resolution optical imaging device is directed. The tape-shaped sample stream follows a trajectory through the viewing zone at a known and repeatable distance from both the front and rear walls of the flowcell as it is discharged downstream thereof.
[00454] The present disclosure provides a technique to automatically achieve a correct working position of the optical high resolution imaging device to focus on the tape-shaped sample stream. The flow cell structure is configured so that the tape-shaped sample stream has a fixed and repeatable location between the flow cell walls that define the flow path of the sample fluid, in a thin tape between layers of PIOAL, which passes through a viewing zone in the flow cell. In the flow cell modalities disclosed, for example, in Figures 1 to 4G, the cross-section of the flow path for the PIOAL can narrow symmetrically in a transition zone and a sample can be inserted through a flat hole, such as a tube with a rectangular lumen in the hole. The narrowing flow path (eg, which narrows geometrically in cross-sectional area by a ratio of 20:1 to 40:1) and also due to an optionally higher linear velocity of the PIOAL compared to the sample flow, cooperate to flatten the sample cross-section in a ratio of about 20:1 to 70:1. Under some modalities, the ratio can be in a range of 10:1 to 100:1, in a range of 50:1 to 100:1, in a range of 70:1 to 80:1. Under some arrangements, the ratio is 75:1. Effectively, due to the combination of flow rate, viscosity and geometry, the sample forms a thin ribbon. The narrowing flow path (for example, which geometrically narrows in cross-sectional area by a ratio of 40:1 or a ratio between 20:1 to 70:1) and a difference in linear velocity of PIOAL compared to the sample flow, cooperate to compress the sample cross section in a ratio of about 20:1 to 70:1. In some embodiments, the cross section thickness ratio can be 40:1. In some embodiments, the cross section thickness ratio can be 30:1.
[00455] As a result, process variations such as sample and PIOAL specific linear velocities do not tend to displace the tape-shaped sample stream from its location in the stream. Regarding the flow cell structure, the location of the tape-shaped sample stream is stable and repeatable.
[00456] In another aspect, this invention relates to a kit comprising the particle contrast agent compositions of this invention. The kit may also contain instructions for using the particle contrast agent composition according to any of the methods described in this document. The kit can further include an organelle and/or intracellular particle alignment liquid (PIOAL). The kit may also contain a programmable storage medium and related software for image-based identification of particles such as neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocytes, nucleated RBCs, blastulas, promyelocytes, myelocytes, metamyelocytes, bacteria, fungi, protists, protozoa or parasites. The kit may also comprise one or more buffers, which may include isotonic buffers and/or diluents. The kit and/or buffer can further comprise a surfactant, a pH adjusting agent and/or an antimicrobial agent. In other embodiments, the kit can also comprise a cleaning or purge solution. The kit may also comprise standards for the positive and negative controls. In some embodiments, the standard may comprise a standard stained cell reagent. The kit may also comprise disposable materials such as micropipettes, disposable tips or tubes for transferring kit components. The kit can contain any one or any combination of two or more such kit components.
The discrimination of blood cells in a blood sample is an exemplary application for which embodiments of the present invention are particularly well suited. The sample is prepared using automated techniques and presented to a high-resolution optical imaging device as a thin ribbon-shaped sample stream to be imaged periodically, while the ribbon-shaped sample stream flows through a field of view. . Particle images (such as blood cells) can be distinguished from one another, categorized, subcategorized, and counted using programmed pixel image data processing techniques, either exclusively automatically or with limited human assistance to identify and count the cells or particles. In addition to cell images, which can be stored and made available in the case of unusual or critical particle features, the output data includes a count of occurrences of each specific category and/or subcategory of the cell or particle distinguished in the recorded sample images .
[00458] The counts of the different particles found in each image can be further processed, for example, used to accumulate statistically significant and accurate ratios of cells from each distinguished category and/or subcategory in the sample as a whole. The sample used for visual discrimination can be diluted, however, the proportions of cells in each category and/or subcategory are represented in the diluted sample, specifically after several images are processed.
[00459] The apparatus, compositions and methods disclosed in this document are useful for discriminating and quantifying cells in samples based on visual distinctions. The sample may be a biological sample, for example, a body fluid sample comprising white blood cells, including, without limitation, blood, serum, bone marrow, lavage fluid, effusions, exudates, cerebrospinal fluid, pleural fluid, peritoneal fluid and fluid amniotic. In some embodiments, the sample may be a solid tissue sample, for example, a biopsy sample that has been treated to produce a cell suspension. The sample can also be a suspension obtained from the treatment of a faecal sample. A sample can also be a laboratory or production line sample that comprises particles, such as a cell culture sample. The term sample can be used to refer to a sample obtained from a patient or laboratory or any fraction, portion or aliquot thereof. The sample can be diluted, divided into portions or colored in some processes.
[00460] In one aspect, the systems, compositions and methods of this disclosure provide surprisingly high quality images of cells in a stream. In one aspect, the visual analyzer can be used in methods of this disclosure to provide an automated image-based differential WBC count. In certain embodiments, the methods of this disclosure refer to automated identification of visual distinctions, including morphological features and/or anomalies to determine, diagnose, predict, predict and/or support a diagnosis to determine whether an individual is healthy or has a disease, affection, anomaly and/or infection and/or being responsive or unresponsive to treatment. The system can further comprise the particle counter in some embodiments. Applications include categorizing and/or subcategorizing and counting cells in a fluid sample, such as a blood sample. Other similar uses for counting additional types of particles and/or particles in other fluid samples are also envisioned. The system, compositions and methods of this invention can be used for real-time categorization and subcategorization and image visualization using any suitable automated particle recognition algorithm. Images captured for each sample can be stored for viewing at a later date.
[00461] In another aspect, the apparatus, compositions and methods of this invention provide surprisingly more accurate image-based cell categorization and subcategorization and signaling, which reduces the manual review rate compared to the manual review rate when using the current automated analyzers. Systems, compositions and methods reduce the manual review rate and allow manual review to be performed on the instrument. In addition, the systems, compositions and methods of this disclosure also reduce the percentage of samples flagged during automated analysis that require manual review.
The present disclosure further relates to systems, methods and compositions for combining a whole blood count (CBC) counter with an analyzer, such as a visual analyzer, to obtain a CBC and an expanded differential white blood cell count image-based and an image-based expanded platelet count thus extending the effective detection range for counting platelets.
[00463] Consequently, in some embodiments, the present disclosure provides an apparatus and a method for analyzing a sample that contains particles, e.g., blood cells. In accordance with this disclosure, a visual analyzer is provided to image a sample comprising particles suspended in a liquid. In some embodiments, the visual analyzer comprises a flow cell and an autofocus component, in which a liquid sample containing particles of interest is forced to flow through a flow cell that has a viewing port through which a camera attached to an objective lens captures digital images of particles. Exemplary autofocus techniques that may be deployed using embodiments of the present invention are disclosed in co-pending U.S. Patent Application, the contents of which are incorporated herein by reference. The flow cell is coupled to a source of sample fluid, such as a diluted and/or treated blood sample or other body fluid sample, as described herein, and to a source of a clear coating fluid or fluid alignment fluid. intracellular organelle and/or particle (PIOAL).
[00464] In one embodiment, the apparatus further comprises a particle counter that has at least one detection range, as well as an analyzer and a processor. The analyzer and processor are configured to provide additional information to correct counting, categorization and subcategorization errors associated with the particle counter and further determine the precise particle count or the precise concentration of different categories and/or subcategories of particles in the sample.
[00465] The present disclosure provides methods and compositions useful for aligning intracellular and/or particle organelles in conducting image-based sample analysis. In some embodiments, this disclosure relates to methods and compositions for combined counting and imaging system capable of performing a whole blood count (CBC) and an image-based expanded white blood cell differential (WBC) that can identify and count cell types such as WBCs, RBCs and/or platelets, including, for example, neutrophils, lymphocytes, monocytes, eosinophils, basophils, reticulocytes, nucleated RBCs, blastulas, promyelocytes, myelocytes or metamyelocytes and to provide image-based information for WBC counts and morphologies, red blood cell counts and morphologies, and platelet counts and morphologies (PLT).
[00466] In other embodiments, this disclosure relates to a PIOAL that can be used in image-based particle analysis as described in this document. Counting categories and/or subcategories of cells in blood samples are used in this disclosure as non-limiting examples of the types of samples that can be analyzed. In some embodiments, cells present in the samples may also include bacterial or fungal cells, as well as white blood cells, red blood cells and/or platelets. In some embodiments, particle suspensions obtained from tissues or aspirates can be analyzed.
[00467] The discrimination of blood cells in a blood sample is an exemplary application for which the subject is particularly well suited. The sample is prepared using automated techniques and presented to a high-resolution optical imaging device as a tape-shaped sample stream to be imaged periodically while the sample flows through a field of view. Particle images (such as blood cells) can be distinguished from one another, categorized, subcategorized and/or counted using programmed pixel image data processing techniques, either exclusively automatically or with assistance human limited ability to identify and count cells or particles. In addition to cell images, which can be stored and made available in case of unusual or critical features, the output data includes a count of occurrences of each specific cell or particle category and/or subcategory distinguished in the recorded sample images. The counts of the different particles found in each image can be further processed, for example, used to accumulate the statistically significant and accurate proportional ratios or functions thereof, from cells of each distinguished category and/or subcategory in the sample as a whole. The sample used for visual discrimination can also be highly diluted, however, the proportions of cells in each category and/or subcategory are represented in the distribution for the diluted sample, particularly after several images are processed.
[00468] In some aspects, samples are presented, imaged and analyzed in an automated way. In the case of blood samples, the sample can be substantially diluted with a suitable diluent or saline, which reduces the extent to which the visualization of some cells can be obscured by other cells in the undiluted or less diluted sample. Cells can be treated with agents that enhance the contrast of some aspects of the cell, for example, using permeabilizing agents to produce permeable pigments in cell membranes and histologically to adhere to and reveal features such as granules and the nucleus. In some embodiments, it may be desirable to color an aliquot of the sample to count and characterize particles that include reticulocytes, nucleated red cells and platelets and for the characterization and differential analysis of white blood cells. In other embodiments, samples containing red blood cells may be diluted prior to introduction into the flow cell and imaging.
[00469] According to some modalities, the details of sample preparation apparatus and methods for sample dilution, permeabilization and histological staining, in general, are obtained using precision pumps and valves operated by one or more programmable controllers and are not fundamental to this revelation. Examples can be found in patents assigned to International Remote Imaging Systems, Inc., such as U.S. 7,319,907, which pertains to programmable controls. Similarly, techniques for distinguishing between certain categories and/or subcategories of cells by their attributes, such as relative size and color, can be found in U.S. document 5,436,978 relating to white blood cells. The disclosures of such patents are incorporated herein by reference. Under some embodiments, sample preparation techniques may include staining, lysing, permeabilization, and other processing modalities, such as those described in co-pending U.S. Patent Application, the contents of which are incorporated herein by reference.
[00470] The term optical high resolution imaging device can include devices that can image particles with sufficient visual distinctions to differentiate morphological features and/or alterations. Exemplary high optical resolution imaging devices may include devices with an optical resolution of 1 µm or less that include, for example, 0.4 to 0.5 µm, such as, for example, 0.46 µm.
[00471] In some embodiments, the images obtained in any of the compositions and/or methods of this invention may be digitized images. In some modalities, the images obtained are microscopy images. In certain modalities, images can be taken manually. In other embodiments, at least part of the procedure for obtaining the images is automated. In some embodiments, images can be obtained using a visual analyzer comprising a flow cell, a high resolution optical imaging device or the digital image capture device, optionally with an auto focus feature.
[00472] In one modality, the images provide information related to cytosolic components, cell nucleus and/or nuclear components of the cell. In one modality, the images provide information related to the granular component and/or other morphological features of the cell. In one modality, the images provide information related to the cytosolic, nuclear and/or granular components of the cell. Images and/or granular and/or nuclear resources are crucial for cell categorization and subcategorization, both independently and in combination with one another.
[00473] In one aspect of the methods of this invention, cells contacted with the particle contrast agent composition and/or imaged are nucleated red cells. In yet another aspect, the methods of this invention relate to a method for performing image-based categorization and subcategorization of red blood cells comprising: a) generating images of a portion of the red blood cells; and b) determine the morphology of the imaged red cells. As used herein, red blood cells (red blood cells) can include, for example, normal or abnormal red blood cells, reticulocytes, nucleated red blood cells and/or malaria-infected cells. In some embodiments, imaging is performed using the apparatus of this disclosure, such as an apparatus comprising a particle counter, a visual analyzer, and a processor.
As used herein, an exemplary whole blood count (CBC) may include a test panel typically ordered by a physician or other medical professional that provides information about particles and/or cells in a patient's blood sample. Exemplary cells circulating in the bloodstream can be divided broadly into three types: including, but not limited to, for example, white blood cells (eg, leukocytes), red blood cells (eg, erythrocytes) and platelets (eg. example, thrombocytes).
[00475] As used herein, abnormally high or low counts may indicate the presence of a disease, disorder and/or condition. As such, a CBC is one of the blood tests commonly performed on the drug, due to the fact that it can provide an overview of a patient's general health status. Consequently, a CBC is routinely performed during annual physical examinations.
[00476] As used herein, typically a phlebotomist collects the blood sample from the individual, the blood is usually drawn into a test tube that typically contains an anticoagulant (eg, EDTA, sometimes citrate) to prevent it from clotting. The sample is then transported to a laboratory. Sample is sometimes taken from a finger puncture using a Pasteur nugget for immediate processing through an automated counter. In one embodiment, the particle image is captured while the particle is surrounded by a sheath fluid or PIOAL. In certain modalities, the blood sample can be viewed on a slide prepared with a sample of the patient's blood under a microscope (a blood film or peripheral smear). In certain modalities, the whole blood count is performed using an automated analyzer.
[00477] As used in this document, in general, blood analyzers can aspirate a very small amount of specimen through a narrow tubing. Sensors can detect the count and/or number of cells passing through the tubing and can identify the cell type. Exemplary sensors may include light (eg visible, UV or IR) and/or electrical impedance detectors. Exemplary detection parameters can include size, volume and/or cellular resources. In certain embodiments, sensors can detect visible light and non-visible light in a wavelength spectrum in the range of about 200 nm to about 10,000 nm. In certain embodiments, sensors can detect a wavelength between about 380 nm and about 760 nm.
[00478] As used in this document, the data/parameters of a blood count can include, for example, total red blood cells; hemoglobin - the amount of hemoglobin in the blood; hematocrit or packed cell volume (PCV); mean corpuscular volume (MCV) - the mean volume of red blood cells (anemia is classified as microcytic or macrocytic based on whether this value is above or below the expected normal range. Other conditions that can affect the MCV include thalassemia, reticulocytosis, and alcoholism) ; mean corpuscular hemoglobin (MCH) - the average amount of hemoglobin per red cell, in picograms; mean corpuscular hemoglobin concentration (MCHC) - the mean concentration of hemoglobin in the cells; red blood cell distribution amplitude (RDW) - the variation in cell volume of the red blood cell population; total white blood cells; neutrophil granulocytes (may indicate bacterial infection, typically increased in acute viral infections). Due to the segmented appearance of the nucleus, neutrophils are sometimes called "secs". The nucleus of less mature neutrophils is not segmented but is band-shaped or elongated. Less mature neutrophils—those that have recently been released from the bone marrow into the bloodstream—are known as "bands." Other data/parameters for a blood count may also include, for example, lymphocytes (eg increased with some viral infections such as glandular fever and in chronic lymphocytic leukemia (CLL) or decreased by HIV infection); monocytes (may be increased in bacterial infection, tuberculosis, malaria, Rocky Mountain spotted fever, monocytic leukemia, chronic ulcerative colitis, and regional enteritis; eosinophil granulocytes (eg, increased in parasitic infections, asthma, or allergic reaction); granulocytes from basophil (eg, increased in bone marrow related conditions such as leukemia or lymphoma.
[00479] As used in this document, the data/parameters of a blood count may also include, for example, data associated with platelets, including platelet numbers, information about their size and the range of sizes in the blood; mean platelet volume (MPV) - a measure of mean platelet size.
[00480] In another aspect of the methods of this invention, the cells contacted with the particle contrast agent composition and/or imaged are anomalous cells, such as malaria-infected cells, atypical lymphocytes. In some aspects of this invention, cells are abnormal cells that can be used to identify, predict, diagnose, predict or support a diagnosis of a condition, disease, infection and/or syndrome.
[00481] In another aspect of the methods of this invention, the cells are platelets.
[00482] Unless expressly stated otherwise, references to "particle" or "particles" made in this disclosure are understood to encompass any distinct or shaped object dispersed in a fluid. As used herein, "particle" can include all measurable and detectable components (eg, through imaging and/or other measurable parameters) in biological fluids. Particles are of any material, any shape and any size. In certain embodiments, particles can comprise cells. Examples of particles include, but are not limited to, cells, including blood cells, fetal cells, epithelial cells, stem cells, tumor cells or bacteria, parasites or fragments of any of the aforementioned or other fragments in a biological fluid. Blood cells can be any blood cell, including any normal or abnormal, mature or immature cells that potentially exist in a biological fluid, for example, red blood cells (RBCs), white blood cells (WBCs), platelets (PLTs) and others cells. Members also include immature or abnormal cells. Immature WBCs can include metamyelocytes, myelocytes, promyelocytes and blastulae. In addition to mature RBCs, members of RBCs can include nucleated RBCs (NRBCs) and reticulocytes. PLTs can include "giant" PLTs and PLT nodes. Blood cells and elements formed are further described elsewhere in this disclosure.
[00483] Exemplary particles may include elements formed in biological fluid samples that include, for example, spherical and non-spherical particles. In certain embodiments, particles can comprise non-spherical components. Image projection of non-spherical components can be maximized at the focal plane of the high-resolution optical imaging device. In certain embodiments, non-spherical particles are aligned in the focal plane of the high-resolution optical imaging device (aligned in a plane substantially parallel to the direction of flow). In some modalities, platelets, reticulocytes, nucleated RBCs and WBCs including neutrophils, lymphocytes, monocytes, eosinophils, basophils and immature WBCs including blastulas, promyelocytes, myelocytes or metamyelocytes are counted and analyzed as particles.
[00484] As used in this document, detectable and measurable particle parameters may include, for example, visual and/or non-image based indices of size, shape, symmetry, contour and/or other characteristics.
[00485] In another embodiment, this disclosure refers to a method for generating particle images using, for example, the kits of this invention in methods comprising, for example: 1) illuminating particles with light on a visual analyzer ; 2) obtain a digitized image of sample particles encased in a PIOAL; and 3) analyze the samples containing particle based on the image information. In other embodiments, the method may further comprise contacting the sample containing particles with a composition of particle contrast agent prior to illuminating the treated sample.
[00486] In one embodiment, the analyzed particles comprise at least one of a spherical particle, a non-spherical particle, or both. In another embodiment, the particles comprise at least one spherical particle. In yet another embodiment, the particles comprise at least one non-spherical particle. In another embodiment, an image projection of non-spherical particles or particles having non-spherical components is maximized in a plane substantially parallel to the flow direction. The particles can be, for example, WBCs, RBCs and/or platelets. In one embodiment, at least 50% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In another aspect, the use of the PIOALs of this invention in a flow cell allows at least 90% of the non-spherical particles to be aligned in a plane substantially parallel to the flow direction.
[00487] The flow of cells smaller than the thickness of the tape-shaped sample stream wrapped in PIOAL results in the parallel alignment of such cells with respect to the direction of flow. In one embodiment of this disclosure, at least 92% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In yet another embodiment, at least 90% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In another modality, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or at least 95% of the particles are substantially aligned, more specifically at 20 degrees with respect to a plane substantially parallel to the direction of flow. In another embodiment, the percentage of non-spherical particles and/or spherical particles that are aligned in a plane substantially parallel to the flow direction can be any range between any two of the mentioned percentages, for example, at least 75 to 85%, 75 to 80% and other ranges such as 75 to 92%.
[00488] Shear forces in the direction parallel to the direction of flow as a result of the flow of larger cells in the sample wrapped in PIOAL, such as WBCs, results in the positioning, repositioning and/or better positioning of nuclear structures, cytosolic structures or granules or other intracellular components or structures closer to a plane parallel to the direction of flow.
[00489] In one embodiment, the non-spherical particles comprise red blood cells. In another aspect of this invention, the spherical particles comprise white blood cells or nucleated red cells.
[00490] In one embodiment of the methods of this invention, the particles are non-spherical particles. In one embodiment, the analyzed particles comprise at least one of a spherical particle, a non-spherical particle, or both. In another embodiment, the particles comprise at least one spherical particle. In yet another embodiment, the particles comprise at least one non-spherical particle. In another embodiment, an image projection of non-spherical particles or particles having non-spherical components is maximized in a plane substantially parallel to the flow direction. The particles can be, for example, RBCs, including reticulocytes and nucleated RBCs, platelets and/or WBCs, including a neutrophil, lymphocyte, monocyte, eosinophil, basophil, or immature WBC, including a blastula, promyelocyte, myelocyte or metamyelocyte. In one embodiment, at least 50% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In another aspect, the use of the PIOALs of this invention in a flow cell allows at least 90% of the non-spherical particles to be aligned in a plane substantially parallel to the flow direction.
[00491] In one embodiment of this disclosure, the image cross-section comprises at least one of a differentially colored nuclear structure, differentially colored cytosolic structure or differentially colored granules in a WBC, including a neutrophil, lymphocyte, monocyte, eosinophil, basophil or WBC immature including a blastula, promyelocyte, myelocyte or metamyelocyte. In another modality, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 %, 93%, 94% or at least 95% of spherical particles and/or non-spherical particles have nuclear structures, cytosolic structures or granules in the focal plane or depth of field of the high resolution optical imaging device.
[00492] In some embodiments of the methods of this invention, the image information is the image cross-section of a particle. In some aspects, the image cross-section comprises at least one of a differentially colored nuclear structure, a differentially colored cytosolic structure, or differentially colored granules in a WBC, including a neutrophil, lymphocyte, monocyte, eosinophil, basophil, or immature WBC, including a blastula, promyelocyte, myelocyte or metamyelocyte.
[00493] In one embodiment, the methods of this invention provide surprisingly high quality images of cells with a high percentage of particles and particle content in focus in the flow, which are useful for obtaining automated image-based WBC differentials as well as automated identification of morphological abnormalities useful in determining, diagnosing, predicting, predicting or sustaining a diagnosis to determine whether an individual is healthy or has a disease, condition, abnormality or infection and/or is responsive or non-responsive to treatment.
[00494] In another aspect, the compositions and methods of this invention provide more accurate image-based cell categorization and subcategorization and signaling that greatly reduce the hand review rate compared to current analyzers.
As used herein, exemplary white blood cells (WBC) may include, for example, neutrophils, lymphocytes, monocytes, eosinophils, basophils, immature granulocytes including metamyelocytes, myelocytes, promyelocytes and abnormal white blood cells and blastulae. As used herein, red blood cells (red blood cells) can include, for example, normal and abnormal red cells, reticulocytes, and nucleated red cells.
[00496] As used herein, the viscosity agent may include viscosity agents or viscosity modifiers. An exemplary agent/viscosity modifier has a characteristic viscosity that is different from the sample viscosity so that when the PIOAL and the viscosity agent are mixed, the viscosity of the PIOAL is changed or and/or increased to maximize particle alignment . In certain embodiments, the difference in viscosity and/or a speed difference between the tape-format sample stream and the PIOAL can introduce shear forces to act on the particles while in flow, thus reducing misalignment and/or causing the particles to line up.
[00497] As used herein, the particle contrast agent compositions can be adapted for use in combination with an intracellular organelle and/or particle alignment liquid (PIOAL) in a visual analyzer to analyze particles in a sample of a individual. The example PIOAL is useful, as an example, in methods for automatically recognizing different types of particles in a sample from an individual.
[00498] In another aspect, cells can be wrapped in PIOAL when images are taken. Suitable exemplary intracellular organelle alignment liquids are described herein.
[00499] In one embodiment, this disclosure refers to a PIOAL for use in a visual analyzer. In certain embodiments, the PIOAL may comprise at least one of a buffer; a pH adjusting agent; a tampon; an agent/viscosity modifier; ionic strength modifier, a surfactant, a chelating agent and/or an antimicrobial agent.
[00500] In one aspect, the PIOAL may comprise two or more agents/viscosity modifiers.
[00501] In one aspect, the PIOAL of this invention can have a viscosity between about 0.001 to about 0.01 Pa.s (1 to about 10 centipoise). In one embodiment, the PIOAL of this invention can comprise an agent/viscosity modifier. In one embodiment, PIOAL comprises up to 100% of a viscosity agent.
As used herein, the viscosity agent and/or viscosity modifier may include any substance suitable for achieving a viscosity of about 0.001 to about 0.01 Pa.s (1 to about 10 centipoise), with optical characteristics, including optical clarity, suitable for use in an imaging system. Generally speaking, the viscosity modifier or agent is non-toxic, biocompatible and leaves the cell structure and contents substantially intact. The viscosity agent and/or viscosity modifier may comprise at least one of glycerol; glycerol derivative; ethylene glycol; propylene glycol (dihydroxypropane); poly(ethylene glycol); water soluble polymer and/or dextran. In one aspect, the agent/viscosity modifier in PIOAL can be glycerol. As an example, in one aspect, the viscosity modifier/agent in PIOAL may be a glycerol derivative. As an example, in one aspect, the agent/viscosity modifier in PIOAL may be polyvinylpyrrolidone (PVP). As another example, the agent/viscosity modifier in PIOAL can be ethylene glycol. As another example, the agent/viscosity modifier in PIOAL can be propylene glycol (dihydroxypropane). As another example, the agent/viscosity modifier in PIOAL can be poly(ethylene glycol). As another example, the agent/viscosity modifier in PIOAL can be water-soluble polymer or dextran. In other aspects, the agent/viscosity modifier in PIOAL may comprise two or more of glycerol, glycerol derivative; ethylene glycol; propylene glycol (dihydroxypropane); polyvinylpyrrolidone (PVP); poly(ethylene glycol); water soluble polymer or dextran. The viscosity agent/viscosity modifying agents can include any agent suitable for providing a viscosity of from about 0.001 to about 0.01 (1 to about 10 centipoise), with optical characteristics that include optical clarity, suitable for use in an imaging system.
As used herein, other exemplifying agents/viscosity modifiers may include, for example, natural hydrocolloids (and derivatives) such as acacia, tragacanth, alginic acid, carrageenan, locust bean gum, guar gum, xanthan gum, arabic gum, guar gum, gelatin, cellulose, alginates, starches, sugars, dextrans; gelatin; sugars (and derivatives), such as dextrose, fructose; polydextrose; dextrans; polydextranes; saccharides; and polysaccharides; semi-synthetic hydrocolloids (and derivatives) such as glycerol, methylcellulose, hydroxy ethyl starch (heta-starch), sodium carboxy methyl cellulose, hydroxyethyl cellulose, hydroxy-propyl-methyl cellulose, polyvinylpyrrolidone (PVP); synthetic hydrocolloids (and derivatives), such as poly(vinyl alcohol) (PVA) and/or Carbopol®. Other cell compatible viscosity modifiers/agents are also considered useful for this purpose.
[00504] In another aspect, the agent/viscosity modifier in the PIOAL may be glycerol present in a concentration of about 1 to about 50% (v/v) of the PIOAL. As an example, in one embodiment, the viscosity modifier/agent can be present in the PIOAL at a concentration of from about 5.0% to about 8.0% (v/v). In another aspect, the viscosity modifier/agent may be present at a concentration of about 6.5% (v/v). In one embodiment, the viscosity modifier/agent is glycerol present at a concentration of about 6.5% (v/v).
[00505] In yet another embodiment, the PIOAL may comprise a glycerol viscosity modifier/agent present at a concentration of about 30% (v/v).
[00506] In another aspect, the agent/viscosity modifier in the PIOAL may be PVP present at a concentration of about 0.5 to about 2.5% (weight to volume). As an example, in one embodiment, the PVP viscosity modifier/agent may be present in the PIOAL at a concentration of from about 1.0 to about 1.6% (weight to volume). In one modality, PVP is present at a concentration of about 1.0% (weight by volume).
[00507] In another aspect, the agent/viscosity modifier in PIOAL can be PVP and glycerol. As an example, in one embodiment, glycerol may be present in PIOAL at a concentration of about 5% (v/v) in combination with about 1% (weight by volume) of PVP.
[00508] In one embodiment, the PIOAL of this invention can be used in a visual analyzer to generate particle images. In one aspect, the visual analyzer comprises a flow cell with a symmetrical flow path and an auto focus component.
[00509] A viscosity agent and/or viscosity adjusting/modifying agents, such as glycerol, may be included in PIOAL. The viscosity agent or viscosity modifying agent when introduced can suitably adjust the viscosity of the PIOAL to the desired range. Any suitable viscosity agent can be used, which sufficiently increases the viscosity of the PIOAL, which has adequate optical characteristics to allow high quality imaging of flow cells. PIOAL will have a viscosity adequate to align cells and/or cell structures in a single plane that is substantially parallel to the direction of flow, thus increasing, in part, the in-focus contents of the particles.
[00510] PIOAL can be used with any analyzer of this disclosure.
[00511] As used herein, the term "glycerols" encompasses glycerol and a glycerol derivative (hereinafter called a glycerol derivative). Examples of a glycerol derivative include thioglycerol, polyglycerol and the like. Usable examples of polyglycerol may include diglycerol, POLYGLYCERIN No. 310 (Sakamoto Yakuhin Kogyo Co., Ltd.), POLYGLYCERIN No. 750 (Sakamoto Yakuhin Kogyo Co., Ltd.), POLYGLYCERIN No. 500 (Sakamoto Yakuhin Kogyo Co., Ltd., Ltd.) and the like.
[00512] In another embodiment, the PIOAL of this disclosure additionally comprises a pH adjusting agent. In one aspect, the final pH of the PIOAL and/or the sample is between about 6.0 to about 8.0. In another aspect, the final pH of the PIOAL and/or the sample is between about 6.6 to about 7.4. In one aspect, the final pH of the PIOAL can be the same as the pH of the prepared sample 12B (referring to Figure 8).
Exemplary pH adjusting agents may include, for example, acids (examples include organic acids and mineral acids), bases (examples include organic bases and alkali metal and alkaline earth metal hydroxides). Exemplary organic acids can include acetic, lactic, formic, citric, oxalic and uric acids. Exemplary mineral acids can include, for example, hydrochloric, nitric, phosphoric, sulfuric, boric, hydrofluoric, hydrobromic and perchloric acids. Exemplary organic bases can include, for example, pyridine, methylamine, imidazole, benzimidazole, histidine, phosphazene and cation hydroxides. Exemplary alkali metal and alkaline earth metal hydroxides may include, for example, potassium hydroxide (KOH), barium hydroxide (Ba(OH)2), cesium hydroxide (CsOH), sodium hydroxide (NaOH), strontium hydroxide (Sr(OH)2), calcium hydroxide (Ca(OH)2), lithium hydroxide (LiOH) and rubidium hydroxide (RbOH).
[00514] In some embodiments, with the use of a buffer, the pH of the PIOAL is preferably maintained from about 6.0 to about 8.5, more preferably from about 7.0 to about 8.0. In some embodiments, it is preferable to add a buffering agent to the PIOAL to adjust the pH of the PIOAL. Any suitable buffering agent or agents can be used, provided the agent or agents adjust the pH of the PIOAL to the proper range. Examples of such a buffering agent include STF, Good's buffers (specifically, tris-buffer, methyl ester sulfonate, bis-tris, ADA, PIPES, ACES, MOPSO, BES, MOPS, TES, HEPES, DIPSO, TAPSO, POPSO, HEPPSO , EPPS, tricine, bicine, TAPS and the like), disodium hydrogen phosphate, sodium dihydrogen phosphate, monobasic potassium phosphate, veronal sodium HCl, collidine-HCl, tris(hydroxymethyl)aminomethane-maleic acid, tris(hydroxyl) methyl)aminomethane, which can be used alone or in combination.
[00515] In another embodiment, the PIOAL of this invention comprises an ionic strength modifier to adjust the ionic strength of the resulting formulation. Exemplary ionic strength modifiers may include sulfates, pyrosulfates, phosphates, pyrophosphates (eg, potassium pyrophosphate), citrates, cacodylates of Li+, Na+, K+, Mg++ Ca++ Cl-Br-HCO-3 or other suitable salts In one embodiment , PIOAL may be isotonic.
[00516] Surfactants can be added to PIOAL. The types of surfactants are not particularly limited as long as they are compatible with other components of PIOAL and compatible with the sample stream in tape format and the particles in the sample. Surfactants can include, for example, cationic, anionic, nonionic and ampholytic surfactants. Exemplary surfactants may include polyoxyethylene alkyl ether type surfactants, polyoxyethylene alkylphenyl ether type surfactants, (eg, NISSAN NONION NS-240 (NOF CORPORATION, trademark)), polyoxyethylene sorbitan alkyl ester type surfactants (eg, RHEODOL TW-0120 (Kao Corporation, Trademark)), polyol copolymers (eg, PLURONIC F-127, F-123, F-109, F-87, F-86, F-68, T-1107, T-1102 (BASF Corporation, Trademark)), MEGA-8, sucrose monocaprate, deoxy-BIGCHAP, n-octyl-β-D-thioglucoside, n-nonyl-β-D-thiomaltoside, n-heptyl-β-D-thioglucoside , n-octyl-β-D-thioglucoside, CHAPS, CHAPSO and the like can be used. Other surfactants may include Triton-X-100 and Tween 20 at concentrations compatible with the sample and the sample stream in tape format.
[00517] The concentration of the surfactant in the PIOAL is preferably the concentration level at which particles, such as cells in the sample, are unaffected and/or remain substantially intact. Specifically, the concentration is preferably from 5 to 5,000 mg/L, more preferably from 100 to 3,000 mg/L.
[00518] When the particles contained in the sample are analyzed with the analyzer, amorphous salts such as ammonium phosphate, magnesium phosphate, calcium carbonate may be precipitated in the sample. Chelating agents can be added to PIOAL to dissolve such amorphous salts. The addition of chelating agents enables not only the dissolution of amorphous salts, but also the inhibition of PIOAL oxidation. Useful examples of a chelating agent include salts of EDTA, CyDTA, DHEG, DPTA-OH, EDDA, EDDP, GEDTA, HDTA, HIDA, methyl-EDTA, NTA, NTP, NTPO, EDDPO and the like. The concentration of the chelating agent in the PIOAL is preferable in the range of 0.05 to 5 g/L.
[00519] In another embodiment, the PIOAL may additionally comprise one or more antimicrobial agents. In some aspects, the antimicrobial agent can be, for example, substances that have fungicidal activity (fungicidal agents) and/or substances that have bactericidal activity (bactericidal agents). In certain embodiments, suitable antimicrobial agents can include, for example, parabens, isothiazolinone, phenolics, acidic preservatives, halogenated compounds, quaternes and alcohol. Exemplary parabens can include Parabens and Paraben salts. Isothiazolinones may include methyl chloro isothiazolinone, methyl isothiazolinone, benzisothiazolinone ProClin 150, ProClin 200, ProClin 300 and ProClin 950. Exemplary phenolic types may include phenoxyethanol, benzyl alcohol and phenethyl alcohol. Exemplary acid preservatives may include dehydroacetic acid, benzoic acid, ascorbic acid, salicylic acid, formic acid, propionic acid. Halogen compounds may include 2-bromo-2-nitropropane-1,3-diol, chloroacetamide, chlorobutanol, chloroxylenol, chlorphenesin, dichlorobenzyl alcohol, iodopropynyl butylcarbamate, methyl-dibromo glutaronitrile. Exemplary quaternions may include benzalkonium chloride, benzalkonium chloride, chlorhexidine, hexamidine diisethionate, and polyaminopropyl biguanide. Exemplary alcohols can include ethyl alcohol and isopropyl alcohol. Examples thereof include triazine antimicrobial agents, thiazole bactericidal agents (for example benzisothiazolone etc.), pyrithione, pyridine bactericidal agents (for example 1-hydroxy pyridine-2-thiosodium etc.), 2-phenoxyethanol and the like . Specifically, Proxel GXL (Avecia), TOMICIDE S (API Corporation) and the like can be used. Bactericidal agents and/or fungicidal agents help to improve the stability of PIOAL.
[00520] In one modality, the concentration of the antimicrobial agent can be from 0.01% to 0.5% (weight by volume). The concentration can be from 0.03 to 0.05% (weight to volume).
[00521] The sample that is submitted for analysis using the analyzer with the PIOAL in the modality is not particularly limited. Samples obtained from the living organism (biological samples) are normally used. Alternatively, such samples can be diluted, purified, contacted with a contrast agent or the like for use. Specifically, examples of such a sample can include blood, semen, cerebrospinal fluid and the like. Samples may also include particle suspensions derived from tissue samples. PIOAL in modality is suitably used when particles (red blood cells, white blood cells, bacteria, etc.) are analyzed.
[00522] The PIOAL of this invention can be used in a visual analyzer that forms particle images. In one aspect, the visual analyzer comprises a flow cell that can maintain the flow of a tape-shaped sample stream with predetermined dimensional characteristics, such as an advantageous tape-format sample stream thickness. In some embodiments, the flow cell can have a symmetrical flow path and be used in combination with an auto focus component.
[00523] This disclosure relates to a method for imaging a particle comprising: 1) contacting the sample with a composition of particle contrast agent; 2) illuminate the prepared particle; 3) obtain a digitized image of the particle in a tape-shaped sample stream encased in a PIOAL; and; 4) analyze image information to categorize or subcategorize particles. In some embodiments, the particle can be at least one of a WBC, red blood cells and/or platelet, including, for example, a neutrophil, lymphocyte, monocyte, eosinophil, basophil, reticulocyte, nucleated red blood cells, blastula , promyelocyte, myelocyte or metamyelocyte, cell, bacteria, parasites, particulate matter, cell nodule, cell component and immature granulocyte. In some embodiments, platelets, reticulocytes, nucleated RBCs and WBCs including neutrophils, lymphocytes, monocytes, eosinophils, basophils and immature WBCs including blastula, promyelocyte, myelocyte or metamyelocyte are counted and analyzed based on the particle image information.
[00524] In some embodiments, the visual analyzer comprises a flow cell with a symmetrical or an asymmetrical flow path and an autofocus component.
[00525] In general, the exemplary PIOAL and methods of using it are useful when employed in combination with an automated analyzer found in research and/or medical laboratories. Exemplary automated analyzers are instruments designed to measure different formed elements and/or other characteristics in diverse biological samples, quickly including, for example, human body fluid samples, with minimal human assistance. Exemplary automated analyzers can include, for example, hematology analyzers and/or cell counters that can perform, for example, the determination of the whole blood count (CBC). Exemplary analyzers can process samples individually, in batches or continuously.
[00526] In one aspect, the exemplary analyzer/system comprises an automated particle counter configured to detect a plurality of particles that satisfy one or more selection criteria and to provide a particle count thereof, wherein the selection criteria encompass members of at least two categories among said particles. An analyzer, which may comprise a processor, which may include counter components, is programmed to distinguish particles of at least two categories. A distribution of each of the particles is determined using the analyzer. The processor uses the distribution to correct the particle count for members of at least one of at least two categories and/or subcategories. In some embodiments, the particle counter comprises at least one channel configured to provide particle count of at least one category and/or subcategory of particles based on a predetermined range based on volume, size, shape, and/or other criteria . For example, members of at least one category and/or subcategory comprise at least one type of particle selected from a group consisting of subcategories of white blood cells (WBCs), red blood cells (RBCs), giant platelets (PLTs) and nucleated red cells ( NRBCs). In a particle counter, due to similar size or other measured characteristic, cells such as giant PLTs and NRBCs can be counted as WBCs. By operating the apparatus as described in this document, the particle count or concentration of giant PLTs and NRBCs can be accurately measured.
[00527] The sample can be an isolated and/or prepared biological sample that includes, for example, a body fluid sample, a blood, serum, cerebrospinal fluid, pleural fluid, peritoneal fluid, saliva, seminal fluid, tears, sweat, milk , amniotic fluid, lavage fluid, bone marrow aspirate, effusions, exudates, or other sample obtained from an individual (eg, biopsy sample that has been treated to produce a cell suspension or a laboratory or production line sample which comprises particles). In some embodiments, the sample may be a solid tissue sample, for example, a biopsy sample that has been treated to produce a cell suspension. The sample can also be a suspension obtained from the treatment of a faecal sample. A sample can also be a laboratory, chemical, industrial or production line sample that comprises particles, such as a cell culture sample. The term sample can be used to refer to a sample obtained from a patient or laboratory or any fraction, portion or aliquot thereof. The sample can be diluted, divided into portions or treated with a contrast agent in some procedures.
[00528] The methods disclosed in this document are applicable to samples from a wide range of organisms, including mammals, for example, humans, non-human primates (for example, monkeys), horses, cows or other types of livestock, dogs, cats or other mammals kept as pets, rats, mice or other laboratory animals; birds, for example, chickens; reptiles, for example, alligators; fish, for example, salmon and other bred species; and amphibians.
[00529] Samples can be obtained by any conventional method, eg excretion, extraction, collection, aspiration or a biopsy. The sample can be from an individual considered healthy, for example, a sample taken as part of a routine physical examination. The sample may also be from an individual who has, is at risk for, or is suspected of having a disorder. The disorder can be the result of an illness, a genetic abnormality, an infection, an injury, or unknown causes. Alternatively or in addition, the methods can be useful for monitoring an individual during the course of treatment for a disorder. Where there are signs of non-response to treatment and/or therapy, a clinician may choose an alternative or additional agent. Depending on the individual's condition and the specific disorder, if any, samples may be collected once (or twice, three times, etc.) daily, weekly, monthly, or annually.
[00530] Particles may vary depending on the sample. The particles can be biological cells, for example blood cells, fetal cells, stem cells, tumor cells or fragments thereof. In some embodiments, the particles can be an infectious agent, for example, a virus or bacteria.
[00531] References made to "blood cells" in this disclosure are understood to encompass any normal or abnormal, mature or immature cells that potentially exist in a biological fluid, e.g., red blood cells (RBCs), white blood cells (WBCs), platelets (PLTs) and other cells. In general, normal RBCs, PLTs and WBCs have a particle diameter in the range of 6 to 8 µm, 2 to 3 µm and 8 to 15 µm, respectively. Normal RBCs, PLTs and WBCs are present in whole blood samples from normal patients in an approximate concentration range of 3.9 to 5.7 x 1012 cells/L, 1.4 to 4.5 x 1011 cells/L, 3.5-11 x 109 cells/L, respectively. See, Barbara J. Bain, Blood Cells, A Practical Guide, 4th. Edition, Blackwell Publishing, 2007, 34 to 36.
[00532] Reference to a "formed element" is understood to encompass non-fluid elements present in biological fluid samples. Elements formed include, for example, classes of blood cells based on scientific classification or physiological function including erythrocytes (RBCs), leukocytes (WBCs) and platelets (PLTs), WBC nodules, leukocyte subclasses, which include mature lymphocytes and immature leukocytes such as monocytes, neutrophils, eosinophils, basophils. "Formed elements" for use herein will also include particles such as microorganisms, bacteria, fungi, parasites or fragments thereof or other cell fragments. Major members of WBCs include, but are not limited to, neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Members also include immature or abnormal cells. For example, immature WBCs can include metamyelocytes, myelocytes, promyelocytes. In addition to mature RBCs, members of RBCs can include nucleated RBCs (NRBCs) and reticulocytes. PLTs can include regular PLTs and "giant" PLTs that are close to the size of regular WBCs. Reference in this disclosure to a "member" or "members" of a category and/or subcategory of particles is understood to encompass individual particles within a category or subcategory of particles.
[00533] Unless expressly stated otherwise, the reference made to a "category" of particles in this disclosure is understood to encompass a group of particles detected using at least one measured, detected or derived detection criterion, such such as size, shape, texture or color. In some embodiments, the members of at least one category and/or subcategory of particles counted by the apparatus of this disclosure will be of the same type as the element formed.
[00534] Such particles can be detected in a "channel". Reference in this disclosure to a "channel" is understood to encompass a portion of the particle counter comprising a detector coupled to a signal source, which provides an output that varies with greater or lesser detection of particles satisfying at least a channel detection criterion. For example, a channel detection criterion can be based on particle size or volume. In some embodiments, the number of channels in a particle counter is one (1). In some other embodiments, the number of channels in a particle counter is two or more.
[00535] A category and/or subcategory of particles detected in a particle counter channel may comprise different classes and subclasses of particles and grouped members of particles into two or more subclasses. Reference in this disclosure to a "category" of particles is understood to encompass an array of particles that meet measured, detected or derived criteria for such size, shape, texture or color. In some embodiments, the members of at least one category and/or subcategory of particles counted by the apparatus of this disclosure will be of the same type as the element formed.
[00536] As used in this document, "alignment" can be characterized in part by the alignment of spherical particles and/or non-spherical particles. For example, particles such as non-spherical particles can be aligned in a plane substantially parallel to the direction of flow. In certain embodiments, the alignment of the non-spherical particles, which is characterized by the orientation of the particles, enhances an image projection of the non-spherical particles under imaging conditions at the focal plane of the high-resolution optical imaging device. Particles, such as spherical particles, can have an increase in the amount of intraparticle contents in focus of particles and cells that is effective in generating the visual distinctions for particle categorization and subcategorization. Intraparticle structures of particles, such as spherical particles, can be positioned, repositioned and/or better positioned so as to be substantially parallel with respect to the direction of flow. For example, intracellular structures, organelles or lobes can further be positioned, repositioned and/or better positioned so as to be substantially parallel with respect to the flow direction.
[00537] The reference made in this disclosure to the "class" of particles is understood to encompass a group of particles based on scientific classification. For example, three major classes of blood cells exist in a whole blood sample, including RBCs, WBCs, and PLTs.
[00538] Reference in this disclosure to "member" or "members" of particles is understood to encompass particles in a category or subcategory of particles. For example, each category of blood cells can be further divided into subcategories or members. Major members of WBCs include, but are not limited to, neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Members also include immature or abnormal cells. For example, immature WBCs can include metamyelocytes, myelocytes and promyelocytes. In addition to mature RBCs, members of RBCs can include nucleated RBCs (NRBCs) and reticulocytes. PLTs can include regular PLTs and "giant" PLTs that are close to the size of regular WBCs.
[00539] A reference to "immature cells" is understood to encompass cells at a certain stage of development, for example, within the bone marrow or shortly after release from the bone marrow, but before full development, in order to make a cell mature.
[00540] It is understood that the reference made to "abnormal cells" encompasses cells with irregular morphological characteristics or cells associated with a particular disease or condition or associated irregularities which may, in some cases, be associated with certain diseases or conditions. Examples of a particular disease include, but are not limited to, erythrocytosis, polycythemia, anemia, erythroblastopenia, leukocytosis, leukopenia, lymphocytosis, lymphocytopenia, granulocytosis, granulocytopenia or agranulocytosis, neutrophilia, neutropenia, eosinophilia, eosinopenia, basophilia, basopenia, thrombocytopenia pancytopenia. A class of cells can increase or decrease in the bloodstream. In some conditions, abnormal cells much larger than normal white blood cells exist in a small concentration in a blood sample. Variations in size, shape, color and/or intracellular structures may be associated with certain diseases or conditions.
[00541] The reference made in this disclosure to "particle counting" or "particle counting" is understood to encompass the quantities of particles obtained from a channel of a particle counter. Reference in this disclosure to the "concentration" of a class or member of particles is understood to mean several particles per unit volume (eg, per liter) or per sample of a known volume. For example, a particle counter can provide counts or concentrations or other count-based functions for categories of particles, while a visual analyzer can provide counts, concentrations, ratios, or other concentration-based parameters for each category or subcategory of particles. .
[00542] The reference in this disclosure to "ratio" is understood to encompass any quantitative ratio and/or proportional ratio of two categories/subcategories, classes or members of particles. Examples of such a ratio include, but are not limited to, a ratio by concentration, weight and/or amounts of particles. Typically, the ratio is related to the numerical fraction of the count of one category, class, or member through the count of another category, class, or member of that type. In some embodiments, determinations using weighted counts or weighted counts and/or proportional ratios can also be performed.
[00543] Therefore, the embodiments of the present invention encompass hybrid systems and methods, for example, that combine electronic cell counting and photographic cell imaging techniques, for example, to analyze cells that may be difficult to distinguish electrically or to analyze cells present in quantities that make it difficult to obtain an accurate electronic count of them.
[00544] The present disclosure also relates to a surprising and unexpected particle contrast agent composition for quickly generating the visual distinctions in a sample. The particle contrast agent composition can be specifically useful in automated flow cytometry systems. The particle contrast agent composition is comprised of a combination of a particle contrast agent, a permeabilizing agent and a fixative agent. In one embodiment, the particle contrast agent composition is a blend of Crystal Violet, Novo Methylene Blue, Saponin and Gluteraldehyde. In an embodiment that is surprisingly effective, under staining conditions, Crystal Violet is present in amounts sufficient to result in concentrations of about 7.8 µm, Novo Methylene Blue is present in amounts sufficient to result in concentrations of about 735 µm, Saponin is present in amounts sufficient to result in concentrations between about 50 mg/L and about 750 mg/L, the composition additionally includes Eosin-Y present in amounts sufficient to result in concentrations of about 27 µm and a gluteraldehyde is present in sufficient amounts to result in concentrations of 0.1% or below 0.1%.
[00545] Such illustrative examples are provided to introduce the reader to the general matter discussed in this document and are not intended to limit the scope of the concepts disclosed. The following sections describe various additional features and examples with reference to the drawings in which like numerals indicate like elements and directional descriptions are used to describe illustrative embodiments, however, like illustrative embodiments, they should not be used to limit the present disclosure. Elements included in the illustrations in this document may have been drawn out of scale.
[00546] The particle contrast agent composition of the invention, when applied to a blood fluid sample, generates cell staining in such a sample similar to that of a blood smear treated with a standard blood smear dye and, in particular, similar to Wright's staining of a blood smear. Wright's stain is a histological pigment that facilitates the differentiation of blood cell types (eg, WBC). It is mainly used for staining peripheral blood smears and bone marrow aspirates that are examined under a microscope light. In cytogenetics, it is used to stain chromosomes to facilitate the diagnosis of syndromes and diseases. There are related stains known as Buffered Wright Stain, Wright-Giemsa Stain, and Buffered Wright-Giemsa Stain. Because the Wright staining process involves alcohol solvent, such a staining process is destructive to viable cells and does not generate substantially intact cells. May-Grünwald stain, which produces a more intense coloration, also has a longer performance time.
Aspects and embodiments of the present invention are based on the surprising and unexpected finding that certain particle contrast agent compositions, including e.g. dye/stain compositions and/or combinations thereof, have unexpected properties and effectiveness when used to perform automated image-based sample analysis, such as blood analysis.
[00548] The compositions and method disclosed in this document can be used with many different types of hematology imaging systems. In particular, the compositions and methods described in this document can be used with an image-based sample analysis, such as a flow cell analysis. An example of such a flow cell analysis might include known traditional methods of flow cytometry. Additionally, the compositions and methods described in this document can be advantageously used with the flow cell analysis systems and methods described briefly below and further described in the co-deposited applications entitled "Flowcell Systems And Methods For Particle Analysis In Blood Samples", Application No. __/___,___, filed March 17, 2014 and "Hematology Systems and Methods", Application No. PCT, filed March 17, 2014, both of which are incorporated herein by reference.
[00549] PARTICLE CONTRAST AGENT COMPOSITION
[00550] Figure A1 is a schematic diagram of the preparation of a particle contrast agent composition, according to an embodiment. In block 208, a particle contrast agent 202, a permeabilizing agent 204, and a fixative agent 206 are combined to create the particle contrast agent composition 210. In one embodiment, the particle contrast agent 202, the agent of permeabilizing agent 204 and fixing agent 206 are combined at the same time. In other embodiments, one of particle contrast agent 202, permeabilization agent 204, and fixative agent 206 is combined with another of particle contrast agent 202, permeabilization agent 204, and fixative agent 206, which is then combined with the last of particle contrast agent 202, permeabilizing agent 204 and fixing agent 206 in any order. The combination in block 208 can be performed in any order and in any suitable manner.
[00551] In alternative embodiments, one of the permeabilizing agent 204 and the fixing agent 206 is not included in the 210 particle contrast agent composition. In still further embodiments, the additional materials are combined in block 208 as a part of the composition. of particle contrast agent 210, as described in greater detail below.
[00552] The 210 particle contrast agent composition may be provided as a part of a kit. Particle contrast agent composition 210 can be supplied ready-made or as one or more components that must be combined. Particle Contrast Agent
The 202 particle contrast agent can be any contrast agent that can produce visible distinctions, such as those similar to a Wright stain. Examples of such contrast agents include Alcian Blue and Alcian Blue 86 (PAS, neutral and acidic mucosubstances); Alizarin Red S; Allura AC Red (azo red dye #40); Aniline Blue (cilia enhanced with oxalic acid); Auramine O; Azura B; Azura C; Brown Bismarck; FCF Brilliant Blue (Comassie Blue); Bright cresyl blue; Bright Green; Carmine (red nuclear dye composed of carminic acid and potassium alum); Congo red; Chlorosol E black (nucleus black, cyto gray, glycogen pink); cresyl violet acetate; Red Darrow; bluish eosin; Erythrosine B (red dye #3); Ethyl eosin; Fast Green FCF (green dye #3); Basic fuchsin- (nuclei and flagella); Fluorescein- (Mercurochrome); Giemsa - peripheral blood smears; Harris hematoxylin-regressive nuclear dye; Indigo carmine (blue dye #2); Janus B Green (mitochondria); Jenner's stain - (peripheral blood smears); Light Green SF yellowish; MacNeal- (tetrachrome blood dye); Malachite green; Methyl orange; Martius Yellow; Mayer's hematoxylin - progressive nuclear stain; Methyl Violet 2B; Methenamine silver - periodic acid; methylene violet; May Grunwald- hematological stain; MTT-formazan dye; Mucicarmin - primary tumor dye; Neutral red; Nigrosine; Nile Blue A; Nuclear Fast Red I.C. 60760; NaphtalAS; Nitrotetrazolium blue - fast formazan dye; Orange G; Orange II; Orcein; Pap smear EAS- bright cytoplasmic dye; Pararosanilin; Pararosanalin; Periodic acid Schiff - (PAS, specific carbohydrate dye); Philoxin B; Protargol S; Pyronine B; Pyronine Y; Resazurin; Romanowsky-Giemsa; Bengal rose; Safranin O; Sudan Black B; Sudan III- (with alpha-naphthol myeloid dye granules); Sudan IV- triglyceride dyes; Tartrazine- (azo dye Yellow #5); Thionine-methchromatin dyes; Triphenyl tetrazolium; TTC- Formazan red dye; Toluidine blue O; Wright's stain - (fix, buffer and pigment for conventional blood smears); and Wright Giemsa.
[00554] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in the 210 particle contrast agent composition, as described in greater detail in this document, with the use of a 202 particle contrast agent which includes at least one of Crystal Violet, New Methylene Blue, Safranin O, Eosin Y, and Methyl Green. Particle contrast agent 202 is added in an amount effective for staining viable and/or substantially intact cells for image-based categorization and subcategorization. Particle contrast agent 202 can be any combination of two or more of the aforementioned particle contrast agents. The 202 particle contrast agent can be selected to effectively obtain "Wright-like" staining images of vital and/or substantially intact cells.
[00555] In one embodiment, the 202 particle contrast agent includes Crystal Violet. The Violet Crystal may be present in amounts sufficient to reach from about 1 µm to about 100 µm under staining conditions. As used in this document, the term "under staining conditions" refers to when the component is mixed with the sample. The Violet Crystal may be present in amounts sufficient to reach from about 6 µm to about 10 µm under staining conditions. The Violet Crystal may be present in sufficient amounts to reach about 7.8 µm under staining conditions. The Violet Crystal may be present in sufficient amounts to reach approximately 7.8 µm under staining conditions. Violet Crystal can be purified to at least 90% purity. The Violet Crystal can be purified to at least 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% purity. Violet Crystal can be purified to at least 99% purity. The particle contrast agent 202 can be Crystal Violet alone or it can be Crystal Violet combined with one or more additional particle contrast agents.
[00556] In one embodiment, the 202 particle contrast agent includes New Methylene Blue. Novo Methylene Blue can be present in amounts sufficient to reach from about 70 µm to about 2.4 mM under staining conditions. New Methylene Blue can be present in amounts sufficient to reach from about 500 µm to about 950 µm under staining conditions. New Methylene Blue may be present in amounts sufficient to reach about 735 µm under staining conditions. New Methylene Blue may be present in sufficient amounts to reach approximately 735 µm under staining conditions. New Methylene Blue can be purified to at least 70% purity. The New Methylene Blue can be purified to at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% purity. New Methylene Blue can be purified to at least 100% purity.
[00557] In some embodiments, surprisingly effective results are achieved when the 202 particle contrast agent includes both Crystal Violet and New Methylene Blue. The ratio of Crystal Violet to New Methylene Blue can be from about 1:1 to about 1:500 (molar/molar). The ratio of Crystal Violet to New Methylene Blue can be from about 1:50 to about 1:160 (molar/molar). The ratio of Crystal Violet to New Methylene Blue can be from about 1:90 to about 1:110 (molar/molar).
[00558] In one embodiment, the 202 particle contrast agent includes Eosin Y. Eosin Y may be present in amounts sufficient to reach from about 3 µm to about 300 µm under staining conditions. Eosin Y can be present in amounts sufficient to reach from about 10 µm to about 50 µm under staining conditions. Eosin Y may be present in amounts sufficient to reach about 27 µm under staining conditions. Eosin Y may be present in amounts sufficient to reach approximately 27 µm under staining conditions. Eosin Y can be purified to at least 80% purity. Eosin Y can be purified to at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% purity. Eosin Y can be purified to at least 100% purity.
[00559] In some embodiments, surprisingly effective results are achieved when the 202 particle contrast agent is a combination of Crystal Violet, Novo Methylene Blue and Eosin Y, each having any combination of concentrations and purities as described above. In some embodiments, the particle contrast agent 202 is, specifically, Crystal Violet present in amounts sufficient to reach about 7.8 µm, New Methylene Blue present in amounts sufficient to reach about 735 µm, and Eosin Y present in quantities sufficient to reach about 27 µm. In some embodiments, the particle contrast agent 202 is specifically at least 99% pure, Crystal Violet present in sufficient amounts to achieve about 7.8 µm, at least 99% pure, New Methylene Blue present in quantities sufficient to achieve about 735 µm and at least 99% purity, Eosin Y present in quantities sufficient to achieve about 27 µm.
In one embodiment, the particle contrast agent 202 includes Safranin O. Safranin O may be present in amounts sufficient to reach from about 1 µm to about 100 µm under staining conditions. Safranin O may be present in amounts sufficient to reach from about 3 µm to about 30 µm under staining conditions. Safranin O may be present in amounts sufficient to reach about 9 µm under staining conditions. Safranin O may be present in amounts sufficient to reach approximately 9 µm under staining conditions. Safranin O can be purified to at least 80% purity. Safranin O can be purified to at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% purity. Safranin O can be purified to at least 100% purity.
[00561] In one embodiment, the 202 particle contrast agent includes Methyl Green. Methyl Green can be present in amounts sufficient to reach about 0.1 g/L under staining conditions. Methyl Green may be present in sufficient amounts to reach approximately 0.1 g/L under staining conditions. Methyl Green can be purified to at least 80% purity. Methyl Green can be purified to at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98% or 99% purity. Methyl Green can be purified to at least 100% purity.
[00562] In some embodiments, the particle contrast agent 202 includes one or more of Crystal Violet, New Methylene Blue, Safranin O, Eosin Y, and Methyl Green in amounts effective to generate visual distinctions in particles, e.g., accentuating up the intracellular content features of particles in a sample when presented for imaging. The 202 particle contrast agent may be present in sufficient amounts to accentuate and/or color the subcellular structures of neutrophils, lymphocytes, monocytes, eosinophils and basophils, as well as reticulocytes, nucleated red blood cells, platelets, blastula, promyelocyte, myelocyte, metamyelocyte or cell fragments. Visual or visual distinctions can include any particle or intraparticle features that can be visualized or otherwise detectable using any light source (eg, UV, visible, IR).
[00563] In embodiments where the 210 particle contrast agent composition includes two or more 202 particle contrast agents, the amounts of each of the 202 particle contrast agents may be adjusted accordingly, depending on the agent's ability to Particle Contrast 202 have independent, competitive, and/or enhancing effects on the generation of visual distinctions for particle categorization and subcategorization. permeabilizing agent
[00564] In some embodiments, the permeabilizing agent 204 may include a surfactant. In some embodiments, permeabilizing agent 204 can include a saponin. In alternative embodiments, permeabilizing agent 204 can include at least one of a quaternary ammonium salt, a nonionic surfactant, and a zwitterionic surfactant. The permeabilizing agent can alter the permeability of a cell to increase the accessibility of the 202 particle contrast agent to intracellular contents. The permeabilizing agent can be selected and included in sufficient amounts to enable a rapid one-step coloring process.
[00565] Examples of a nonionic surfactant may include (1) polyoxyethylene alkyl or aryl ethers (polyethoxylates), including straight chain aliphatic hydrophobes etherified to poly(ethylene glycol) or polyoxyethylene ethanol, e.g. Brij® 35; (2) branched-chain aliphatic/aromatic hydrophobes (e.g., octyl phenol) etherified to poly(ethylenic glycol), e.g., Triton X®-100; (3) straight chain aliphatic/aromatic hydrophobes (e.g. n-nonylphenol) etherified to poly(ethylene glycol), e.g. Igepal® C0897; and (4) straight chain aliphatic hydrophobes (e.g., carboxylic acid) esterified to poly(ethylene glycol), e.g., Myrj® 53 and others. Examples of nonionic polyoxyethylene alkyl or aryl ethers surfactants (polyethoxylates) may include polyoxyethylene(4) lauryl ether (Brij® 30); polyoxyethylene(23) lauryl ether (Brij® 35); polyoxyethylene(2) cetyl ether (Brij® 52); polyoxyethylene(20) cetyl ether (Brij® 58); polyoxyethylene(2) stearyl ether (Brij® 72); polyoxyethylene(10) stearyl ether (Brij® 76); polyoxyethylene(20) stearyl ether (Brij® 78); polyoxyethylene(2) oleyl ether (Brij® 92); polyoxyethylene(10) oleyl ether (Brij® 96); polyoxyethylene(20) oleyl ether (Brij® 98); polyoxyethylene(21) stearyl ether (Brij® 721); polyoxyethylene(100) stearyl ether (Brij® 700); and others. Additional examples of non-ionic surfactants may include Triton X®-100 (unreduced or reduced), Triton®X-114 unreduced or reduced), Triton X®-165 and Triton X®-305 (unreduced and reduced) and others.
[00566] In one embodiment, the permeabilizing agent 204 can include Brij® 35 in amounts sufficient to result in concentrations from about 0.10 g/L to about 0.20 g/L under staining conditions. Brij® 35 can be present in sufficient amounts to result in concentrations from about 0.10 g/L to about 0.16 g/L under staining conditions. Brij® 35 can be present in amounts sufficient to result in concentrations from about 0.012 g/L to about 0.14 g/L.
[00567] Examples of zwitterionic surfactants may include TDAPS (tetradecyl dimethyl ammonium propane sulfonate), CHAPSO (3-[(3-cholamidopropyl) dimethylammonium]-2-hydroxy-1-propane sulfonate), N, N-dimethyl N oxides -alkyl having from about 12 to about 16 carbon atoms, dimethylamine N-lauryl oxide (LO), DDAPS (N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate) and others.
[00568] In some embodiments, the permeabilizing agent 204 includes an agent sufficient to lyse red blood cells. In some embodiments, the permeabilizing agent 204 includes an agent sufficient to lyse red cells other than reticulocytes or nucleated red cells. In some embodiments, the permeabilizing agent 204 includes an agent sufficient to lyse red blood cells while white blood cells, reticulocytes, nucleated red cells, platelets, and other cells remain substantially intact. In some embodiments, the permeabilizing agent 204 makes the limbs and/or nuclear membranes of white blood cells, reticulocytes, nucleated red cells, and/or platelets more permeable and/or porous to facilitate access of the particle contrast agent 202.
[00569] In some embodiments, the permeabilizing agent 204 is selected so that it can quickly create the pores or cracks necessary to allow the particle contrast agent 202 to enter cells in the sample.
[00570] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in some modalities of the 210 particle contrast agent composition using a 204 permeabilizing agent that includes 5PD-Litic available from Clinical Diagnostic Solutions (CDS) in Ft. Lauderdale, Florida, USA 5PD-Litic includes saponin. 5PD-Litic is generally described in U.S. Patent No. 6,632,676, incorporated herein by reference.
[00571] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in some embodiments of the 210 particle contrast agent composition using a permeabilizing agent 204 that includes a saponin present in sufficient amounts to result in concentrations from about 10 mg/L to about 1000 mg/L under staining conditions. In some embodiments, saponin is present in amounts sufficient to result in concentrations from about 50 mg/L to about 750 mg/L. In some embodiments, the saponin may be a quaternary saponin ether substituted with ammonium. fixative agent
[00572] In some embodiments, fixing agent 206 can be selected to ensure that white blood cells do not decompose during staining and imaging. In some embodiments, fixing agent 206 can ensure that other cells and cell structures do not decompose. Examples of fixing agents may include gluteraldehyde; formaldehyde; crosslinking agents; ammonia picrate in isotonic saline solution (eg for methylene blue staining); ethyl alcohol; methanol (for example, at room temperature, -20°C or -70°C); Heidenhain's Susa - HgCh, NaCl trichloroacetic acid, formalin; De Bouin - Picric Acid, Formalin, Acetic Acid; Duboseq-Brasil - Bouinas with 80% EtOH; Carnoy's - EtOH, chloroform, acetic acid; From Zenker - HgCl2, K2CrO7, NaSO4.H2O; acetocarmine; De Gatensby - Chromic acid, osmium tetroxide, NaCl; De Baker - Formalin, CaCl2,; De Smith - K2Cr2O7, formalin, acetic acid; 1% methyl green, 1% acetic acid; Phenol, Formalin, Glycerol, Gentian Violet; Schaudin - HgCl2, EtOH, acetic acid; De Champy - Chromic acid, K2CrO7, OsO4; De Fleming - Chromic acid, OsO4, acetic acid; Silver-Formaldehyde - Formaldehyde, AgNO3; Streck Tissue Fixative - Bronopol, diazolidinyl urea, ZnSO4.7H2O, sodium citrate; 1% imidazolidinyl urea in PBS; Glyoxal: Glyofix, Prefer, Safefix, Histochoice; Glidant-Hidantoin; Dimethylol urea; Sodium hydroxymethylglycinate; Karnovsky; mercuric chloride (B-5); From Hollande; and others. In addition, the suitable exemplary fixative may include any of the following, either alone or in combination.
[00573] In some embodiments, the fixative agent 206 may be an oxidizing agent, a mercurial, a picrate, a HEPES-glutamic acid (HOPE) buffer-mediated organic solvent buffering effect fixative or a water-soluble preservative. Examples of oxidizing agents include potassium dichromate, chromic acid, potassium permanganate and others. Examples of mercurial include B-5, Zernker's fixed and others. Examples of water-soluble preservatives include methyl paraben, propylparaben, dimethylol urea, 2-pyridinethiol-1 oxide, ascorbic acid, potassium sorbate and others.
[00574] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in some embodiments of the 210 particle contrast agent composition using a 206 fixing agent that includes at least one of glutaraldehyde and formaldehyde.
[00575] In some embodiments, surprisingly effective results can be achieved with the use of a fixing agent 206 that includes 0.1% gluteraldehyde by weight or less. Additional components
[00576] In some embodiments, optional additional components 212 may optionally be combined in block 208 in the 210 particle contrast agent composition. Examples of additional components 212 may include buffer components, viscosity modifying agents, an antimicrobial agent , an osmotic adjustment agent, an ionic strength modifier, a surfactant, a chelating agent and others. In some embodiments, surprisingly effective results can be achieved when the 210 particle contrast agent composition includes a phosphate buffered saline solution.
Exemplary viscosity modifying agents include natural hydrocolloids (and derivatives) such as carrageenan, locust bean gum, guar gum and gelatin; sugars (and derivatives), such as dextrose, fructose; polydextrose; dextrans; polydextranes; saccharides; and polysaccharides; semi-synthetic hydrocolloids (and derivatives) such as methylcellulose, carboxymethylcellulose; Synthetic hydrocolloids (and derivatives), such as Carbopol®; and Clays (and derivatives) such as Bentonite and Veegum®. Fast one-step coloring process
[00578] Figure A2 is a flowchart of a rapid coloring process in one step 300, according to an modality. Although the rapid one-step staining process 300 may contain several sub-steps, the term "one-step" is used to identify that the sample does not need to be introduced into multiple different solutions during the staining process. Particle contrast agent composition 210 is prepared in block 302, as described above with reference to Figure A1. Optionally, in some embodiments, components, such as any 202 particle contrast agents, can be purified in block 306. Purifying the 202 particle contrast agents can reduce the level of precipitates formed upon contact with a sample, thereby reducing , the background and enhancing image-based blood sample analysis results with a decreased need for additional review of images or slides or hand-prepared microscopy.
[00579] In block 308, the particle contrast agent composition 210 is combined with the sample. The particle contrast agent composition 210 can be combined with the sample in any suitable manner, including a mixture. The combination in block 308 can include diluting the sample with a certain amount of the 210 particle contrast agent composition. The sample can be diluted with the 210 particle contrast agent composition. The dilution amount can be selected to provide a optimal number of cells per frame during an image-based analysis. The amount of dilution can be selected to provide an optimal amount of white blood cells per frame during an image-based analysis. The amount of dilution can otherwise be selected to provide an optimal volume for any other non-image based analysis.
[00580] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in some embodiments of the 210-particle contrast agent composition with the use of a ratio of the 210-particle contrast agent composition to the sample from about 2:1 to about 20:1. The ratio of the 210 particle contrast agent composition to the sample can be from about 3:1 to about 10:1. The ratio of the 210 particle contrast agent composition to the sample can be from about 3:1 to about 4:1. The ratio of the 210 particle contrast agent composition to the sample can be about 3:1 or about 4:1. In some embodiments, surprisingly effective results can be achieved using a ratio of the 210 particle contrast agent composition to the sample of approximately 3:1 or approximately 4:1.
[00581] Surprisingly effective results can be achieved using a particle contrast agent with 40 ml of 5PD-Litic and 50 ml of Phosphate Buffered Saline with a 10:1 dilution ratio of the contrast agent composition of particle 210 for the sample. Surprisingly effective results can be achieved using a particle contrast agent with 40 ml of 5PD-Litic, extra saponin and 40 ml of Phosphate Buffered Saline with a 5:1 dilution ratio of the contrast agent composition of particle 210 for the sample. Surprisingly effective results can be achieved using a particle contrast agent with 40 ml of 5PD-Litic, extra saponin and 36 ml of Phosphate Buffered Saline with a 4:1 dilution ratio of the contrast agent composition of particle 210 for the sample.
In some embodiments, the sample is combined with the 210 particle contrast agent composition at elevated temperatures, such as any of the temperatures described below with reference to incubation.
[00583] As used herein, the combined sample and 210 particle contrast agent composition is called a sample mixture.
[00584] In block 310, the sample mixture is incubated for a certain amount of time at a certain temperature. Incubation can increase the permeability of cells or their internal structures so as to allow the 202 particle contrast agent to better infiltrate the cells or cell structures. Incubation time and temperature can be selected to enable the Particle Contrast Agent composition 210 to properly penetrate, fix, and color the sample. Incubation time and temperature can be selected to ensure RBC lysing while keeping WBCs, platelets and nucleated RBCs substantially intact.
[00585] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved in some embodiments of the 210 particle contrast agent composition by incubating the sample mixture at temperatures of about 37 °C and about 60°C for about 1 to 60 seconds. The sample mixture can be heated to temperatures of about 46 °C and about 49 °C. The sample mixture can be incubated for between 40 and 50 seconds. The sample mixture can be incubated for up to one hour. In some embodiments, surprisingly effective results can be achieved by incubating the sample mixture at about 48°C for about 45 seconds. In some embodiments, surprisingly effective results can be achieved by incubating the sample mixture at about 47°C for about 45 seconds.
[00586] In some embodiments, the combination in block 308 and the incubation in block 310 are completed in approximately the same amount of time or less time than is necessary for a sample mixture to be processed in the imaging equipment and for the lines from the imaging equipment are purged and/or cleaned. In this way, a first sample mix can be imaged while a second sample mix is combined and incubated. When the first sample mix has been imaged and the imaging equipment has been cleaned, the second sample mix can be immediately imaged.
[00587] In alternative embodiments, the combination in block 308 and the incubation in block 310 are completed in less than twice the time required for a sample mixture to be processed in the imaging equipment and for the lines of the imaging equipment to be purged and/or cleaned. In this way, while a first sample mix is imaged, a second sample mix can be ready to be imaged and a third sample mix and fourth sample mix can be in the mix and incubation process. When the first sample mix has been imaged and the imaging equipment has been cleaned, the second sample mix can be immediately imaged. The third sample mix may be nearing completion of its blending and incubation, and the fourth sample mix may still be in the blending and incubation step. When the second sample mix has been imaged and the imaging equipment has been cleaned, the third sample mix can be immediately imaged, while the fourth sample mix starts the completion of the mix and incubation and a fifth sample mix starts the mix and incubation. The process can go on indefinitely to continuously image sample mixtures.
[00588] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved by combining certain modalities of the 210 particle contrast agent composition, certain ways of combining the particle contrast agent composition 210 with the sample, and certain ways to incubate the sample mixture.
[00589] Specifically, surprisingly effective results can be achieved with the use of a 210 particle contrast agent composition including 90% purity or more of Crystal Violet at about 7.8 µm under staining conditions, 70% purity or more New Methylene Blue at about 735 µm under staining conditions, 80% pure or more Eosin-Y at about 27 µm under staining conditions, pretreated saponin at about 50 mg/L at about from 750 mg/L under staining conditions and glutaraldehyde to about 0.1% or less under staining conditions; wherein the 210 particle contrast agent is combined with the sample at a 210 particle contrast agent to sample ratio of about 3:1 and about 4:1; and where the resulting sample mixture is incubated at about 48°C for about 45 seconds.
Certain 210 particle contrast agent compositions and effective staining procedures enable "Wright-like" stained images of vital and/or substantially intact cells to be efficiently obtained with an automated visual analyzer using colorants in a non-alcohol based solvent system. Certain 210 particle contrast agent compositions and effective staining procedures enable rapid staining of samples so that various cellular components, nuclear lobes and granular structures are clearly distinguishable. Certain 210 particle contrast agent compositions and effective staining procedures are suitable for supravital staining. Certain particle contrast agent 210 compositions and effective coloring procedures generate visual distinctions for particle categorization and subcategorization. Certain effective particle 210 contrast agent compositions and staining procedures are effective to enhance the capabilities of intracellular content of particles in a serum, cerebrospinal fluid, pleural fluid, synovial fluid, seminal fluid, peritoneal fluid, amniotic fluid, lavage fluid , bone marrow aspiration fluid, effusions, exudates or blood samples. Certain efficient 210 particle contrast agent compositions and staining procedures are effective for staining neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocytes, nucleated red cells, blastulas, promyelocytes, myelocytes, metamyelocytes, hematic casts, bacteria, epithelial and /or parasites. Certain efficient particle contrast agent 210 compositions and staining procedures are effective to generate visual distinctions for the categorization and subcategorization of particles, e.g., to provide differential staining of primary and secondary granules in cells, to aid in subcategorization of immature granulocytes and their age determination based on differential staining or enhancement of primary and secondary granules. Certain efficient 210 particle contrast agent compositions and staining procedures are effective for generating visual distinctions for counting and characterizing red blood cells, reticulocytes, nucleated red cells and platelets, as well as for differential white blood cell count and white blood cell characterization and analysis. Certain efficient 210 particle contrast agent compositions and staining procedures are effective to generate visual distinctions in vital cells and/or viable cells and/or cells with structures that remain substantially intact. Certain efficient particle 210 contrast agent compositions and staining procedures are effective for staining subcellular structures of neutrophils, lymphocytes, monocytes, eosinophils and basophils, as well as reticulocytes, nucleated red blood cells, platelets, blastula, promyelocyte, myelocyte, metamyelocyte or fragments of cell.
The rapid staining enabled by certain 210 particle contrast agent compositions and effective staining procedures described herein can be used with automated or semi-automated imaging and/or analysis procedures.
[00592] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved with certain modalities of the 210 particle contrast agent composition comprising particle contrast agents in a solvent system that is not based on alcohol that can, for the first time according to the inventors, generate "Wright-like" staining images of vital and/or substantially intact cells that can reveal various cellular components, nuclear lobes and granular structures and render such particle features and/or resources visually distinct cell phones.
[00593] Through non-trivial efforts and experiments, it has been found that surprisingly effective results can be achieved when using a composite 210 particle contrast agent composition as mentioned in Table A1, wherein the Operational Stain Reagent is produced by mixture of 40 ml of Novo Methyl Blue and 5 ml of Crystal Violet. Table A1


[00594] Figure A3 is a representative illustration of white blood cells selected from a sample stained with the 210 particle contrast agent composition set forth in Table A1 and stained using the rapid one-step staining procedures set forth above. White blood cells are intact and show staining characteristics of a Wright stain. The various types of white blood cells (eg neutrophils, lymphocytes, monocytes, eosinophils, basophils, etc.) are visually differentiable.
[00595] In some embodiments, cell staining capabilities by the particle contrast agent compositions of this disclosure are mentioned in Table A2. Table A2


[00596] In certain embodiments, the colorant/dye composition is formulated for stability, ease of storage, clearance and/or limited toxicity.
[00597] Figure A4 is a representative illustration of white blood cells selected from a color sample with the 210 particle contrast agent composition according to an embodiment, including cells imaged by manual wet mount imaging and automatic flow imaging. early experiment
[00598] As described with reference to the examples below, various staining compositions and methods were tested and modified to result in the modalities disclosed above.
[00599] In an Early Example 1, there was a two-step staining method in which a sample and an early modality of a particle contrast agent composition were combined and incubated for 40 seconds at 47.5 °C and in then a quenching reagent was applied to the sample mixture. The particle contrast agent composition included Coulter LH Series Dilutent, Coulter LH Series Dilutent, Coulter Lyse S III diff Lytic Reagent, Coulter LH Series Pak Reagent Kit, and Coulter LH Series RETIC PAK Reagent Kit. The results are visualized in Figure A5.
[00600] In an early Example 2, after Example 1, the two-step staining method of Example 1 was replaced by a one-step staining method. The improved Basophil results are visualized in Figure A6 compared to the results of Example 1.
[00601] In an early Example 3, a particle contrast agent composition not including gluteraldehyde resulted in weakened white blood cells that could break due to shear forces in the flow cell. Images of the results from Example 3 showing damaged membranes are shown in Figure A7.
[00602] In an early Example 4, after Example 3, gluteraldehyde was added to the particle contrast agent composition. White blood cell membranes were more intact in Example 4, however, core membranes were still damaged. After making adjustments to the PIOAL to reduce the glycerol content, the white blood cell morphology was mostly unchanged during imaging, as shown in Figure A8.
[00603] In early examples with two dye stains using Novo Methylene Blue and Crystal Violet particle contrast agent compositions, most cell types were well distinguishable, except for eosinophils, which were somewhat inconsistent and not always easy to distinguish from neutrophils, as shown in Figure A9. In Examples 5 and 6 below, a third particle contrast agent was added to the particle contrast agent composition.
[00604] In Example 5, Methyl Green was added to the particle contrast agent composition. Methyl green helped in better staining of eosinophils, however, the cell nucleus is no longer colored with the desired purple color, but with blue. Figure A10 represents the images of neutrophils from Example 5 with blue colored nuclei but with missing granular detail.
[00605] In Example 6, Eosin-Y was used in place of Methyl Green as a third particle contrast agent in the particle contrast agent composition. Eosin-y retained a purple core color and the granule colors consistently with a slightly orange glow, as seen in Figure A11.
[00606] Through the experiment mentioned above and the additional experiment, it was determined that the revealed modalities and claimed modalities provide preferential results.
[00607] Each of the calculations or operations described herein can be done using a computer or other processor that has hardware, software and/or firmware. The various steps of the method may be performed in modules, and the modules may comprise any of a wide variety of digital and/or analog data processing hardware and/or software arranged to perform the method steps described herein. The modules optionally comprise data processing hardware adapted to perform one or more of these steps having suitable machine programming code associated therewith, the modules of two or more steps (or portions of two or more steps) being integrated into a single board. processor or separated on different processor boards in any one of a wide variety of integrated and/or distributed processing architectures. These methods and systems will often use a tangible medium including machine-readable code with instructions to perform the steps of the method described above. Suitable tangible media may comprise a memory (including a volatile memory and/or a non-volatile memory), a storage medium (such as a magnetic recording on a floppy disk, a hard disk, a tape, or the like; in an optical memory , such as a CD, a CD-R/W, a CD-ROM, a DVD or the like; or any other digital or analog storage medium), or the like.
[00608] All patents, patent publications, patent applications, journal articles, books, technical references and the like discussed in the present disclosure are hereby incorporated by reference in their entirety for all purposes.
[00609] Different arrangements of components represented in the drawings or described above, as well as components and steps not shown or described, are possible. Similarly, some features and subcombinations are useful and can be used without reference to other features and subcombinations. Embodiments of the invention have been described for illustrative rather than restrictive purposes, and alternative embodiments will be apparent to readers of this patent. In certain cases, method steps or operations can be performed or executed in different orders, or operations can be added, deleted or modified. It can be understood that, in certain aspects of the invention, a single component may be replaced by multiple components, and multiple components may be replaced by a single component, to provide an element or structure or to perform a particular function or functions. Except where such substitution is not operational to practice certain embodiments of the invention, such substitution is considered within the scope of the invention. Accordingly, the present invention is not limited to the embodiments described above or shown in the drawings, and various embodiments and modifications can be made without departing from the scope of the claims below.

权利要求:
Claims (6)
[0001]
1. A method of imaging a plurality of particles using a particle analysis system configured for combined viscosity and geometric hydrofocus, wherein the particles included in a blood fluid sample (25) have a sample fluid viscosity, wherein the method is characterized in that it comprises: flowing a sheath fluid (426) along a flow path (422) of a flow cell (22, 420), wherein the sheath fluid (426) ) has a coating fluid viscosity different from the sample fluid viscosity by a viscosity difference within a predetermined range of viscosity difference; injecting the blood fluid sample (25) through an outlet port (P, 331, 413) into the sheath fluid (426) flowing into the flow cell (22, 420) so as to provide a stream of fluid of sample (32, 428) surrounded by sheath fluid (426), wherein: the outlet port (P, 331, 413) has a height (H(I)) and a width (W(I)), and the height (H(I)) is less than the width (W(I)); flow the sample fluid stream (32, 428) and the coating fluid (426) through a reduction in the size of the flow path (21, 419) towards an imaging location (432), so that the viscosity hydrofocus effect induced by an interaction between the coating fluid (426) and the sample fluid stream (32, 428) associated with the viscosity difference, in combination with a geometric hydrofocus effect induced by an interaction between the coating fluid (426) and the sample fluid stream (32, 428) associated with the reduction in flow path size, are effective to provide a target imaging state in at least a portion of the plurality of particles at the location of imaging (432) while a viscosity agent in the sheath fluid maintains cell viability in the sample fluid stream so as to leave cell structure and content intact when the cells extend from the sample fluid stream. ra (32, 428) for the flowing coating fluid (426); and forming a tape-shaped sample stream (32, 428) at the imaging location (432); and generate images of the plurality of particles at the imaging site (432).
[0002]
2. Method according to claim 1, characterized in that: the loop-shaped sample stream (32, 428) has a thickness in the range of 2 µm to 10 µm, and the loop-shaped sample stream loop (32, 428) has a width in the range of 500 µm to 3000 µm.
[0003]
3. A system for imaging a plurality of particles in a blood fluid sample (25) having a fluid sample viscosity, wherein the system for use with a sheath fluid (426) has a fluid viscosity of coating different from sample fluid viscosity by a viscosity difference over a predetermined range of viscosity difference, wherein the system is characterized by the fact that it comprises: a flow cell (22, 420) having a flow path and a sample fluid injection tube (29, 412, 400d), wherein the flow path (420) has a reduction in size of the flow path (21, 419); the sample fluid injection tube (29, 412, 400d) has a downstream end (427a) that defines an outlet port (P, 331, 431), the outlet port (P, 331, 431) has a height (H(I)) and a width (W(I)), and the height (H(I)) is less than the width (W(I)); a sheath fluid inlet (401) in fluid communication with the flow path (422) of the flow cell (22, 420) so as to transmit a flow of sheath fluid (426) along the flow path ( 422) of the flow cell (22, 420); a blood fluid sample inlet (402) in fluid communication with the injection tube (29, 412, 400d) of the flow cell, so as to inject a flow of blood fluid sample (32, 428) into the fluid of sheath (426) flows within the flow cell (22, 420), such that the sheath fluid and sample fluid flow through the size reduction of the flow path (21, 419) and toward the an imaging site (432), in which a viscosity hydrofocus effect induced by an interaction between the coating fluid (426) and the sample fluid (32, 428) associated with the viscosity difference, in combination with an effect of Geometric hydrofocus induced by an interaction between the sheath fluid (426) and the sample fluid (32, 428) associated with the reduction in flow path size, provides a target imaging state in at least a portion of the plurality of particles. at the imaging site as a viscosity agent in the coating maintains cell viability in the sample fluid stream so as to leave the structure and contents of the cells intact as the cells extend from the sample fluid stream into the flowing coating fluid (426); and an imaging device (24) that performs imaging of the plurality of particles at the imaging site (432).
[0004]
4. System according to claim 3, characterized in that: the height (H(I)) is in a range of 50 μm to 250 μm, and the width (W(I)) is in a range of 500 µm to 3000 µm.
[0005]
5. System according to claim 3, characterized in that the blood fluid sample (25) forms a loop-shaped sample stream (32, 428) at the imaging site (432).
[0006]
6. Particle analysis system according to claim 3, characterized in that the sample stream (32, 428) has a loop shape in the image path.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112015021577B1|2021-06-22|METHOD TO IMAGE A PLURALITY OF PARTICLES USING A PARTICLE ANALYSIS SYSTEM CONFIGURED FOR COMBINED VISCOSITY AND GEOMETRIC HYDROFOCUS AND SYSTEM TO IMAGE A PLURALITY OF PARTICLES IN A BLOOD FLUID SAMPLE

---

US10060846B2|2018-08-28|Hematology systems and methods

---

JP2016520807A5|2019-01-17|

---

US10794900B2|2020-10-06|Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples

同族专利:

---

公开号 | 公开日

---

EP2972200A2|2016-01-20|

---

CN105074420A|2015-11-18|

---

BR112015021902B1|2021-06-15|

---

US20160187246A1|2016-06-30|

---

JP2016520807A|2016-07-14|

---

KR102044593B1|2019-11-13|

---

WO2014146063A2|2014-09-18|

---

BR112015021577A2|2017-07-18|

---

US9470618B2|2016-10-18|

---

JP6523245B2|2019-05-29|

---

CN105074420B|2021-07-27|

---

JP6483658B2|2019-03-13|

---

US20140315238A1|2014-10-23|

---

US9316635B2|2016-04-19|

---

WO2014145983A1|2014-09-18|

---

BR112015021902A2|2017-07-18|

---

US20170003273A1|2017-01-05|

---

KR102053487B1|2019-12-06|

---

KR20150129709A|2015-11-20|

---

CN113484200A|2021-10-08|

---

WO2014146063A3|2015-01-08|

---

US10451612B2|2019-10-22|

---

JP2016520805A|2016-07-14|

---

WO2014146063A9|2014-11-20|

---

KR20150129706A|2015-11-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3888782A|1972-05-08|1975-06-10|Allergan Pharma|Soft contact lens preserving solution|

---

US3822095A|1972-08-14|1974-07-02|Block Engineering|System for differentiating particles|

---

GB1471976A|1974-09-20|1977-04-27|Coulter Electronics|Particle sensing apparatus including a device for orientinggenerally flat particles|

---

DE2543310C2|1975-09-27|1982-04-29|Gesellschaft für Strahlen- und Umweltforschung mbH, 8000 München|Device for counting and classifying particles suspended in a liquid|

---

US4338024A|1980-05-02|1982-07-06|International Remote Imaging Systems, Inc.|Flow analyzer and system for analysis of fluids with particles|

---

FR2484077B1|1980-06-06|1984-07-06|Inst Nat Sante Rech Med|METHOD AND DEVICE FOR MEASURING THE DEFORMABILITY OF LIVING CELLS, ESPECIALLY RED BLOOD CELLS|

---

JPS5774372A|1980-10-27|1982-05-10|Seiko Epson Corp|Fluid ink for printer|

---

DE3315195A1|1982-04-29|1983-11-03|International Remote Imaging Systems Inc., 91311 Chatsworth, Calif.|METHOD FOR ALIGNING PARTICLES IN A FLUID SAMPLE|

---

AU563260B2|1984-11-29|1987-07-02|International Remote Imaging Systems Inc.|Method of operating a microscopic instrument|

---

US4732479A|1985-10-18|1988-03-22|Canon Kabushiki Kaisha|Particle analyzing apparatus|

---

US4983038A|1987-04-08|1991-01-08|Hitachi, Ltd.|Sheath flow type flow-cell device|

---

DE3902079A1|1988-04-15|1989-10-26|Bayer Ag|IN THE. INJECTION FORMS OF GYRASE INHIBITORS|

---

US5123055A|1989-08-10|1992-06-16|International Remote Imaging Systems, Inc.|Method and an apparatus for differentiating a sample of biological cells|

---

JP2939647B2|1990-07-24|1999-08-25|シスメックス株式会社|Automatic focus adjustment method for flow imaging cytometer|

---

JP2874746B2|1990-11-22|1999-03-24|シスメックス株式会社|Flow cell mechanism in flow imaging cytometer|

---

US5412466A|1991-07-26|1995-05-02|Toa Medical Electronics Co., Ltd.|Apparatus for forming flattened sample flow for analyzing particles|

---

EP0556971B1|1992-02-18|1999-12-08|Hitachi, Ltd.|An apparatus for investigating particles in a fluid, and a method of operation thereof|

---

JP3111706B2|1992-02-18|2000-11-27|株式会社日立製作所|Particle analyzer and particle analysis method|

---

US5308526A|1992-07-07|1994-05-03|The Procter & Gamble Company|Liquid personal cleanser with moisturizer|

---

JP3215175B2|1992-08-10|2001-10-02|シスメックス株式会社|Particle analyzer|

---

JP3052665B2|1993-01-26|2000-06-19|株式会社日立製作所|Flow cell device|

---

US5585246A|1993-02-17|1996-12-17|Biometric Imaging, Inc.|Method for preparing a sample in a scan capillary for immunofluorescent interrogation|

---

JP3039594B2|1993-10-08|2000-05-08|株式会社日立製作所|Staining reagent and method of use|

---

JP3290786B2|1993-11-26|2002-06-10|シスメックス株式会社|Particle analyzer|

---

US5812419A|1994-08-01|1998-09-22|Abbott Laboratories|Fully automated analysis method with optical system for blood cell analyzer|

---

AU4741796A|1994-12-23|1996-07-19|International Remote Imaging Systems Inc.|Method and apparatus of analyzing particles in a fluid sample and displaying same|

---

JPH0989753A|1995-09-25|1997-04-04|Hitachi Ltd|Particle analyzer|

---

US6184978B1|1996-05-15|2001-02-06|International Remote Imaging Systems, Inc.|Method and apparatus for verifying uniform flow of a fluid sample through a flow cell and distribution on a slide|

---

WO1997043620A1|1996-05-15|1997-11-20|International Remote Imaging Systems, Inc.|Selectively emphasizing particles of interest from a fluid sample for analysis|

---

KR100200734B1|1996-10-10|1999-06-15|윤종용|Measuring apparatus and method of aerial image|

---

US5985216A|1997-07-24|1999-11-16|The United States Of America, As Represented By The Secretary Of Agriculture|Flow cytometry nozzle for high efficiency cell sorting|

---

US5935857A|1997-08-01|1999-08-10|Coulter International Corp.|Blood diluent|

---

CA2341231C|1998-08-21|2003-10-21|Union Biometrica, Inc.|Instrument for selecting and depositing multicellular organisms and other large objects|

---

US20030059440A1|1998-09-01|2003-03-27|Tim Clarot|Composition and method for moisturizing nasal tissue|

---

US6130745A|1999-01-07|2000-10-10|Biometric Imaging, Inc.|Optical autofocus for use with microtiter plates|

---

JP2000214070A|1999-01-21|2000-08-04|Sysmex Corp|Sheath flow cell and hemanalyzer using the same|

---

US6632676B1|1999-09-24|2003-10-14|Clinical Diagnostic Solutions|Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells|

---

US20040070757A1|2000-12-29|2004-04-15|Moore Richard Channing|High viscosity sheath reagent for flow cytometry|

---

CA2396015A1|1999-12-29|2001-07-05|Union Biometrica, Inc.|High viscosity sheath reagent for flow cytometry|

---

US6974938B1|2000-03-08|2005-12-13|Tibotec Bvba|Microscope having a stable autofocusing apparatus|

---

CA2349995A1|2000-06-14|2001-12-14|Lianne Ing|Viewing particles in a relatively translucent medium|

---

FR2821428B1|2001-02-23|2004-08-06|Abx Sa|REAGENT AND METHOD FOR THE IDENTIFICATION AND COUNTING OF BIOLOGICAL CELLS|

---

JP4838446B2|2001-06-20|2011-12-14|オリンパス株式会社|Microscope equipment|

---

KR100473362B1|2001-10-17|2005-03-08|주식회사 디지탈바이오테크놀러지|Apparatus and method for flow cytometry|

---

US20060148028A1|2002-09-05|2006-07-06|Naohiro Noda|Method for detecting microbe or cell|

---

JP4754828B2|2002-11-18|2011-08-24|イリスインターナショナルインコーポレイテッド|Multi-level controller system|

---

US6825926B2|2002-11-19|2004-11-30|International Remote Imaging Systems, Inc.|Flow cell for urinalysis diagnostic system and method of making same|

---

US6900058B2|2003-03-11|2005-05-31|Bionostics, Inc.|Control solution for photometric analysis|

---

GB0321918D0|2003-09-19|2003-10-22|Aoti Operating Co Inc|Focusing system and method|

---

JP4057539B2|2004-01-09|2008-03-05|浜松ホトニクス株式会社|Sheath flow cell cuvette and manufacturing method thereof|

---

US9176121B2|2004-02-13|2015-11-03|Roche Diagnostics Hematology, Inc.|Identification of blood elements using inverted microscopy|

---

US7394943B2|2004-06-30|2008-07-01|Applera Corporation|Methods, software, and apparatus for focusing an optical system using computer image analysis|

---

JP2006039315A|2004-07-28|2006-02-09|Hamamatsu Photonics Kk|Automatic focusing device and microscope using the same|

---

US7822276B2|2005-02-17|2010-10-26|Iris International, Inc.|Method and apparatus for analyzing body fluids|

---

FR2883972B1|2005-03-31|2007-11-16|C2 Diagnostics Sa|METHOD FOR ANALYSIS OF A BLOOD SAMPLE AND APPARATUS AND REAGENT FOR ITS IMPLEMENTATION|

---

JP2007024844A|2005-07-21|2007-02-01|Sysmex Corp|Method and system for hemanalysis|

---

JP4896534B2|2006-01-31|2012-03-14|シスメックス株式会社|Sheath liquid for particle analyzer|

---

JPWO2007145091A1|2006-06-15|2009-10-29|株式会社ニコン|Cell culture equipment|

---

DE102006027836B4|2006-06-16|2020-02-20|Carl Zeiss Microscopy Gmbh|Microscope with auto focus device|

---

SE530750C2|2006-07-19|2008-09-02|Hemocue Ab|A measuring device, a method and a computer program|

---

CN1945326A|2006-10-13|2007-04-11|江西特康科技有限公司|Five classifying full blood cell analysis method based on vision shape|

---

US9110010B2|2007-05-11|2015-08-18|The United States Of America, As Represented By The Secretary Of The Navy|Electrical detection using confined fluids|

---

EP2153199B1|2007-06-07|2016-10-19|Technion Research & Development Foundation Ltd.|System and method for focusing particles|

---

US9602777B2|2008-04-25|2017-03-21|Roche Diagnostics Hematology, Inc.|Systems and methods for analyzing body fluids|

---

US9017610B2|2008-04-25|2015-04-28|Roche Diagnostics Hematology, Inc.|Method of determining a complete blood count and a white blood cell differential count|

---

US8343978B2|2008-08-04|2013-01-01|Adds Pharmaceuticals Llc|Fast onset orodispersable tablets|

---

WO2010038230A1|2008-10-02|2010-04-08|Focucell Ltd.|Optical imaging based on viscoelastic focusing|

---

KR101133288B1|2008-12-24|2012-04-05|한국과학기술원|Apparatus for Seperating Micro-Particles and Method Thereof|

---

DK2440941T3|2009-06-10|2017-08-28|Cynvenio Biosystems Inc|Sheath flow devices and methods|

---

US20110052446A1|2009-08-31|2011-03-03|Life Technologies Corporation|Flow cells and methods of filling and using same|

---

CA2839542A1|2011-06-17|2012-12-20|Constitution Medical, Inc.|Fixative and staining solutions|

---

KR101849974B1|2011-09-16|2018-04-19|삼성전자주식회사|Numerical aperture controlling unit, variable optic probe and depth scanning method using the same|

---

KR101244285B1|2011-12-21|2013-03-18|충남대학교산학협력단|Micro fluidic chip for droplet generation, micro fluidic chip for droplet-based reaction and appatatus for analysis of reaction in multi-droplets|

---

CN102998437A|2012-11-26|2013-03-27|江苏美诚生物科技有限公司|Sheath fluid used for urinary sediment analysis and preparation method thereof|

---

KR101389554B1|2012-11-26|2014-04-29|경희대학교 산학협력단|Fluidic channel of flow cytometry and detecting method thereof|

---

US9810704B2|2013-02-18|2017-11-07|Theranos, Inc.|Systems and methods for multi-analysis|

---

EP2972208B1|2013-03-15|2018-06-13|Iris International, Inc.|Method and composition for staining and sample processing|

---

US9857361B2|2013-03-15|2018-01-02|Iris International, Inc.|Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples|

---

WO2014145989A1|2013-03-15|2014-09-18|Iris International, Inc.|Method and composition for staining and processing a urine sample|

---

US9316635B2|2013-03-15|2016-04-19|Iris International, Inc.|Sheath fluid systems and methods for particle analysis in blood samples|EP2972208B1|2013-03-15|2018-06-13|Iris International, Inc.|Method and composition for staining and sample processing|

---

US9316635B2|2013-03-15|2016-04-19|Iris International, Inc.|Sheath fluid systems and methods for particle analysis in blood samples|

---

US9857361B2|2013-03-15|2018-01-02|Iris International, Inc.|Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples|

---

WO2015013605A1|2013-07-26|2015-01-29|Abbott Point Of Care, Inc.|Method and apparatus for producing an image of undiluted whole blood sample having wright stain coloration|

---

US9832366B2|2014-09-29|2017-11-28|Biosurfit, S.A.|Focusing method|

---

WO2016050837A1|2014-09-30|2016-04-07|Foss Analytical A/S|Method, device and system for hydrodynamic flow focusing|

---

EP3207358A1|2014-10-17|2017-08-23|Iris International, Inc.|Systems and methods for imaging fluid samples|

---

US20170059459A1|2015-08-27|2017-03-02|Ativa Medical Corporation|Fluid processing micro-feature devices and methods|

---

US9366606B1|2015-08-27|2016-06-14|Ativa Medical Corporation|Fluid processing micro-feature devices and methods|

---

US20170059590A1|2015-08-27|2017-03-02|Ativa Medical Corporation|Fluid holding and dispensing micro-feature|

---

US11071982B2|2015-08-27|2021-07-27|Ativa Medical Corporation|Fluid holding and dispensing micro-feature|

---

US10823657B2|2015-12-23|2020-11-03|Siemens Healthcare Gmbh|Flow cell for analyzing particles in a liquid to be examined|

---

JP6688089B2|2016-01-22|2020-04-28|日本光電工業株式会社|Flow cell and particle analyzer|

---

US10656070B2|2016-03-30|2020-05-19|Siemens Healthcare Gmbh|Aligning a non-spherical biological entity in a sample flow using ambient viscoelastic fluid flows|

---

EP3440830A1|2016-04-06|2019-02-13|Biosurfit, S.A.|Method and system for capturing images of a liquid sample|

---

BE1023760B1|2016-06-24|2017-07-13|Occhio|OPTICAL DEVICE FOR MEASURING A CHARGE IN PARTICLES OF A SAMPLE|

---

JP6347353B2|2016-08-30|2018-06-27|静岡製機株式会社|Grain quality measuring device|

---

KR101967820B1|2017-01-09|2019-04-10|동아대학교 산학협력단|Micro flow device for differential pressure viscometer on a chip and its design method and method for measuring tensile viscosity using the same|

---

USD852979S1|2017-01-24|2019-07-02|Life Technologies Corporation|Capillary electrophoresis cartridge|

---

CN110573858A|2017-03-31|2019-12-13|生命技术公司|Apparatus, system and method for imaging flow cytometry|

---

EP3630342A4|2017-05-25|2021-03-24|Abbott Laboratories|Methods and systems for sample analysis|

---

DE102017008946A1|2017-09-23|2019-03-28|Universität Greifswald|Method of deforming deformable bodies and devices therefor|

---

WO2019090126A1|2017-11-03|2019-05-09|Streck, Inc.|Linearity control materials|

---

CN108226015A|2018-01-04|2018-06-29|江苏苏净集团有限公司|A kind of new liquid grain count method and system|

---

CN109374608B|2018-10-18|2021-05-28|东北大学|Method for detecting amine collecting agent by spectrophotometry|

---

JP2020071037A|2018-10-29|2020-05-07|アークレイ株式会社|Information processor, measuring system, and program|

---

WO2020264202A1|2019-06-25|2020-12-30|Hemex Health, Inc.|Malaria species detection|

---

WO2021041205A1|2019-08-23|2021-03-04|The Penn State Research Foundation|Methods and systems for estimating proportion of filled virus capsids using cryo-em|

---

CN110619318B|2019-09-27|2021-03-02|腾讯科技（深圳）有限公司|Image processing method, microscope, system and medium based on artificial intelligence|

---

US20210108994A1|2019-10-11|2021-04-15|Beckman Coulter, Inc.|Method and composition for staining and sample processing|

法律状态:
2018-11-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-01-21| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-10-27| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-04-13| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-06-22| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201361799152P| true| 2013-03-15|2013-03-15|

---

US61/799,152|2013-03-15|

---

US14/215,834|2014-03-17|

---

US14/217,034|US10429292B2|2013-03-15|2014-03-17|Dynamic range extension systems and methods for particle analysis in blood samples|

---

US14/216,339|US9279750B2|2013-03-15|2014-03-17|Method and composition for staining and sample processing|

---

US14/217,034|2014-03-17|

---

US14/216,533|2014-03-17|

---

US14/216,811|2014-03-17|

---

US14/216,533|US9322752B2|2013-03-15|2014-03-17|Flowcell systems and methods for particle analysis in blood samples|

---

US14/216,811|US10705008B2|2013-03-15|2014-03-17|Autofocus systems and methods for particle analysis in blood samples|

---

US14/215,834|US9316635B2|2013-03-15|2014-03-17|Sheath fluid systems and methods for particle analysis in blood samples|

---

PCT/US2014/030942|WO2014146063A2|2013-03-15|2014-03-18|Hematology systems and methods|

---